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1  Summary 
 
The  removal  of  apoptotic  cells  (AC)  can  be  regarded  as  an  integral 
component  of  the  program  to  terminate  inflammation.  Clearance  of  AC  by 
professional phagocytes such as macrophages induces an anti-inflammatory 
phenotype  in  the  latter  ones.  Anti-inflammatory  or  M2  polarization  is  also 
observed  in  macrophages  infiltrating  certain  human  tumors.  These  tumor-
associated macrophages (TAM) contribute actively to tumor progression by 
promoting immune evasion, angiogenesis and tumor cell survival. The aim of 
my  Ph.D.  thesis  was  to  approach  the  mechanisms  as  well  as  the 
characteristics of macrophage phenotype alterations induced by AC, and to 
elucidate  a  possible  connection  between  tumor  cell  apoptosis  and  TAM 
generation.   
In the first part of my studies, I investigated the impact of AC on macrophage 
viability. I could show that macrophage survival against pro-apoptotic agents 
increased after the interaction with AC. Protection of macrophages against 
cell  death  required  activation  of  phosphatidylinositol-3  kinase  (PI3K), 
extracellular  signal-regulated  kinase  1/2  (ERK1/2)  and  Ca
2+  signaling,  and 
correlated  with  Bcl-XL  and  Bcl-2  up-regulation  as  well  as  Ser136-Bad 
phosphorylation. Unexpectedly, neither phagocytosis nor binding of apoptotic 
debris to the phagocyte was necessary to induce protection. AC released the 
bioactive  lipid  sphingosine-1-phosphate  (S1P),  dependent  on  sphingosine 
kinase (SphK) 2, as a survival messenger. These data indicated an active role 
of AC in preventing cell destruction in their neighborhood.  
My next aim was to elucidate the mechanism of S1P production by AC. During 
cell death, SphK 2 was cleaved at its N-terminus by caspase-1. Thereupon, 
the truncated but enzymatically active fragment of SphK 2 was released from 
cells. This release was coupled to phosphatidylserine exposure, a hallmark of 
apoptosis  and  a  crucial  signal  for  the  phagocyte/apoptotic  cell  interaction. 
Thus, I observed a link between common signaling events during apoptosis 
and the extracellular production of S1P, which is known to affect immune cell 
attraction and polarization as well as angiogenesis in cancer.  Summary                                                                                                                                    2 
In the next part of my studies, I asked for a correlation between tumor cell 
apoptosis  and  TAM  polarization.  During  co-culture  of  human  macrophages 
with  human  breast  cancer  carcinoma  cells  (MCF-7),  the  latter  ones  were 
killed, while macrophages acquired an alternatively activated phenotype. This 
was characterized by decreased tumor necrosis factor (TNF)-α and interleukin 
(IL)-12-p70 production, but increased formation of IL-8 and IL-10. Alternative 
macrophage activation required tumor cell death, because a co-culture with 
apoptosis-resistant  colon  carcinoma  cells  (RKO)  or  Bcl-2-overexpressing 
MCF-7  cells  failed  to  induce  phenotype  alterations.  These  phenotype 
alterations were also achieved with conditioned media from apoptotic tumor 
cells, which again argued for a soluble factor being involved. Knock-down of 
SphK2, but not SphK1, to attenuate S1P formation in MCF-7 cells, repressed 
the otherwise observed alternative macrophage polarization during co-culture. 
Furthermore,  macrophage  polarization  achieved  by  tumor  cell  apoptosis  or 
substitution  of  authentic  S1P  was  characterized  by  suppression  of  pro-
inflammatory nuclear factor (NF)-κB DNA binding. These findings suggested 
that  tumor  cell  apoptosis-derived  S1P  contributes  to  the  macrophage 
polarization present in human tumors. 
To validate these in vitro data, I used an in vivo tumor model to clarify the 
relevance of SphK2 and S1P in tumor development. The growth of, as well as 
blood  vessel  infiltration  into  SphK2  knock-down  MCF-7  (MCF-7-siSphK2) 
xenografts in nude mice was markedly decreased in comparison to control 
MCF-7  xenografts.  In  contrast,  macrophage  infiltration  was  similar  or  even 
more  pronounced.  These  data  provided  a  first  hint  for  an  in  vivo  role  of 
SphK2-derived  S1P  in  macrophage  polarization  associated  with  tumor 
promotion.    
In summary, these data indicate a new mechanism how AC themselves shape 
macrophage  polarization,  which  results  in  the  termination  of  inflammatory 
responses  and  macrophage  survival.  Furthermore,  my  studies  present 
evidence that human tumors may utilize this mechanism to foster growth via 
increased angiogenesis. 
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2  Zusammenfassung 
 
Die Phagozytose apoptotischer Zellen (AZ) kann als ein integraler Bestandteil 
des  Mechanismus  zur  Beendigung  von  Entzündungsreaktionen  angesehen 
werden. Die Beseitigung von AZ induziert einen anti-inflammatorischen Phä-
notyp in Makrophagen. Ein ähnlicher Phänotyp (M2) ist auch für Makrophagen 
beschrieben,  die  in  humane  Tumore  infiltrieren.  Diese  Tumor-  assoziierten 
Makrophagen  (TAM)  tragen  aktiv  zur  Tumorprogression  bei,  indem  sie  die 
Gefäßbildung  und  das  Überleben  von  Tumorzellen  fördern,  aber  auch  das 
körpereigene  Immunsystem  ausschalten.  Das  Ziel  meiner  Doktorarbeit  war 
es,  die  Mechanismen  und  Charakteristika  der  Makrophagenpolarisierung 
durch AZ besser zu verstehen, und eine mögliche Verbindung von Tumorzell- 
Apoptose und der Ausprägung des TAM- Phänotyps aufzuzeigen. 
Im ersten Teil meiner Studien untersuchte ich den Einfluss von AZ auf die 
Überlebensfähigkeit von Makrophagen. Diese war nach der Interaktion mit AZ 
erhöht. Der Schutz vor Zelltod benötigte die Aktivierung der Phosphatidylinosi-
tol-3  Kinase  (PI3K),  der  Mitogen-aktivierten  Proteinkinasen  ERK1/2,  sowie 
Calcium-Signale, und korrelierte mit vermehrter Expression von Bcl-2 und Bcl-
XL, sowie mit Phosphorylierung von Bad an Ser136. Interessanterweise war 
der Schutzeffekt unabhängig von Phagozytose oder direkter Interaktion zwi-
schen Makrophagen und AZ, sondern vielmehr von der Freisetzung des bio-
aktiven  Lipids  Sphingosin-1-Phosphat  (S1P)  aus  AZ,  generiert  durch  die 
Sphingosinkinase (SphK) 2.      
Mein nächstes Ziel war es den dafür verantwortlichen Mechanismus aufzuzei-
gen. Während des Zelltods fand eine Spaltung der SphK2 durch die Caspase-
1 an deren N-Terminus statt, woraufhin ein enzymatisch aktives Fragment aus 
den AZ freigesetzt wurde. Diese Freisetzung war eng an die Exposition von 
Phosphatidylserin gekoppelt, welche ein Kennzeichen von Apoptose, und ein 
wichtiges Signal bei der Interaktion von Makrophagen und AZ ist. Somit konn-
te  ich  eine  Verknüpfung  zwischen  allgemeinen  Signalwegen  der  Apoptose 
und  der extrazellulären  Produktion  von  S1P  nachweisen.  Von  letzterem  ist 
bekannt, dass es sowohl die Polarisierung und das Anlocken von Immunzel-
len, als auch die Gefäßbildung im Tumor beeinflussen kann. Zusammenfassung                                                                                                                    4 
Im nachfolgenden Teil meiner Studien untersuchte ich eine mögliche Verbin-
dung zwischen Tumorzell-Apoptose und der TAM- Polarisierung. In einer Ko- 
Kultur von menschlichen Makrophagen mit MCF-7 Brustkrebszellen wurden 
letztere getötet, woraufhin die Makrophagen einen alternativ aktivierten Phä-
notyp  annahmen.  Dieser  war  durch  verminderte  Produktion  des  Tumor- 
Nekrose- Faktors (TNF)-α und des Interleukins (IL)-12p70 sowie durch erhöh-
te Freisetzung der Interleukine 8 und 10 charakterisiert. Die alternative Akti-
vierung der Makrophagen in den Ko-Kulturen war Tumorzelltod- abhängig, da 
Apoptose-resistente  Darmkrebszellen  (RKO)  oder  Bcl-2  überexprimierende 
MCF-7 Zellen diese nicht auslösten. Dies war jedoch mit Zellkulturüberstän-
den von apoptotischen Tumorzellen der Fall, was wiederum auf einen lösli-
chen Faktor hindeutete. Das Ausschalten der SphK2, nicht jedoch der SphK1, 
was die S1P- Freisetzung von MCF-7 Zellen unterband, verhinderte die alter-
native Aktivierung von Makrophagen in den Ko-Kulturen. Ein weiteres Charak-
teristikum der Makrophagenpolarisierung durch apoptotische Tumorzellen und 
S1P  war  die  Hemmung  der  DNA-Bindung  des  entzündungsfördernden 
Transkriptionsfaktors NF-κB.  
Um die Relevanz der SphK2 und von S1P in der Tumorentwicklung genauer 
zu  untersuchen,  führte  ich  ein  in  vivo  Tumormodell  durch.  Tumorzell-
Implantate von SphK2-defizienten MCF-7 Zellen in Nacktmäusen wiesen so-
wohl deutlich reduziertes Wachstum, als auch Blutgefäßbildung, im Vergleich 
zu Kontrollimplantaten (MCF-7) auf. Die Einwanderung von Makrophagen war 
jedoch nicht vermindert, sondern eher erhöht. Diese Daten lieferten einen ers-
ten  Hinweis  auf  eine  Rolle  von  SphK2-abhängig  freigesetztem  S1P  in  der 
Makrophagenpolarisierung, in Verbindung mit einer Förderung der Tumorent-
wicklung.  
Zusammengefasst deuten meine Daten auf einen neuen Mechanismus hin, 
wie  AZ  die  Makrophagenpolarisierung  gestalten.  Dieser  Prozess  resultiert  
letztlich in der Beendigung von Entzündungsreaktionen und erhöhter Überle-
bensfähigkeit von Makrophagen. Weiterhin weisen meine Studien darauf hin, 
dass Tumore eventuell diesen Mechanismus nutzen, um ihr Wachstum durch 
vermehrte Gefäßbildung zu sichern.   Introduction                                                                                                                            5 
3  Introduction 
 
3.1  Cell death 
 
Two  principle  control  mechanisms  ensuring  tissue  homeostasis  were 
developed  by  metazoans.  Besides  the  production  of  ‘new’  cells  through 
activation of the cell cycle of progenitor cells, followed by differentiation into 
specialists, death of redundant cells is a major regulator. Different modes of 
physiological cell death with varying morphological characteristics are known, 
including mitotic catastrophe (1), programmed necrosis (2) and autophagy (3). 
However, the major mode found in multicellular organisms is apoptosis. 
Naturally occurring cell death was first described by Carl Vogt in 1842 as a 
unique process accompanied by typical morphological changes, followed by 
more than a hundred reports already in the nineteenth century (4). After a long 
period  of neglect  due  to  its  ‘invisibility’,  the  process  was  rediscovered  and 
named programmed  cell  death  by  Lockshin  and Williams  in  1965  (5).  The 
term apoptosis, the Greek word for the fall of leaves in autumn, was first used 
by Kerr, Wyllie and Currie seven years later (6). In this and following studies, 
they  identified  certain  morphological  criteria  to  discriminate  between 
physiological (apoptosis) and non-physiological cellular demise (necrosis).  
Apoptosis is characterized by nuclear condensation and fragmentation, cell 
shrinkage and controlled cell disintegration through formation of membrane 
vesicles, so-called ‘apoptotic bodies’, whose membrane integrity is maintained 
(6, 7). It is energy-dependent and tightly regulated concerning its initiation, 
execution and termination, the latter ensuring its  ‘immunological silence’ by 
providing  signals  for  rapid  clearance  of  apoptotic  debris  by  professional 
phagocytes  in  vivo  (8,  9).  Furthermore,  aside  from  being  simply  removed, 
apoptotic cells (AC) directly influence the phenotype of their ‘captors’ to shut 
down  inflammation  (10).  Thus,  suppression  of  inflammation  is  an  intrinsic 
feature of apoptotic cell death. 
In contrast, necrosis is usually induced by external force like heat, irradiation, 
mechanical  stress  or  toxins,  which  leads  to  uncontrolled  cell  swelling  and Introduction                                                                                                                            6 
rupture due to loss of cell membrane integrity. The consequence is leakage of 
cytosolic  components  into  the  interstitial  space,  which  may  cause  severe 
inflammation  (9).  Membrane  disintegration  is  also  observed  when 
phagocytosis  of  apoptotic  material  is  defective,  a  process  which  is  termed 
secondary necrosis. It occurs in vivo when the number of AC outstrips the 
phagocytic capacity by far (10).  
 
3.1.1  Roads to apoptosis 
The  key  players  in  classical  apoptotic  cell  death  are  a  family  of  cystein 
proteases, which cleave their substrates after aspartic acid (Asp) residues and 
were therefore named caspases (cysteinyl aspartate proteinases) (11). More 
than a dozen caspase isoforms have been identified in mammals (12). They 
are  highly  conserved  throughout  evolution,  even  down  to  low  complexity 
organisms like hydra (13).  
Most  caspase  isoforms  function  as  major  executioners  of  apoptosis  via 
cleavage of specific targets ensuring efficient physiological cell fragmentation. 
Nevertheless,  additional  properties  have  been  attributed  to  caspase-
dependent  protein  cleavage.  The  most  prominent  example  is  the  role  of 
caspase-1 in inflammation. Its activation in response to pathogens initiates the 
release  of  pro-inflammatory  cytokines  like  interleukin  (IL)-1β  or  IL-18  from 
immune  cells  (14).  Thus  caspase-1,  together  with  other  isoforms,  whose 
specific substrates are yet unidentified, forms the subfamily of inflammatory 
caspases (15). 
Caspases are synthesized as enzymatically inert zymogens (pro-caspases), 
which  are  activated  via  proteolytic  processing  at  cleavage  sites  containing 
Asp-X residues as well (16). Therefore, the most efficient way to activate a 
pro-caspase is to expose it to another active caspase, an activation strategy 
termed the ‘caspase cascade’ (17). Apoptotic caspases are further subdivided 
into initiator and effector caspases, the latter being activated by the first (18). 
The main initiator caspases are caspase-8 and -9. Their respective activation 
is  the  sensitive  step  in  apoptosis  induction.  It  is  coupled  to  two  principally 
different pathways (Figure 1).  Introduction                                                                                                                            7 
Briefly, caspase-8 is activated in the extrinsic cell death pathway upon binding 
of  tumor  necrosis factor  (TNF) family  members,  the death  ligands,  to  their 
specific  death  receptors  on  the  cell  surface.  After  receptor  ligation,  pro-
caspase-8 is recruited to the death-induced signaling complex (DISC) by the 
adaptor protein FADD (Fas-associated death domain) (19). The formation of 
this  complex  results  in  caspase-8  activation,  subsequent  processing  of 
effector caspase-3, -6 and -7, which thereupon execute cell death (20).    
In contrast, caspase-9 is activated via the intrinsic pathway, which is initiated 
by the release of cytochrome c from the mitochondria in response to reactive 
oxygen  and/or  nitrogen  species,  growth  factor  withdrawal  or  DNA  damage 
(21).  Leakage  of  pro-apoptotic  cytochrome  c  from  mitochondria  is  tightly 
regulated  by  members  of  the  Bcl-2  protein  family.  This  family  subsumes 
proteins with pro- as well as anti-apoptotic properties, which share up to four 
Bcl-2 homology domains (BH1-BH4). The anti-apoptotic members, like Bcl-2, 
Bcl-xL or Mcl-1 share all four domains, whereas the pro-apoptotic ones share 
three (BH1-BH3), like Bax and Bak, or possess only the BH3 domain, like 
Bad, Bid or Bim (22). Bcl-2 family proteins regulate apoptosis mainly through 
formation of heterodimers between pro- and anti-apoptotic members. Thus, 
their  function  may  simply  be  neutralization  of  each  other.  A  shift  of  this 
balance in either direction would then determine the cell’s fate (17). However, 
reality seems to be much more complex. Although oversimplified, one may 
subsume  that  BH3-only  proteins  are  activated  by  intrinsic  death  stimuli, 
thereupon inhibit anti-apoptotic or activate pro-apoptotic Bcl-2 family members 
with  high  specificity,  which  equally  results  in  permeabilization  of  the  outer 
mitochondrial  membrane  (MOMP)  (23).  Cytochrome  c  is  released,  induces 
ATP-dependent  heptamerization  of  usually  monomeric  APAF-1  (apoptotic 
protease activating factor 1), which is then called the apoptosome. Caspase-9 
is recruited to the apoptosome and activated by dimerization, whereupon it 
activates effector caspases (24). Importantly, the intrinsic pathway can also be 
induced by death ligands via caspase-8 dependent cleavage of the BH3-only 
protein Bid, which then induces MOMP (17).  
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Figure 1: Signaling towards apoptosis. The extrinsic pathway is triggered by binding of death 
ligands (DL) to their specific death receptors (DR). Upon activation DRs recruit FADD (Fas-
associated death domain), which binds the pro-form of capase-8 (Casp8) to form the death-
induced signaling complex (DISC). Active caspase-8 may cross-activate the intrinsic pathway, 
which is usually activated by defective growth factor (GF) binding to their receptors (GFR), 
DNA damage or irradiation. Thereby, BH3-only proteins activate pro-apoptotic (Bax/Bak) or 
inhibit  anti-apoptotic  (Bcl-2)  Bcl-2  family  members.  Cytochrome  c  is  released  from  the 
mitochondria,  binds  to  APAF-1  (apoptotic  protease  activating  factor-1),  which  ATP-
dependently forms the apoptosome. The holoenzyme of Caspase-9 (Casp9) is recruited to 
the apoptosome and activated. Caspase-9 and -8 again activate the effector caspases which 
execute apoptosis.   
 
3.1.2  Death in disease 
Apoptosis and disruption of its regulatory mechanisms play an essential role 
for the onset or progression of a large number of human pathologies. Since 
apoptosis serves to maintain tissue homeostasis, its control will be defective 
in diseases where the balance between production of ‘new’ cells and removal 
of dispensable cells is disturbed. The connection to cancer development is 
obvious.  Any  mutation  in  pathways  towards  apoptosis  leading  to  protein Introduction                                                                                                                            9 
malfunction will be beneficial for tumor growth and metastasis, since cancer 
cells have to survive in a potentially hostile environment. Therefore, it is not 
surprising  that  indeed  overexpression  of  anti-apoptotic  proteins  of  the  
Bcl-2  family  is  found  for  instance  in  most  human  lymphomas  (25)  and  is 
associated with poor prognosis in several solid tumors (26). A mutation that 
occurs in more than half of human tumors, is inactivation of p53, the so-called 
‘guardian of the genome’ (27). p53 senses DNA-damage, and as a result it 
up-regulates  and/or  activates  a  number  of  pro-apoptotic  proteins,  including 
Bax (28).  
Disease  may  also  arise  from  excessive  depletion  of  particular  cell  types. 
Maybe the most dramatic case is depletion of CD4
+ T cells by the human 
immunodeficiency virus (HIV), which results in impaired immune functions and 
death  due  to  minor  infections  (29).  Neurodegenerative  diseases  like 
Parkinson’s disease, amyotrophic lateral sclerosis and Huntington’s disease 
also originate at least in part from unusual degeneration of certain neuronal 
subsets (30).   
Another example linking apoptosis to pathology is the maintenance of immune 
tolerance.  Autoimmune  diseases  arise  on  the  one  hand  from  defective 
elimination  of  autoimmune  T  or  B  cells.  Recognition  of  pathogens  by  the 
immune system induces rapid amplification of lymphocyte populations. Once 
the pathogen is destroyed, tissue homeostasis must be restored. Defects in 
apoptosis induction may then lead to autoimmunity (31). On the other hand, 
impaired clearance of AC, which represents a malfunction in the termination of 
cell  death,  will  also  result  in  an  enhanced  immune  response  against  the 
body’s  own  tissues,  since  AC  may  then  function  as  autoantigens  (32). 
Furthermore, efficient interaction of AC with phagocytes is a prerequisite for 
the resolution of inflammation (33). Its disruption may have implications in the 
development  of  pathologies  associated  with  chronic  inflammation,  such  as 
atherosclerosis (34). To understand the impact of interaction between AC and 
phagocytes  in  diseases,  one  has  to  take  a  closer  look  at  the  underlying 
molecular mechanisms.    
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3.2  Phagocytosis of apoptotic cells 
 
Clearance of AC is the last step in the apoptotic machinery and is as neatly 
regulated as its initiation or execution. It can be subdivided into three steps: 
 
I) Attraction of phagocytes to the site of tissue damage. 
 
II) Specific recognition of AC by the phagocytes 
 
III) Engulfment of AC or their fragments by the phagocytes 
 
These steps will be explained in detail in the following paragraphs regarding 
their mechanistic principles (Figure 2).  
 
3.2.1  Attraction 
AC  must  be  removed  in  order  to  avoid  secondary  necrosis.  Obviously,  a 
problem  arises,  since  professional  phagocytes  such  as  macrophages  are 
usually not found in close proximity to the dying cells. Therefore it is rational to 
assume that AC provide molecular signals to direct the phagocyte towards its 
‘meal’. Indeed, two different groups observed the release of chemoattractants 
factors from AC (35, 36).  
Aminoacyl-tRNA  synthetase,  an  enzyme  critical  for  decoding  genetic 
information in translation, is split in two fragments during apoptosis. One of 
them, the endothelial monocytes-activating polypeptide II (EMAP II), is able to 
bind  to  IL-8  receptors  upon  release  from  cells  (36).  IL-8  is  an  important 
mediator of leukocyte infiltration into inflamed tissues. Its action is mimicked 
by EMAP II.  
The  most  detailed  study  concerning  macrophage  migration  towards  AC 
provided a direct connection between the apoptotic machinery and the release 
of a chemotactic lipid agent. A cytosolic calcium-independent phospholipase 
A2 (iPLA2) is activated during apoptosis via cleavage of ankyrin repeats by 
caspase-3.  iPLA2  then  generates  arachidonic  acid  (AA)  and 
lysophosphatidylcholine  (LPC)  by  hydrolysis  of  the membrane  phospholipid Introduction                                                                                                                            11 
phosphatidylcholine (PC). Both lipids are released from AC (35, 37), but only 
the latter induces macrophage migration in vitro and in vivo. Thus, LPC exerts 
some anti-inflammatory property by ensuring efficient AC clearance through 
phagocyte  attraction  (38).  However,  its  direct  impact  on  macrophages  is 
usually considered as pro-inflammatory and linked to inflammatory diseases 
such as atherosclerosis (39). Since interaction of AC and phagocytes induces 
anti-inflammatory signaling in the latter ones, we have to proceed and look 
closer at the next step, the specific recognition of AC. 
 
3.2.2  Recognition 
Phagocytes have to discriminate if the target they encounter is a pathogen, a 
necrotic cell or an apoptotic cell in order to respond properly concerning the 
immunological  outcome.  Therefore,  they  have  to  ‘feel’  their  way  towards 
specific recognition. The most efficient way to distinguish AC from necrotic or 
viable cells is sensing molecular changes at their plasma membranes. These 
apoptotic cell-associated molecular patterns (ACAMPs) are also  called ‘eat 
me’  signals.  In  a  complex  network,  they  are  recognized  by  phagocyte 
receptors, often coupled to bridging molecules, which serve to strengthen their 
recognition (40).    
A  critical  hallmark  of  apoptosis-associated  cell  surface  alterations  is 
externalization  of  the  membrane  phospholipid  phosphatidylserine  (PS)  (41, 
42).  In  viable  cells,  PS  is  restricted  to  the  inner  leaflet  of  the  plasma 
membrane.  This  feature  of  phospholipid  asymmetry  is  secured  by 
aminophospholipid translocase, which ‘flips’ PS back to its proper place when 
it appears at the outer leaflet. During apoptosis, activity of aminophospholipid 
translocase is disrupted, which prevents retraction of PS from the cell surface 
(43).  Additionally,  PS  exposure  is  enhanced  by  caspase-3-dependent 
activation  of  scramblase,  an  enzyme  that  promotes  energy-independent, 
bidirectional scrambling of all classes of phospholipids across the membrane 
(44). More recent studies indicate PS oxidation through oxidized cytochrome c  
prior to exposure as a prerequisite for recognition by phagocytes (45).  
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Figure 2: Phagocytosis of AC. I) During apoptosis, a calcium-independent phospholipase A2 
(iPLA2) is activated via cleavage of ankyrin repeats (AR) by caspase-3 (Casp3), hydrolyses 
phosphatidylcholine (PC) to produce lysoPC (LPC), which is then released and serves as an 
attraction  signal  for  macrophages.  II)  Oxidized  cytochrome  c  (Cyt  c)  is  released  from 
mitochondria in AC, oxidizes phosphatidylserine (PS), which is externalized via scramblase. 
The  bridging  molecules  Gas6  and  milk-fat  globule  epidermal  growth  factor  8  (MFG-E8) 
connect PS to the phagocytic receptors Mer and vitronectin receptor (VnR), respectively. AC 
also  exhibit  other  oxidized  phospholipids  (oxLDL  like  sites)  on  their  surface  that  are 
recognized by macrophage scavenger receptors (SRA, LOX1, CD36). Furthermore, CD31 is 
modified  during  apoptosis,  which  binds  to  CD31  on  the  macrophage  surface,  serving  as 
another recognition signal. Downstream of Mer and/or VnR, the ELMO/DOCK/CrkII complex 
is assembled, which activates the G-protein Rac to induce cytoskeletal rearrangement. Rac 
may also be activated via interaction of ATP binding cassette transporter 1 (ABC1) on AC 
with CD91 on the macrophage. III) After specific tethering, the macrophage’s cytoskeleton is 
rearranged and AC are engulfed via a zipper-like mechanism. 
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Albeit the exact mechanism of PS exposure during apoptosis is still under 
investigation,  it  may  not  be  limited  to  AC.  Necrotic  cell  death,  induced  by 
death ligands, also induces PS externalization in some cell types (46). These 
necrotic  cells  are  then  engulfed  by  macrophages,  but  do  not  induce 
inflammation. Since necrosis may also be ‘physiological’ under these special 
conditions,  PS  may  be  a  more  general  marker  of  physiological  cell  death 
associated with anti-inflammatory signaling. 
Phagocytic receptors bind PS on AC usually via specific bridging molecules 
that  may  be  ubiquitous  or  secreted  from  AC.  The  plasma  factor  b2-
glycoprotein I binds to its specific receptor upon interacting with PS (47). Mer 
kinase receptor recognition of PS is mediated via ambilateral GAS6 binding 
and the milk-fat globule epidermal growth factor 8 (MGF-E8) connects PS to 
the vitronectin receptor (VnR) (48). Much attention was given to a receptor 
specific for PS without requisition of a bridging molecule (49). Nevertheless, 
recent  work  suggests  that  this  putative  PS  receptor  is  dispensable  for 
interaction of phagocytes with AC (50).  
Numerous  other  receptors  on  macrophages  participate  in  AC  recognition. 
Most  are  known  from  other  conditions  when  the  macrophages  dinner  is 
served,  which  are  engulfment  of  pathogens  or  recognition  of  oxidized 
lipoproteins (oxLDL). Among them are the scavenger receptors CD36 (51), 
scavenger receptor A (SRA) (52) or oxidized low-density lipoprotein receptor 1 
(LOX1)  (53),  which  recognize  oxidized  phospholipids,  so-called  oxLDL  like 
sites on AC. Furthermore, receptors necessary for pathogen recognition, like 
integrin receptors, complement receptors or Fc receptors are involved (40).  
Another interesting alteration of surface structures on AC is modification of 
CD31. Its expression on viable cells serves as a detachment or ‘don’t eat me’ 
signal via homophilic interaction with macrophage CD31 (54). Disruption of 
this interaction marks cells as suitable targets for phagocytosis. 
 
3.2.3  Removal 
Naturally,  signaling  pathways  towards  engulfment  should  emerge  from  the 
‘eat  me’  signal/macrophage  receptor  interactions  mentioned  above.  They 
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like’  ingestion  process.  Therefore,  phagocytic  receptors  must  be  linked 
mechanistically  to  the  phagocyte’s  actin  filaments.  Unfortunately,  no  direct 
connection could be uncovered by now.  
Two  distinct  signaling  modules  mediating  engulfment  were  identified  by 
genetic  studies  of  phagocytosis  defective  mutants  in  the  worm  C.  elegans 
(55). The proteins forming these complexes have mammalian homologues, 
whose functional properties in phagocytosis of AC were confirmed lately (56).  
One  complex  consisting  of  CrkII,  ELMO  and  DOCK180  is  recruited  to  the 
plasma membrane in nascent phagosomes, serving as a guanine nucleotide 
exchange factor (GEF) for the G-protein Rac1, which then induces changes in 
the  phagocytes  cytoskeleton  (48).  The  Crk-ELMO-DOCK180  complex  is 
possibly activated downstream of VnR (57) or Mer (48) interactions with PS 
on AC, but the exact mechanisms in the context of AC removal remain to be 
elucidated.   
Rac1 activation can also be achieved via activation of GULP, which possibly 
transmits signals downstream of the interaction between ABC1 on AC and 
CD91  on  the  phagocyte’s  membrane  (56).  However,  definite  mechanistic 
studies are still outstanding. This may be partially described to the numerous 
observations relating most of the immunomodulatory effects of AC to ligation 
of  ‘eat  me’  signals  with  phagocytic  receptors,  rather  then  to  the  uptake 
process  per  se.  To  understand  the  impact  of  AC  on  the  macrophage’s 
behavior regarding inflammation, we first have to scrutinize the principles of 
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3.3  Macrophage polarization 
 
Macrophages are part of the body’s innate immune system, the first defense 
line against invading pathogens. They originate from myeloid progenitor cells 
in the bone marrow, which differentiate into monocytes dependent on lineage-
determining  cytokines  like  GM-CSF  (granulocyte  macrophage-colony 
stimulating factor).  
Monocytes are able to surpass the border separating the bone marrow from 
the  blood  stream  and  enter  into  the  latter  one.  Allured  by  an  appropriate 
stimulus, they migrate into different tissues, where they differentiate into tissue 
macrophages under the influence of growth factors like GM-CSF or M-CSF 
(macrophage-colony stimulating factor). There, by changing their morphology 
and  metabolism,  they  acquire  special  features,  depending  on  the  micro-
environment of the respective tissue (58). 
  
3.3.1  Macrophage phenotypes 
Macrophages exhibit high plasticity in their functional responses, which means 
they express different phenotypes in response to micro-environmental signals. 
Their major task is modulation of inflammation, both regarding its initiation and 
its resolution. 
In  1794,  the  surgeon  John  Hunter  defined  inflammation  as  a  salutary 
operation proximate to violence or disease. This crucial insight implicates that 
inflammation, rather than being a disease in itself, usually serves to eliminate 
the sources of disease, followed by implicit resolution and tissue repair (33).  
Inflammation is characterized by the rapid influx of inflammatory cells, such as 
neutrophils, lymphocytes and monocytes.  
The monocytes mature into inflammatory macrophages triggered by microbial 
cell  wall  components  like  lipopolysacharide  (LPS)  and  T  helper  1  (TH1) 
lymphocyte-derived  interferon  (IFN)-γ.  Such  ‘classically  activated’ 
macrophages produce cytotoxic mediators like nitric oxide (NO), superoxide 
(O2
-)  and  TNF-α,  as  well  as  a  variety  of  pro-inflammatory  cytokines  and 
chemokines (59), which mediate killing of pathogens, but also of surrounding  Introduction                                                                                                                            16 
 
 
 
Figure  3:  The  M-Phenotypes.  M1  polarization  is  induced  via  lipopolysacharide  (LPS)  and 
interferon (IFN)-γ. M1 macrophages produce tumor necrosis factor (TNF)-α, interleukins (IL)-1 
and  -12,  as  well  as  cytotoxic  nitric  oxide  (NO)  via  inducible  NO-Synthase  (iNOS)  and 
superoxide  (O2
-).  They  present  antigens  via  major  histocompatibility  complex  II  (MHC  II). 
Three  distinct  M2  phenotypes  are  known.  M2a  is  induced  by  interleukins  (IL)-4  and  -13, 
characterized  by  up-regulation  of  the  arginase  pathway  with  concomitant  polyamine 
production, release of IL-1 receptor antagonist (IL-1ra) and IL-10 and exhibition of MHC II, the 
mannose receptor (MR) and scavenger receptors (SR). M2b polarization is mediated by toll-
like receptor ligands (TLRL) and IL-1 receptor ligands (IL-1RL), accompanied with TNF-α, IL-1 
and IL-10 release as well as MHC II expression. The M2c phenotype is induced by IL-10, 
characterized by arginase induction, IL-10 and transforming growth factor (TGF)-β release, 
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resident tissue cells and other immune cells. Although excess resident cell 
destruction may end in failure of organ function (60), induction of apoptosis 
during inflammation usually determines its end.  
First, pro-inflammatory reactions are terminated by death of immune cells like 
neutrophils and lymphocytes, and second by recognition and removal of the 
apoptotic  debris  by  macrophages.  After  AC  recognition  the  previous  ‘killer’ 
macrophages actively contribute to healing by releasing growth factors, anti-
inflammatory  cytokines  like  IL-10  and  TGF-β,  pro-angiogenic  and  matrix-
remodeling factors, and suppress O2
- as well as NO formation (61). These 
‘healer’  macrophages  were  often  classified  as  ‘de-activated’,  which  is 
apparently  inexact.  It  may  be  owed  to  the  fact  that  the  term  ‘alternatively 
activated’  macrophage  was  given  away  earlier  (62).  Usually,  alternative 
activation is defined as T helper 2 (TH2) lymphocyte mediated stimulation of 
macrophages  with  IL-4,  IL-10  or  IL-13,  which  occurs  during  i.e.  allergic 
responses,  and  dampens  O2
-  release,  blocks  NO  production  via  arginase 
expression, enhances IL-10 generation and induces expression of scavenger 
receptors (59).  
Since several macrophage phenotypes apart from the ‘classically activated’ 
are known, which could all be termed ‘alternatively activated’, I prefer to use 
the  classification  introduced  by  Alberto  Mantovani,  who  denominated 
‘classically  activated’  macrophages  as  M1  and  otherwise  polarized 
macrophages as M2 (63). An overview of the different faces of macrophage 
activation  is  given  in  Figure  3,  especially  regarding  the  distinct  M2 
phenotypes.   
 
3.3.2  Macrophage polarization by apoptotic cells 
During the last decade, plenty of evidence was provided that AC modulate 
innate immune responses aside from simply being removed (Figure 4). One of 
the first studies reported down-regulation of TNF-α and IL-1β, as well as up-
regulation  of  IL-10  in  co-cultures  of  human  monocytes  with  AC  after 
stimulation with LPS (64). Later, an AC-mediated anti-inflammatory phenotype 
was confirmed for human macrophages. This phenotype was characterized by 
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platelet-activating  factor  (PAF),  which  again  prevented  LPS-induced  pro-
inflammatory  cytokine  production  (65).  Strong  supporting  argumentation 
emerged  from  studies  in  CD14  knockout  mice  (66).  In  this  model, 
phagocytosis  of  AC  was  blocked,  but  neither  TGF-β  production  nor  down-
regulation  of  TNF-α  was  affected.  Although  AC  remained  persistent,  the 
resolution of inflammation was unimpaired, unlinking it from the process of 
clearance. However, mechanistic details how AC modulate the macrophage 
phenotype are ill defined. 
Since recognition of externalized PS is a prominent feature of macrophage/AC 
interaction,  many  studies  investigated  its  impact  in  immunomodulation, 
unfortunately with special emphasis on the role of the putative PS receptor 
(PSR).  PS  recognition  by  PSR  was  mechanistically  connected  with  TGF-β 
production (49). Additionally, a pro-inflammatory phenotype was observed in 
PSR knock-out mice (67, 68). Recent reports disagreed with the assumption 
that the putative PSR participates in AC-mediated immune regulation (50, 69, 
70), therefore this topic remains contradictory. However, other macrophage 
receptors recognizing PS, such as VnR or Mer might be relevant. 
Studies in Mer-deficient mice revealed its importance in AC clearance (71, 
72).  Indeed,  Mer  deficiency  in  macrophages  revealed  a  pronounced  pro-
inflammatory  phenotype,  although  in  a  model  unrelated  to  AC  recognition 
(73).  More  evidence  is  given  for  the  VnR.  A  mutant  form  of  MGF-E8,  the 
bridging  molecule  that  links  PS  to  VnR,  inhibited  IL-10  production  by 
macrophages (74). Along that line, inhibition of VnR on murine macrophages 
reduced  TGF-β  and  PGE2  production  in  response  to  AC  (75).  PGE2 
production was diminished by pharmacological inhibition of cyclooxygenase 
(COX)-2,  the  rate  limiting  enzyme  in  PGE2  production  (65).  Therefore  one 
may suggest COX-2 induction by AC via VnR. The authors went on and linked 
VnR-dependent  TGF-β  production  to  reduced  NO  generation  in  LPS-
stimulated  macrophages,  thus  providing  evidence  that  AC  interfere  with 
macrophage cytotoxicity. Unfortunately, in another study, PS-enriched Jurkat 
cells  did  not  show  prevention  of  LPS-induced  NO  generation,  although 
apoptotic  Jurkat  cells  actively  did.  Therefore,  one  must  conclude  that  PS 
exposure alone is insufficient in down-regulating NO production (76). Taking 
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one  must  suggest  that  factors  other  than  TGF-β  account  for  inhibition  of 
macrophage NO-production.  
Beside  NO,  macrophages  produce  reactive  oxygen  species  (ROS)  to  kill 
pathogens. ROS generation was inhibited by PS-enriched Jurkat cells (76) as 
well as AC in LPS-stimulated murine macrophages (77). In macrophages, AC 
provoked  rapid  activation  of  the  immunoregulatory  transcription  factor 
peroxisome  proliferator-activated  receptor  (PPAR)-γ.  PPAR-γ  prevented 
protein kinase C (PKC)-α-mediated activation of NADPH-oxidase, a protein 
complex, which is crucial for ROS induction (77). Although a potential role of 
PS in affecting PPAR-γ remains unclear, it is intriguing to speculate on the 
involvement of PPAR-γ in AC-mediated immunomodulation (78).  
Recently, the group of Ucker showed that LPS-induced nuclear factor (NF)-κB 
activation was impaired in macrophages that had recognized AC (79). NF-κB 
inhibition partly is a rational explanation for macrophage polarization by AC, 
since  it  is  the  most  prominent  pro-inflammatory  transcription  factor  in 
macrophages (80). However, considering that contact of macrophages with 
AC provokes active anti-inflammatory signaling rather than de-activation, NF-
κB inhibition alone is insufficient to explain their phenotype transition. Indeed, 
anti-inflammatory signaling per se was unrelated to NF-κB, thus arguing for 
additional transcriptional modulator systems under the control of AC (81). As 
an explanation for NF-κB inhibition, depletion of transcriptional co-activators 
was suggested (79). Interestingly, this is an established function of PPARs 
(82), thus putting PPAR-γ into focus once more.  
The  direct  interaction  between  macrophages  and  AC  appears  multifaceted 
and  yet  another  level  of  complexity  is  added  by  findings  that  AC  secrete 
soluble, potentially immunomodulatory factors. Chen et al. observed TGF-β 
release  from  apoptotic  T-cells,  which  repressed  LPS-mediated  TNF-α 
production in murine macrophages (83). This is interesting, since most studies 
did  not  identify  the  origin  of  TGF-β  production,  with  their  approach  of 
discriminating whether binding and/or phagocytosis of AC was necessary for 
TGF-β  release.  In  addition,  evidence  emerged  that  IL-10  and  IL-4  are 
released from AC (84, 85).  
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Figure  4:  Macrophage  polarization  by  AC.  AC  release  lysophosphatidylcholine  (LPC), 
transforming growth factor (TGF)-β and interleukin (IL)-10 and  express phosphatidylserine 
(PS) on their surface. Bridging of PS to the vitronectin receptor (VnR) via milk-fat globule 
epidermal  growth  factor  8  (MFG-E8)  is  associated  with  TGF-β  and  IL-10  release  from 
macrophages,  suppression  of  lipopolysacharide  (LPS)/interferon  (IFN)-γ  induced  tumor 
necrosis factor (TNF)-α and IL-1β production and shedding of prostaglandin (PG) E2, possibly 
via cyclooxygenase (COX)-2 induction. PS externalization may also activate the peroxisome 
proliferator-activated  receptor  (PPAR)-γ,  which  inhibits  protein  kinase  (PK)  Cα  induced 
NADPH-oxidase  assembly  and  subsequent  reactive  oxygen  species  (ROS)  production. 
PPAR-γ is able to inhibit nuclear factor (NF)-κB DNA transcriptional activity by scavenging its 
cofactor  p300,  which  may  also  occur  in  macrophages  after  AC-interaction.  Moreover, 
macrophages  release  platelet  activating  factor  (PAF)  after  encounter  of  AC,  although 
mechanistic details are unclear. Mer kinase, coupled to PS via Gas6, may further be capable 
of suppressing pro-inflammatory responses. The same is true for TGF-β and IL-10, which 
may bind to their specific receptors on the macrophage surface. Speculative mechanisms are 
marked with ‘?’.   
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Besides IL-10 and TGF-β as protein factors, also lipid mediators are secreted 
during  apoptosis.  As  mentioned  under  paragraph  3.2.1,  LPC  and  AA  are 
generated by caspase-3 dependent cleavage. Discussing a putative role of  
LPC  in  macrophage  polarization,  it  is  interesting  that  immunosuppressive 
properties of AC rather are caspase-3 independent, since caspase-3 deficient 
MCF-7 breast cancer cells effectively acted immunosuppressive (86).  
Although an immune regulatory function of AC is now generally accepted, the 
discussion  of  underlying  molecular  pathways  remains  heterogeneous.  A 
precise definition of the type of macrophage/AC interaction that affects the 
anti-inflammatory  responses  elicited  during  cell  demise  is  needed  to 
understand,  and  finally  interfere  with,  its  contribution  to  human  diseases. 
However, there might be no single molecular switch that controls the pro- vs. 
anti-inflammatory  phenotype,  because  physiological  cell  death  obviously 
provides  a  variety  of  signaling  patterns  that  can  be  recognized  by 
macrophages.  
 
3.3.3  Macrophages in cancer development 
In  the  19
th  century,  Rudolf  Virchow,  the  founder  of  cellular  pathology, 
observed  the  presence  of  leukocytes  in  human  tumors  using  the  newly 
discovered technique of microscopy. He connected the infiltration of immune 
cells with cancer progression, suggesting that cancer emerged from chronic 
irritation. Although this observation sank into oblivion for about a century, the 
consequences of immune cell infiltration into tumors were put into perspective 
again in recent years.  
Macrophages  are  a  major  cellular  constituent  of  the  leukocyte  infiltrate  of 
tumors  (87).  In breast  cancer, TAM may  even  comprise up  to  50%  of  the 
tumor  mass  (88).  The  presence  of  tumor-associated  macrophages  (TAM) 
correlates with a poor survival prognosis for patients with solid human tumors, 
especially in breast, prostate, ovarian and cervical cancer (89). TAM acquire 
complex  functions  in  their  interactions  with  neoplastic  cells  and  multiple 
evidence  suggests  that  they  are  part  of  the  program  that  promotes  tumor 
growth and progression (90).  
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they  show  reduced  capacity  in  the  production  of  anti-tumor  molecules  like 
TNF-α or NO. Contrarily, TAM support tumor survival, growth, metastasis and 
seem to play a major role in tumor angiogenesis and immune evasion (90-92). 
Especially in breast cancer development, the pro-angiogenic property of TAM 
was  highlighted.  When  macrophage  infiltration  into  breast  tumors  was 
abolished  in  a  mouse  model,  tumor  development  was  delayed  due  to 
inaccurate  vascular  development,  which  usually  is  a  prerequisite  for  tumor 
malignancy  (93).  Furthermore,  macrophage  infiltration  was  positively 
correlated  with  high  tumor  blood  vessel  density,  and  the  presence  of  pro-
angiogenic cytokines like vascular endothelial growth factor (VEGF), IL-8 and 
TGF-α (94).     
TAM  polarization  seems  to  represent  the  composition  of  the  surrounding 
tumor microenvironment. Tumor-derived molecules such as IL-4, IL-10, TGF-
β, PGE2 and chemokines, as well as tumor hypoxia are held responsible for 
TAM  generation  (87,  90,  95).  Recently,  another  concept  of  tumor-induced 
macrophage  polarization  was  introduced.  Administration  of  apoptotic  tumor 
cells  reduced  macrophage  cytotoxicity  against  vital  tumor  cells  (96). 
Furthermore, disruption of AC recognition by macrophages or dendritic cells in 
vivo  induced  tumor  regression  (97).  Interestingly,  TAM  share  several 
activation  patterns  with  AC-stimulated  macrophages.  They  express  low  of 
amounts of the pro-inflammatory cytokines TNF-α, IL-12p70, IL-1β and IL-6 
when stimulated with LPS, probably due to defective NF-κB signaling, but high 
amounts of IL-10 or TGF-β (98). Therefore it is tempting to speculate, that 
tumors  utilize  the  physiological  role  of  macrophages  in  the  resolution  of 
inflammation  associated  with  tissue  repair  and  angiogenesis,  by  providing 
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3.4  Sphingosine-1-phosphate 
 
Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator, i.e. a lipid that 
plays  a  role  in  cellular  signaling  rather  than  being  simply  a  component  of 
cellular  membranes  or  a  means  to  store  energy.  Its  intracellular 
concentrations are always low, whereas in plasma it can reach concentrations 
of 0.2 to 0.9 µM, usually bound to lipoproteins.  
S1P  is  found  far  downstream  in  the  pathway  of  sphingolipid  metabolism 
(Figure  5).  De  novo  synthesis  of  sphingolipids  occurs  by  condensation  of 
serine and palmitoyl-CoA to form 3-ketosphinganine which is then converted 
into ceramide via multiple catalytical steps. Ceramide can also be released via 
hydrolysis  of  membrane  sphingomyelin  by  sphingomyelinases,  and  is 
subsequently  deacylated  by  ceramidases  to  sphingosine.  Sphingosine  and 
other  sphingoid  bases  can  be  phosphorylated  by  sphingosine  kinases 
(SphKs)  to  form  S1P.  Turnover  of  S1P  is  mediated  either  by  reversible 
dephosphorylation to sphingosine by specific S1P phosphohydrolases (SPPs) 
or by irreversible cleavage by S1P lyase (SPL) (99).  
S1P was originally defined as a second messenger with intracellular activity. 
Although no direct intracellular target for S1P was identified up to date, this 
view is still supported by several studies. The cellular balance between pro-
apoptotic ceramide/sphingosine and anti-apoptotic S1P seems to be critical to 
determine cell viability. Furthermore, S1P is activated by growth factors like 
VEGF  and  mediates  intracellular  signaling  via  mitogen-activated  protein 
kinases (MAPK) or calcium (Ca
2+) currents (100). In a similar fashion, TNF-α 
induces S1P, which in turn activates NF-κB (101).    
New roads were opened by the identification of a family of five G protein- 
coupled receptors specific for S1P (S1PR1-5) in higher organisms. S1P binds 
to its receptors with affinities ranging from 2 nM to 63 nM (102). Coupling of 
S1P to its specific receptors is important for the growth of new blood vessels, 
vascular  maturation,  cardiac  development,  directed  cell  movement  and 
immunity  (103).  Its  importance  was  supported  by  S1PR  knock-out  studies, 
which revealed severe developmental vascular defects, resulting in prenatal 
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activated downstream of S1PRs read like the ‘who-is-who’ in cellular signaling 
(Figure 5). 
 
 
 
 
Figure 5: Production and actions of sphingosine-1-phosphate. S1P may be synthesized de 
novo  via  condensation  of  serine  and  palmitoyl-CoA,  or  by  sphingomyelinase  (SMase)-
mediated  hydrolysis  of  sphingomyelin  to  ceramide.  Ceramide  can  be  reconverted  to 
sphingomyelin by sphingomyelin synthase (SMSyn). Ceramidases (CDase) convert ceramide 
into sphingosine, whereas the reverse reaction is catalyzed by ceramide synthase (CDSyn). 
Sphingosine  is  phosphorylated  by  sphingosine  kinases  (SphK)  to  S1P.  S1P  degradation 
occurs  via  reconversion  to  sphingosine  by  S1P  phosphohydrolase  (SPP)  or  irreversible 
degradation by S1P lyase (SPL). S1P is exported from cells by ATP binding cassette (ABC) 
transporters, where it binds to its five specific receptors (S1PR1-5). Downstream of S1PRs, 
many  cellular  signaling  pathways  are  activated,  either  directly  or  via  G-proteins  (Gi,  Gq, 
G12/13).  Among  these  are  pathways  mediated  by  phospholipase  C  (PLC),  Rac,  p38, 
extracellular signal-regulated kinases (ERK), phosphatidylinositol-3 kinase (PI3K), Rho, jun N-
terminal kinase (JNK), or adenylyl cyclase (AC).   
 
Although considerable amount of data concerning S1P related signaling have 
been obtained, mechanistic explanation how S1P, after being produced inside 
cells, surmounts the plasma membrane to bind to its specific receptors in an 
autocrine or paracrine fashion are limited. Once activated, SphK1 translocates 
and binds to the plasma membrane, a process bringing S1P in close proximity 
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transporters facilitate the release of S1P from mast cells (105) and platelets 
(106).  Alternatively,  a  splice  variant  of  SphK1  (SphK1a),  is  exported  from 
cells, provoking extracellular production of S1P, which contributes to the high 
vascular S1P concentration observed in mice (107). 
 
3.4.1  Sphingosine kinases 
S1P is produced by phosphorylation of sphingosine by sphingosine kinases, 
an  enzyme  family  consisting  of  two  isoenzymes,  SphK1  and  2,  which, 
although facilitating the same reaction, may have distinct or even antithetic 
biological  virtues  (108).  Sphingosine  kinases  are  conserved  across  most 
eukaryotic organisms. They contain five conserved domains termed C1 to 5 
(Figure  6).  The  C1-C3  domains  comprise  the  putative  catalytic  domain  of 
SphKs, with the C2 domain containing the ATP binding site. In the C4 domain, 
which  is  unique  for  SphKs,  resides  the  sphingosine  binding  site  (109).  In 
humans,  alternative  splice  variants for  both  enzymes  have  been  described 
recently (107, 110). For SphK1 three proteins (SphK1a to c), consisting of 
384,  398  and  470  amino  acids  are  known,  whereas  the  two  SphK2 
isoenzymes  (SphK2S  and  L)  consist  of  618  and  654  amino  acids  (111). 
SphK2 diverges from SphK1 in its central region and has an elongated amino 
terminus.  Although  single  knock-out  mice  have  no  unusual  phenotype, 
SphK1/SphK2 double knock-out is lethal, due to defects in neurogenesis and 
angiogenesis as well as increased apoptosis (112). This means that SphKs, 
also  often  unlike  in  their  function,  may  compensate  for  each  other  during 
development.  
SphKs exhibit different kinetic properties and also have dissimilar expression 
profiles during development as well as in tissues (113). They differ in their 
substrate specificity, where special attention has been paid to the property of 
SphK2  to  phosphorylate  the  immunomodulatory  sphingosine  analogue 
FTY720 (114, 115). Phosphorylated FTY720 is an agonist for S1PRs, where it 
either mimics S1P responses or induces their down-regulation upon activation 
(116).  S1PR1  down-regulation  inhibits  lymphocyte  migration  towards  S1P 
gradients,  which  may  be  critical  for  prevention  of  immune  responses  to 
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SphKs, but is a competitive inhibitor of SphK1 and a noncompetitive one of 
SphK2  (117).  Last,  SphKs  react  in  opposite  ways  to  increasing  salt 
concentrations,  addition  of  detergents  and  serum  proteins  like  BSA  (117). 
Both SphKs are activated by anionic phospholipids, especially PS, although 
mechanistic explanations are limited.  
SphKs vary not only in their responses to their biochemical ambiance, but also 
in terms of activation and the congruent physiological functions. A good deal 
of data is available dealing with the activation of SphK1, but substantially less 
is  known  for  SphK2.  Indeed,  most  of  the  functions  of  S1P  listed  in  the 
previous paragraph were attributed to SphK1 activity (113). In the following, I 
will  focus  on  regulation  of  apoptosis,  where  the  opposing  roles  of  the  two 
SphK isoforms are most prominent (Figure 6). 
Many studies in various cell types observed that overexpression of SphK1 and 
thus increased S1P production promotes cell growth (118). SphK1 accounts 
for  the  elevated  levels  of  S1P  downstream  to  growth  factor  signaling, 
transmitting  their  pro-proliferative  and  anti-apoptotic  functions.  S1P  formed 
such  a  like  may  furthermore  inhibit  ceramide  synthesis,  shifting  the 
ceramide/S1P balance, i.e. apoptosis or survival, further in the direction of 
S1P and survival (108). Inversely, efficient apoptosis induction may require 
SphK1 degradation. TNF-α or DNA damage induce SphK1 cleavage by the 
p53  driven  activation  of  cystein  protease  cathepsin  B,  which  leads  to  a 
decrease  in  intracellular  levels  of  S1P  (119).  In  sharp  contrast,  SphK2 
overexpression suppresses cell growth by inhibition of DNA synthesis directly 
via  its  nuclear  localization  (120).  Furthermore  it  induces  apoptosis  through 
cytochrome  c  release  and  caspase-3  activation,  which  is  surprising,  since 
both SphK isoforms catalyze the same reaction. One possible mechanism for 
SphK2-dependent  apoptosis  was  revealed,  when  a  BH3  domain  was 
identified  in  its  amino  acid  sequence  (121).  SphK2,  like  other  BH3-only 
proteins, physically interacts with an anti-apoptotic Bcl-2 family protein, in this 
case Bcl-xL, and thus may induce apoptosis as described in chapter 1.1.2. 
Nevertheless, disruption of SphK2 interaction with Bcl-xL only partly reduced 
its apoptosis-inducing capability (108).  
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Figure 6: Sphingosine kinases and their different functions in apoptosis. Sphingosine kinases 
(SphK) contain five conserved domains (C1-5), with an ATP binding site residing in C2, the 
sphingosine binding site in C4 and a calcium/calmodulin binding site (Ca
2+). Compared to 
SphK1, SphK2 is elongated at its N-terminus (containing a nuclear localization signal (NLS)) 
and between C4 and C5. SphK1 is phosphorylated by extracellular signal-regulated kinases 
(ERK)  upon  binding  of  growth  factors  (GF)  to  their  receptors,  translocates  to  the  plasma 
membrane where it phosphorylates sphingosine to sphingosine-1-phosphate (S1P). S1P is 
externalized, binds to its receptors (S1PR) to induce survival. During apoptosis, DNA damage 
leads to activation of cathepsin B via p53, which cleaves SphK1, thereby terminating its pro-
survival properties. SphK2 translocates to the endoplasmatic reticulum (ER), produces S1P, 
which  is  reconverted  to  sphingosine  by  S1P  phosphohydrolase  (SPP).  Pro-apoptotic 
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The proposed mechanism was that SphK2 and S1P phosphohydrolase act in 
concert with ceramide synthase at the ER to convert recently produced S1P 
back to sphingosine, and subsequently to ceramide. Therefore, the differential 
virtues of SphKs and S1P production during apoptosis may depend on their 
subcellular localization.       
 
3.4.2  Sphingosine-1-phosphate and cancer 
As outlined in chapter 1.1.3, tumor cells are notorious for being opportunistic 
in utilizing all possible means to escape from physiological cell death. Given 
the importance of S1P in this regard, it is not surprising that several mutations 
interfering  with  its  bioregulation  were  found  in  tumors.  Over-expression  of 
SphK1  as  well  as  reduced  expression  of  S1P-Lyase  has  been  reported 
recently. In accordance, down-regulation of SphK1 in cancer cells reduced 
growth and enhanced chemosensitivity (122). This raises the possibility that 
SphK1 is an oncogene, and represents a suitable target for chemotherapy. 
Furthermore, both SphK isoforms promote migration of cancer cells towards 
growth factors, indicating implications in cancer metastasis (123, 124).  
The  most  direct  evidence  implicating  S1P  in  tumorigenesis  emerged  from 
studies investigating its effects on tumor angiogenesis. A monoclonal antibody 
directed  against  S1P  itself,  induced  substantial  retardation  of  tumor 
progression in nude mice xenografted with human breast, ovarian and lung 
cancer  cells  (125).  Furthermore,  the  antibody  neutralized  S1P-stimulated 
release  of  pro-angiogenic  cytokines  like  vascular  endothelial  growth  factor 
(VEGF) and IL-8, as well as VEGF-induced angiogenesis in vivo. Although an 
antibody against S1P might be interesting regarding cancer therapy, its action 
surely  will  be  broadly  unspecific.  More  specific  solutions  will  be  targeting 
specific S1PRs on the cellular surface. Interestingly, FTY720 reduced primary 
and metastatic tumor growth in a mouse model by internalization of S1PRs 
(126).  Additionally,  or  as  a  prerequisite,  it  inhibited  tumor-associated 
angiogenesis  and  increased  tumor  cell  apoptosis.  Taken  together,  highly 
significant evidence links S1P to tumor growth and angiogenesis. It will be 
beneficial to understand exactly, how S1P is produced in tumors, and how it 
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identification  of  drugable  targets  in  the  S1P  pathway,  leading  to  the 
development of new anticancer pharmaceuticals. 
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3.5  Aims of this study 
 
Cells  entering  the  route  of  programmed  cell  death  are  recognized  and 
removed  by  professional  phagocytes.  The  uptake  of  AC  prior  to  cell 
membrane disintegration, averts an inflammatory response in the surrounding 
tissue  by  preventing  contact  of  neighboring  cells  with  cellular  constituents 
derived from secondary necrosis. During the last decade, it became apparent 
that suppression of inflammation is an intrinsic feature of apoptotic cell death, 
achieved  furthermore  via  induction  of  an  anti-inflammatory  phenotype  in 
macrophages. Such a macrophage phenotype, also termed M2 polarized, is 
observed  as  well  in  several  solid  human  tumors.  Detailed  information 
regarding alternative macrophage activation and its induction by AC is needed 
to understand how inflammation is regulated. Since this phenomenon may be 
utilized by human tumors, mechanistic insights will provide targets for tumor 
therapy. 
The  first  part  of  my  studies  dealt  with  the  question  whether  macrophage 
survival  is  influenced  by  AC.  The  phenotype  alterations  in  macrophages 
regarding this topic, as well as the level of interaction between macrophages 
and AC required to modify macrophage survival, were investigated.  
Macrophage  survival  was  induced  by  liberation  of  S1P  from  AC.  Thus  I 
performed  experiments  to  elucidate  the  underlying  mechanistic  principles. 
More specifically, I questioned whether classical signals elicited during cell 
death, such as caspase activation or PS exposure participated in this process. 
To  determine  a  connection  between  development  of  the  macrophage 
phenotype observed in tumors and tumor cell death, I designed a co-culture 
system of human macrophages with different tumor cell lines. I asked whether 
macrophages were capable of inducing tumor cell death, and whether this 
would  then  induce  M2  polarization.  Again, a  special focus  was  put  on  the 
responsible macrophage/AC interaction.  
After exploring the mechanisms that enabled apoptotic tumor cells to induce 
alternative  macrophage  polarization,  I  planned  to  validate  these  principal 
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Thus,  the  aims  of  this  study  were  to  identify  new  characteristics  of  AC-
dependent macrophage polarization. Since macrophage activation by AC is 
very controversially discussed at present, especially concerning the required 
signals  provided  by  AC,  my  studies  attempted  to  provide  respective  new 
mechanistic insights. Furthermore, I was interested in investigating whether 
there was a connection between tumor cell death and pro-tumor macrophage 
polarization. Again, insights in mechanisms how AC polarize macrophages, 
will be critical in order to develop therapeutic strategies for the treatment of 
human diseases depending on inflammation and/or apoptosis.   
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4  Materials and Methods  
 
4.1  Materials 
4.1.1  Chemicals and Reagents 
 
All chemicals were of the highest grade of purity commercially available. 
 
3,3'-Dihexyloxacarbocyanine iodide 
(DiOC6(3)) 
Molecular Probes, Leiden (Netherlands) 
 
4´,6-Diamidino-2-Phenylindol (DAPI)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
40% Acrylamide/Bis-acrylamide (37.5% : 
1.0% w/v)  
Roth GmbH, Karlsruhe 
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-
benzimidazolylcarbocyanine chloride 
(JC-1) 
Biomol GmbH, Hamburg 
Accutase  PAA Laboratories GmbH, Cölbe 
Adenosine triphosphate (ATP)  Roche Diagnostics GmbH, Mannheim 
Agar-Agar  Roth GmbH, Karlsruhe 
Agarose  peqLab Biotechnologie GmbH, Erlangen 
Ammonium chloride (NH4Cl)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Ammonium persulfate (APS)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Ampicillin  Biomol GmbH, Hamburg 
Blocking buffer  Rockland Immunochemicals Inc, Gilberts-
ville (USA) 
Bovine Serum Albumin (BSA)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Brome phenol blue  Fluka GmbH, Buchs 
Capase-3 substrate (Ac-DEVD-AMC)  Alexis Biochemicals, Grünberg 
CHAPS  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Chloroform  Merk Eurolab GmbH, Darmstadt 
Dimethylsulfoxide (DMSO)   Roth GmbH, Karlsruhe 
Dithiothreitole (DTT)   Roth GmbH, Karlsruhe 
Ethanol   Roth GmbH, Karlsruhe 
Ethylene diamine tetra acetate (EDTA)   Sigma-Aldrich Chemie GmbH, Deisenhofen 
Ethylene glycol tetra acetate (EGTA)   Sigma-Aldrich Chemie GmbH, Deisenhofen 
Geneticindisulfate (G418)  Roth GmbH, Karlsruhe 
Glucose  Roth GmbH, Karlsruhe Materials and Methods                                                                                                             33                                 
Glycerol  Roth GmbH, Karlsruhe 
Glycine   Serva GmbH, Heidelberg 
HEPES   Roth GmbH, Karlsruhe 
Isopropanol   Merck EuroLab GmbH, Darmstadt 
LB-Broth (Lennox)   Roth GmbH, Karlsruhe 
L-glutamine   PAA Laboratories GmbH, Cölbe 
Lymphocyte separation medium (Ficoll)  PAA Laboratories GmbH, Cölbe 
Magnesium chloride (MgCl2)  Roth GmbH, Karlsruhe 
Magnesium sulfate (MgSO4)  Roth GmbH, Karlsruhe 
Methanol (MeOH)   Roth GmbH, Karlsruhe 
Milk powder  Merck EuroLab GmbH, Darmstadt 
Neomycin (G 418)  PAA Laboratories GmbH, Cölbe 
Nonidet P-40   ICN Biomedicals GmbH, Eschwege 
Omega(7-nitro-2-1,3-benzoxadiazol-4-
yl)-D-erythro-Sphingosine (NBD-
Sphingosine) 
Avanti Polar Lipids, Alabaster (USA) 
Paraformaldehyde (PFA)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Phenylmethylsulphonylfluoride (PMSF)   Sigma-Aldrich Chemie GmbH, Deisenhofen 
poly(dI-dC)  Pharmacia, Uppsala (Sweden)  
Potassium chloride (KCl)   Merck EuroLab GmbH, Darmstadt 
Potassium hydrogen carbonate (KHCO3)   Merck EuroLab GmbH, Darmstadt 
Potassium hydrogen phosphate 
(KH2PO4)  
Merck EuroLab GmbH, Darmstadt 
Protease inhibitor mix   Roche Diagnostics GmbH, Mannheim 
Roti®-Fect  Roth GmbH, Karlsruhe 
Semicarbazide    Sigma-Aldrich Chemie GmbH, Deisenhofen 
Sodium borate   Merck EuroLab GmbH, Darmstadt 
Sodium chloride (NaCl)   Merck EuroLab GmbH, Darmstadt 
Sodium fluoride (NaF)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Sodium hydrogen phosphate  (Na2HPO4)   Merck EuroLab GmbH, Darmstadt 
Sucrose  Roth GmbH, Karlsruhe 
Tetraethylendiamine (TEMED)   Roth GmbH, Karlsruhe 
Tris-HCl   Roth GmbH, Karlsruhe 
Triton X-100   Roth GmbH, Karlsruhe 
Tryptone  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Tween 20   Roth GmbH, Karlsruhe 
Yeast extract   Life Technologies, Paisley (Scotland) 
β-glycerophosphate    Sigma-Aldrich Chemie GmbH, Deisenhofen 
β-mercaptoethanol  Sigma-Aldrich Chemie GmbH, Deisenhofen 
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4.1.2  Buffers and Solutions 
 
Antibody solution: 
TBS             50% (v/v) 
Blocking Buffer        50% (v/v) 
Tween 20           0.06% (v/v) 
 
Blocking solution: 
Triton X-100          0.1% 
BSA            3% 
In PBS 
 
10 x blotting buffer: 
Tris-HCl           250 mM 
Glycine           1.9 M 
pH             8.3 
 
Buffer D: 
HEPES/KOH         20 mM 
Glycerol          20% (v/v) 
KCl            100 mM 
EDTA           0.5 mM 
Nonidet P-40         0.25% (v/v) 
DTT            2 mM 
PMSF           0.5 mM 
pH             7.9 
 
Buffer F: 
Ficoll            20% (v/v) 
HEPES/KOH         100 mM 
KCl            300 mM 
DTT            10 mM 
PMSF           0.5 mM Materials and Methods                                                                                                             35                                 
pH            7.9 
 
Caspase buffer:  
HEPES          100 mM  
Sucrose           10% (v/v)  
CHAPS           0.1% (v/v)  
EDTA             1 mM  
pH            7.5 
 
EMSA running buffer: 
Running buffer (glycerol tolerant)   Amersham  Biosciences  Europe 
GmbH, Freiburg 
 
Fractionation buffer: 
Tris-HCl          20 mM 
EDTA           2 mM 
EGTA           5 mM 
DTT            1 mM 
Protease inhibitor mix      1 x 
pH            7.5 
 
Fixation buffer: 
PFA            4% (v/v) 
Sucrose          10% (v/v) 
In PBS 
 
2 x HBS: 
HEPES          50 mM 
NaCl            280 mM 
Na2HPO4          1.5 mM 
pH            7.05 
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MgCl2            2 mM 
EDTA             100  M 
KCl             10 mM 
DTT             1 mM 
PMSF           0.5 mM 
pH             7.9 
 
LB agar: 
Tryptone          10 g/l 
Yeast extract         5 g/l 
NaCl            10 g/l 
Agar-Agar          15 g/l 
 
LB medium: 
Tryptone           10 g/l 
Yeast extract         5 g/l 
NaCl            10 g/l 
 
Leucocyte washing buffer: 
EDTA           2 mM 
In PBS 
 
Lower Tris Buffer:  
Tris/HCl           1.5 M  
pH             8.8 
 
Nuclear lysis buffer: 
HEPES          50 mM 
KCl             50 mM 
NaCl             300 mM 
EDTA             100  M 
Glycerol           10% (v/v) 
DTT             1 mM Materials and Methods                                                                                                             37                                 
PMSF           0.5 mM 
pH             7.9 
 
p53 lysis buffer: 
Tris/HCl           50 mM 
EDTA             5 mM 
NaCl             150 mM 
Nonidet P-40         150 mM 
PMSF           0.5 mM 
DTT             1 mM 
Protease inhibitor mix       1 x 
pH            8.0 
 
PBS: 
NaCl             137 mM 
KCl             2.7 mM 
Na2HPO4           8.1 mM 
KH2PO4           1.5 mM 
pH             7.4 
 
 
4% PFA for perfusion: 
PFA             4% (v/v) 
Sodium borate        3.8% (v/v) 
pH            9.5 
In PBS 
 
Potassium phosphate buffer: 
KH2PO4          1 M 
pH            8.5 
 
4 x SDS-PAGE sample buffer: 
Tris/HCl           125 mM 
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Glycerol           20% (v/v) 
Brome phenole blue        0.002% (w/v) 
DTT             5 mM 
pH             6.9 
 
SDS separating gel (10%): 
H20 distilled          4.9 ml 
Lower Tris buffer        2.5 ml 
40% Acrylamide/Bis-acrylamide     2.5 ml  
(37.5% : 1.0% w/v) 
SDS 10% (w/v)        100 µl 
Ammonium persulfate 10% (w/v)    50 µl 
TEMED          5 µl   
 
SDS stacking gel (4%): 
H20 distilled          6.4 ml 
Upper Tris buffer        2.5 ml 
40% Acrylamide/Bis-acrylamide     1 ml   
(37.5% : 1.0% w/v) 
SDS 10% (w/v)        100 µl 
Ammonium persulfate 10% (w/v)    50 µl 
TEMED          5 µl   
 
10 x SDS running buffer: 
Tris/HCl           250 mM 
Glycine           1.9 M 
SDS             7 mM 
pH             7.1 
 
SOC medium:  
Tryptone           20 g/l  
Yeast extract         5 g/l 
NaCl            0.5 g/l  
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MgSO4          10 mM 
Glucose          2 mM 
 
Sphingosine kinase 2 assay buffer: 
HEPES          50 mM 
MgCl2             15 mM 
KCl            1 M 
NaF            10 mM 
Semicarbazide        1.5 mM 
pH            7.4 
 
Sphingosine kinase lysis buffer: 
Tris/HCl          20 mM 
Glycerol          20% (v/v) 
β-mercaptoethanol        1 mM 
EDTA           1 mM 
NaF            15 mM 
β-glycerophosphate       40 mM 
Protease inhibitor mix      1 x 
pH            7.4 
 
10 x TBS: 
Tris/HCl           500 mM 
NaCl             1.5 M 
pH             7.4 
 
5 x Tris borate EDTA buffer (TBE): 
Tris/HCl           445 mM 
Sodium borate         445 mM 
EDTA             10 mM 
 
TE (Trypsin/EDTA): 
Trypsin           0.5 g/l 
EDTA             0.2 g/l Materials and Methods                                                                                                             40                                 
 
0.2%/0.1% Triton X-100: 
Triton X-100          0.2%/0.1% 
In PBS 
 
1 x TTBS: 
TBS             1 x 
Tween 20           0.06% (v/v) 
 
Upper Tris Buffer:  
Tris/HCl           0.5 M  
pH             6.8  
 
4.1.3  Kits 
 
Annexin V-FITC/PI Apoptosis Kit  Coulter-Immunotech GmbH, Hamburg 
BD Cytometric Bead Array Flex Sets 
IL-8, IL-10, TNF-α 
BD Biosciences, Heidelberg 
BD  Cytometric  Bead  Array  Human 
Inflammation Kit 
BD Biosciences, Heidelberg 
Cell Line Nucleofector Kit V  Amaxa AG, Cologne 
HiSpeed Plasmid Maxi Kit  Qiagen GmbH, Hilden 
QIAprep Spin Miniprep Kit  Qiagen GmbH, Hilden 
QuickChange XLII Kit   Stratagene GmbH, Amsterdam (Netherlands) 
Standard DC Protein Assay Kit  Bio-Rad Laboratories GmbH, Munich 
pSilencer™ 4.1-CMV neo Kit  Ambion Inc, Austin (USA) 
 
4.1.4  Antibodies 
 
Primary antibodies: 
Anti-actin (rabbit, polyclonal)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Anti-Bad-Ser136 (rabbit, polyclonal)  Cell Signalling Technology Inc., Beverly (USA) 
Anti-Bcl-2 (mouse, monoclonal)   BD Transduction Laboratories, Heidelberg 
Anti-Bcl-XL (rabbit, polyclonal)  BD Transduction Laboratories, Heidelberg Materials and Methods                                                                                                             41                                 
Anti-Caspase-1 (rabbit, polyclonal)  Cell Signalling Technology Inc., Beverly (USA) 
Anti-CD31 (rat polyclonal)  BD Transduction Laboratories, Heidelberg 
Anti-CD44-PE (mouse monoclonal)  Ancell, Bayport (USA) 
Anti-F4/80 (rat polyclonal)  EBioscience Inc, San Diego (USA) 
Anti-HA (mouse, monoclonal)  Covance, Richmond (USA) 
Anti-p50 (rabbit polyclonal)  Santa Cruz Biotechnology, Heidelberg 
Anti-p65 (rabbit, polyclonal)  Santa Cruz Biotechnology, Heidelberg 
Anti-S1P1 (rabbit, polyclonal)  Orbigen Inc, San Diego (USA) 
Anti-SphK1 (rabbit, polyclonal)  Exalpha Biologicals Inc, Maynard (USA) 
Anti-SphK2 (rabbit, polyclonal)  Exalpha Biologicals Inc, Maynard (USA) 
Anti-SphK2-C (rabbit, polyclonal)  Abgent Inc, San Diego (USA) 
Anti-SphK2-N (rabbit, polyclonal)  Abgent Inc, San Diego (USA) 
Anti-V5 (rabbit, polyclonal)  Abgent Inc, San Diego (USA) 
 
Secondary antibodies: 
IRDye800-labelled anti-mouse   Li-COR Biosciences GmbH, Bad Homburg 
Alexa Fluor 488-labelled anti-mouse  Invitrogen Corporation, Carlsbad 
Alexa Fluor 546-labelled anti-rabbit   Invitrogen Corporation, Carlsbad 
Cy3-labelled anti-rat  Jackson Immunoresearch, West Grove (USA) 
IRDye680-labelled anti-mouse   Li-COR Biosciences GmbH, Bad Homburg 
IRDye680-labelled anti-rabbit   Li-COR Biosciences GmbH, Bad Homburg 
IRDye800-labelled anti-rabbit   Li-COR Biosciences GmbH, Bad Homburg 
 
4.1.5  Media and reagents for cell culture 
 
Bovine insulin  Sigma-Aldrich Chemie GmbH, Deisenhofen 
DMEM high glucose  PAA Laboratories GmbH, Cölbe 
EMEM  PAA Laboratories GmbH, Cölbe 
FCS  PAA Laboratories GmbH, Cölbe 
L-glutamine  PAA Laboratories GmbH, Cölbe 
Lymphocyte separation medium  PAA Laboratories GmbH, Cölbe 
Non essential amino acids  PAA Laboratories GmbH, Cölbe 
PBS (Instamed 9.55 g/ml)   Biochrom AG, Berlin 
Penicillin/Streptomycin   PAA Laboratories GmbH, Cölbe 
RPMI 1640  PAA Laboratories GmbH, Cölbe 
Sodium pyruvate  PAA Laboratories GmbH, Cölbe 
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4.1.6  Stimulants and Inhibitors 
 
12-Tetradecanoyl-phorbol-13-acetate 
(TPA)  
Sigma-Aldrich Chemie GmbH, Deisenhofen 
Ac-YVAD-CMK  Alexis Biochemicals, Grünberg 
Anti-Fas  Immunotools, Frisoythe 
Bapta-AM  Molecular Probes, Leiden (Netherlands) 
Cycloheximide   Sigma-Aldrich Chemie GmbH, Deisenhofen 
Cytochalasin D  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Dimethylsphingosine (DMS)  Biomol GmbH, Hamburg 
Etoposide  Alexis Biochemicals, Grünberg 
FTY720  Cayman Chemical, Ann Arbor (USA) 
Interferon-γ (IFN-γ)  Roche Diagnostics GmbH, Mannheim 
Lipopolysacharide (LPS)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
LY294002  Alexis Biochemicals, Grünberg 
Lysophosphatidic acid (LPA)  Avanti Polar Lipids, Alabaster (USA) 
Lysophosphatidylcholine (LPC)   Avanti Polar Lipids, Alabaster (USA) 
PD98059  Alexis Biochemicals, Grünberg 
Platelet activating factor (PAF  Avanti Polar Lipids, Alabaster (USA) 
Sphingosine-1-phosphate (S1P)  Biomol GmbH, Hamburg 
Staurosporine (Sts)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Tumor necrosis factor-α (TNF-α)  Biomol GmbH, Hamburg 
   
4.1.7  Oligonucleotides 
 
All  oligonucleotides  were  from  biomers.net  GmbH  (Ulm),  unless  stated 
otherwise. 
 
IRD-700 labeled oligonucleotides for EMSA analysis: 
NF-κB  (consensus site in boldface letters) (127) :  
5’-GCC AGT TGA GGG GAC TTT CCC AGG C-3’ 
3’-C GGT CAA CTC CCC TGA AAG GGT CCG-5’ 
 
Primers for site-directed mutagenesis of SphK2: 
Single base changes in primers compared to wild type SphK2 are indicated 
with boldface letters. 
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1) N-terminal caspase-1 cleavage site (D138A): 
5’-CGC ACC TTC CGG GCA GCT GGG GCC GCC ACC TAC G-3’ 
5’-C GTA GGT GGC GGC CCC AGC TGC CCG GAA GGT GCG-3’ 
 
2) C-terminal caspase-1 cleavage site (D552A): 
5’-GC CAC CTA GGC GCT GCC CTG GTG GCA GCT CCG C-3’ 
5’-G CGG AGC TGC CAC CAG GGC AGC GCC TAG GTG GC-3’ 
 
3) Phosphatidylserine binding site (T219A): 
5’-C AAC CTC ATC CAG GCA GAA CGA CAG AAC CAC G-3’ 
5’-C GTG GTT CTG TCG TTC TGC CTG GAT GAG GTT G-3’ 
 
Sequence  specific  hairpin  siRNA  oligonucleotides  for  SphK2  knock-
down: 
5'-GAT CCA CTA AAC AAG CTT GGT ACC TTC AAG AGA GGT ACC AAG 
CTT GTT TAG TTT A-3' 
5'-AGC TTA AAC TAA ACA AGC TTG GTA CCT CTC TTG AAG GTA CCA 
AGC TTG TTT AGT G-3' 
 
Sequencing primers for pSilencer™ 4.1-CMV neo: 
5'-AGG CGA TTA AGT TGG GTA-3' 
5'-CGG TAG GCG TGT ACG GTG-3' 
 
Specific siRNA: 
Commercially  available  siRNA  against  SphK1,  SphK2  and  caspase-1  was 
obtained from Qiagen GmbH (Hilden). Sequence information is restricted to 
the  manufacturer.  Specificity  was  assured  with  siCONTROL  non-targeting 
Duplex #1 from Dharmacon Inc (Lafayette (USA)).  
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4.1.8  Expression plasmids 
 
pRc/CMVbcl2: 
Plasmid  encodes  the  Bcl-2  gene,  based  on  the  pRc/CMV  vector  from 
Invitrogen  Corporation  (Carlsbad).  The  vector  was  established  in  our  lab 
previously (128). 
 
pmaxGFP: 
Expression plasmid for green fluorescent protein (GFP), obtained from Amaxa 
AG (Cologne).  
 
HA-hSphK2/pCMV5: 
The  plasmid  carries  the  gene  for  N-terminally  HA-tagged  human  SphK2  
(111), based on the pCMV5 vector. The plasmid was a kind gift from Taro 
Okada (Kobe University).  
 
V5-mSphK2/pCDNA3.1: 
Expression plasmid for murine SphK2 with C-terminal V5-tag (108), based on 
the pcDNA3 vector from Invitrogen Corporation (Carlsbad). The plasmid was 
a kind gift from Sarah Spiegel (Virginia Commonwealth University, Richmond). 
 
pSilencer™ 4.1-CMV neo: 
The plasmid is designed to knock-down specific genes via insertion of hairpin 
siRNA. It was obtained from Ambion Inc, Austin (USA). Expression is driven 
by a CMV promoter. The plasmid also carries the gene for resistance against 
the selection marker neomycin. 
 
4.1.9  Cell lines and bacteria 
 
XL1-Blue super competent bacteria from Stratagene GmbH, Amsterdam 
Genotype:  recA1  endA1  gyrA96  thi-1  hsdR17  supE44  relA1  lac  [F´  proAB 
lacIqZ.M15 Tn10(Tetr)]. 
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Primary human monocytes: 
Primary  human  monocytes  were  isolated  from  Buffy  Coats,  which  were 
obtained from DRK-Blutspendedienst Baden-Württemberg-Hessen, Frankfurt. 
 
Jurkat T cells:  
Jurkat  T  cells  are  derived  from  a  14  year  old  boy  with  acute  lymphatic 
leukemia (ALL).  This T cell line was established in 1977 (129). 
 
HEK293 cells: 
HEK 293 cells were generated by transformation of human embryonic kidney 
cell cultures with sheared adenovirus 5 DNA, and were first described in 1977 
(130). 
 
MCF-7 cells: 
MCF-7 human breast adenocarcinoma cells were established from the pleural 
effusion  of  a  69-year-old  Caucasian  woman  with  metastatic  mammary 
carcinoma (after radio- and hormone therapy) in 1970 (131). 
 
THP-1 cells: 
THP-1  human monocytes  were  obtained from  the  peripheral  blood  of a  1-
year-old boy with acute monocytic leukemia (AML) at relapse in 1978 (132). 
 
RKO cells: 
The RKO cell line is a poorly differentiated colon carcinoma cell line, which 
was developed by Michael Brattain in 1984 (133). 
 
RAW 264.7 cells: 
RAW 264.7 mouse monocytes/macrophages were established from ascites of 
a  tumor  induced  in  a  male  mouse  by  intraperitoneal  injection  of  Abselon 
Leukaemia Virus (A-MuLV) in 1977 (134).   
 
Colo 201 cells: 
Colo 201 human colon adenocarcinoma cells are derived from ascitic fluid of a 
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HepG2 cells: 
HepG2 hepatocellular carcinoma cells were established from a 15 year old 
Caucasian male in 1980 (136). 
 
NIH 3T3 cells:  
NIH 3T3 mouse fibroblasts were established from a NIH Swiss mouse embryo 
in 1969 (137). 
 
A549 cells: 
A549 lung carcinoma cells are derived from a 58 year old Caucasian male 
(138). 
 
Caco-2 cells: 
Caco-2  colon  adenocarcinoma  cells  were  isolated  from  a  primary  colonic 
tumor in a 72-year-old Caucasian male in 1977 (139). 
 
4.1.10 Mice 
 
MCF-7  xenograft  models  were  accomplished  with  seven-week-old  NMRI-
nu/nu female mice obtained from Harlan Winkelmann GmbH, Borchen. These 
experiments were performed in close cooperation with the Institute of Clinical 
Pharmacology,  especially  with  Dr.  Susanne  Schiffmann.  The  Institute  of 
Clinical Pharmacology bought the mice and cared for approval by the local 
Ethics Committee for Animal Research. 
 
4.1.11 Instruments 
 
Autoclave HV 85   BPW GmbH, Süssen 
B250 Sonifier   Branson Ultrasonics, Danbury (USA) 
Bacteria clean bench UVUB 1200  Uniequip GmbH, Martinsried 
Bacteria incubator B5042   Heraeus GmbH, Hanau 
CASY®   Schärfe System, Reutlingen 
Centrifuge 5415 R   Eppendorf GmbH, Hamburg Materials and Methods                                                                                                             47                                 
Centrifuge CR 3.22   Jouan GmbH, Unterhaching 
Centrifuge MR 23i   Jouan GmbH, Unterhaching 
Centrifuge ZK380   Hermle GmbH, Wehingen 
Cryotome Jung CM 3000   Leica Microsystems, Bensheim 
FACSCanto flow cytometer  BD Biosciences GmbH, Heidelberg 
Fluorescence  microscope  Axiovert 
200M  
Carl Zeiss MicroImaging Inc, Göttingen 
Holten LaminAir clean bench   Jouan GmbH, Unterhaching 
IG 150 (cell culture incubator)   Jouan GmbH, Unterhaching 
LabLine Orbit Shaker   Uniequip GmbH, Martinsried 
Magnetic stirrer Combimag RCH  IKA Labortechnik GmbH & Co. KG, Staufen 
Mastercycler Thermocycler   Eppendorf GmbH, Hamburg 
Mini-PROTEAN  3  System  (SDS-
PAGE)  
Bio-Rad Laboratories GmbH, München 
Mithras LB940 multimode reader  Berthold Technologies, Bad Wildbad 
NanoDrop ND-1000   Peqlab Biotechnologie GmbH, Erlangen 
Nucleofector  Amaxa AG, Cologne 
Odyssey infrared imaging system  Li-COR Biosciences GmbH, Bad Homburg 
Pipettes (10  l, 100  l, 1.000  l)   Eppendorf GmbH, Hamburg 
Plastic material (cell culture)   Greiner Bio-One GmbH, Frickenhausen 
Pure water system Purelab Plus   ELGA LabWater GmbH, Siershahn 
Sub-Cell® GT electrophoresis system   Bio-Rad Laboratories GmbH, München 
Thermomixer 5436   Eppendorf GmbH, Hamburg 
Trans-Blot SD blotting machine   Bio-Rad Laboratories GmbH, München 
Ultra-Sonifier   MSE, Loughborough (England) 
UV-Transilluminator gel documentation 
system  
Raytest GmbH, Straubenhardt 
 
4.1.12 Software 
 
Aida Image Analyzer v 3.11   Raytest GmbH, Straubenhardt 
AxioVision Software   Carl Zeiss MicroImaging Inc, Göttingen 
BD FACSDiva
TM Software   BD Biosciences GmbH, Heidelberg 
FCAP Array v 1.0.1  Soft Flow, Burnsville (USA) 
MikroWin 2000    Berthold Technologies Bad Wildbad  
Peptide Cutter  Freeware on the www  
WoLF PSORT  Freeware on the www Materials and Methods                                                                                                             48                                 
4.2  Methods 
4.2.1  Cell culture 
RAW  264.7  mouse  monocytes/macrophages,  THP-1  human  monocytes, 
Jurkat  T  cells,  MCF-7  breast  carcinoma  cells,  Colo  201  human  colon 
adenocarcinoma  cells  and  Hep-G2  hepatocellular  carcinoma  cells  were 
maintained  in  Roswell  Park  Memorial  Institute  (RPMI)  1640.  HEK293 
embryonal kidney, RKO colon carcinoma cells and NIH 3T3 mouse fibroblasts 
were cultured in Dulbecco’s modified eagle medium (DMEM) with 4.5 g/l D-
glucose, A549 lung carcinoma cells in DMEM/Ham’s F12 and Caco-2 colon 
adenocarcinoma in Earle’s minimal essential medium (EMEM). All media were 
supplemented  with  5  mM  glutamine,  100  U/ml  penicillin,  100  µg/ml 
streptomycin and 10% heat-inactivated FCS. HEK293 medium also contained 
1 mM sodium pyruvate, Caco-2 medium contained 1 x non essential amino 
acids and MCF-7 medium was supplemented with 1mM sodium pyruvate, 1 x 
non essential amino acids and 10 µg/ml bovine insulin. Cells were kept in a 
humidified atmosphere of 5% CO2 in air at 37° C and were transferred twice a 
week. 
 
4.2.2  Human monocyte isolation and culture  
Human monocytes were isolated essentially as described (140). In brief, mo-
nocytes  were  isolated  from  buffy  coats  (DRK-Blutspendedienst  Baden-
Württemberg-Hessen,  Institut  für  Transfusionsmedizin  und  Immunhäma-
tologie  Frankfurt  am  Main,  Frankfurt,  Germany)  using  Ficoll-Hypaque  gra-
dients. 50 ml Falcon tubes were layered with 15 ml lymphocyte separation 
medium, blood cells were added, followed by density gradient centrifugation 
(1000 x g, 10 min, RT). Peripheral blood mononuclear cells (PBMCs) were 
collected,  washed  twice  with  PBS  and  were  allowed  to  adhere  to  culture 
dishes (Primaria 3072, BD Becton Dickinson GmbH, Heidelberg) for 1 h at 
37° C. Non-adherent cells were removed. Monocytes we re then differentiated 
into macrophages with RPMI 1640 containing 10% AB-positive human serum 
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4.2.3  Induction of apoptosis and necrosis   
For the generation of apoptotic cells (AC), cells were cultured in appropriate 
medium  (4.2.1)  without  FCS.  Apoptosis  in  macrophages  was  generally 
induced in full medium (141). Inhibitors were added 2 h prior to cell death 
induction.  Stimulus  concentrations  are  listed  in  Table  1.  Subsequently,  AC 
were  washed  twice  prior  to  the  addition  to  macrophages.  Necrosis  was 
induced  by  heating  Jurkat  cells  for  30  min  at  56° C  (77).  Cell  death  was 
quantified  by  flow  cytometry  after  staining  with  annexin-V  and  propidium 
iodide (4.2.6). Agonist concentrations and incubation times were chosen to 
provoke roughly 80% apoptotic cell death. 
 
Table 1: Induction of apoptosis  
 
Cell line  Stimulus  Concentration 
 
Human primary macrophages 
 
TNF-α/CHX  10 ng/ml/10 µg/ml 
THP-1 monocyte-derived macrophages 
 
Etopopside  250µM 
RAW 264.7 
 
Etoposide  250 µM 
Jurkat 
 
Staurosporine  
Anti-Fas 
Etoposide  
0.5 µg/ml 
0.05 ng/ml 
100 µM 
RKO  Staurosporine    0.5 µg/ml 
 
MCF-7  Staurosporine   0.5 µg/ml 
 
HEK293 
 
Staurosporine  
TNF-α/CHX  
0.5 µg/ml  
50 ng/ml/10 µg/ml 
NIH 3T3  Staurosporine  0.5 µg/ml 
 
         
4.2.4  Production and characterization of conditioned media  
To  produce  apoptotic  cell  conditioned  medium  (ACM),  cells  were  washed 
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for  another  4  h  in  appropriate  medium  (4.2.1)  with  10%  FCS.  ACM  was 
harvested by centrifugation (13.000 x g, 5 min) and filtration through 0.2 µm 
pore filters, to remove apoptotic bodies (35, 142). Conditioned media from 
necrotic  (NCM)  or  viable  (VCM)  cells  were  prepared  respectively.  Two 
different protocols were used for protein degradation in conditioned media. 
First,  for  heat  inactivation,  media  were  heated  at  100° C  for  1  h.  Second, 
enzyme digestion was carried out with 50 µg/ml proteinase K or 0.1% trypsin 
at  37° C  for  1  h.  Afterwards,  enzymes  were  inactivat ed  by  heat  treatment 
and/or the use of excess soybean trypsin inhibitor. Extraction of lipids was 
performed with 1 volume of chloroform and was repeated at least twice (35). 
Specific extraction of S1P was performed essentially as described (143). In 
brief,  a  two  step  partitioning  protocol  with  chloroform/methanol/HCL 
(100:200:1)  was  used,  first  in  alkaline  conditions  followed  by  re-extraction 
under acidic conditions. The acidic organic phase was evaporated to dryness 
and the lipid extract was resolved in PBS containing 0.4% fatty acid free BSA 
for  cell  culture,  or  ethanol  for  quantitative  analysis,  for  30  min  at  37° C, 
followed by sonication for 10 sec. Macrophages were generally exposed to 
conditioned media for 16 h. Inhibitors were added 2 h prior to conditioned 
medium.  
 
4.2.5  Co-culture experiments  
Different  co-culture  set-ups  with  THP-1  monocyte-derived  macrophages  or 
primary human macrophages were performed. THP-1 cells were differentiated 
to macrophages at a density of 2x10
5 cells/ml, with 50 nM TPA for 24 h. TPA 
was removed by washing and the cells were cultured for another 24 h without 
TPA.  Apoptotic,  necrotic  or  viable  cells  were  added  at  a  ratio  of  1:5.  Co-
cultures  were  maintained  for  16  h  at  37° C.  Afterwar ds  residual  AC  were 
washed off. Conditioned media from co-cultures were produced as described 
in 4.2.4. In one set of experiments, transwell inserts (Greiner Bio-One GmbH, 
Frickenhausen)  were  used  to  ensure  spatial  separation  between 
macrophages and AC (144). Primary human monocyte-derived macrophages 
were cultured at a density of 2x10
5 cells/ml. Following differentiation, tumor 
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days. Subsequently, residual tumor cells were removed from the plates by 
incubations  with  accutase  (145)  for  5  min,  which  left  adherence  of 
macrophages unaltered. Remaining macrophages were treated with 1 µg/ml 
LPS and 100 U/ml IFN-γ or exposed for a second time to equal amounts of 
tumor cells. In some experiments, higher ratios of tumor cells compared to 
macrophages were used, as indicated.  
       
4.2.6  Quantification of cell death  
To distinguish apoptosis from necrosis, the annexin V-FITC/propidium iodide 
(PI) apoptosis kit was used. Annexin V-FITC (extinction: 492 nm; emission: 
520 nm) binds to PS on the surface of apoptotic and necrotic cells, but the 
DNA intercalating dye PI (extinction: 550 nm; emission: 617 nm) only enters a 
cell  when  its  cell  membrane  integrity  is  lost  during  necrosis.  Cells  were 
harvested by centrifugation (500 x g, 5 min, 4° C) a nd resolved in 500 µl 1 x 
binding buffer. Annexin V-FITC (5 µl) and PI (2 µl) where added and the cell 
solution was incubated on ice for 10 min, protected from direct light exposure. 
The measurement of annexin V-FITC and/or PI positive cells was performed 
with the FACSCanto flow cytometer and the BD Cell Quest Pro Software. To 
quantify cell death at the level of the mitochondria, the mitochondrial dye JC-1 
was used. JC-1 stains mitochondria in living cells in a membrane potential 
(DY)-dependent  fashion.  JC-1  monomer  is  in  equilibrium  with  so  called  J-
aggregates, which are favored at higher mitochondrial membrane potential. 
The monomer JC-1 has green fluorescence (emission: 527 nm), while the J-
aggregates have red fluorescence (emission: 590 nm). In AC, the dye stays in 
the cytoplasm and fluoresces green, while in healthy cells, the dye aggregates 
in the mitochondria and fluoresces red (146). Cells were harvested, resolved 
in PBS, 1 µM JC-1 was added, and cells were kept on ice for 20 min prior to 
analysis via flow cytometry. Alternatively, DIOC6(3), a positively charged dye 
(emission: 501 nm), which accumulates selectively in the mitochondria, was 
used to monitor the mitochondrial membrane potential (DY). Cell suspensions 
were incubated with 40 nM DIOC6(3) for 30 min on ice, followed by analysis 
using the FACSCanto flow cytometer.  
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4.2.7  Cell death quantification in co-cultures 
Co-cultures of human macrophages and tumor cells were harvested after 12, 
24  or  48  h  by  incubation  with  accutase  for  30  min,  which  removed  both 
macrophages and tumor cells. Cell death was quantified by flow cytometry 
after  incubations  with  a  monoclonal  human  CD44  antibody  coupled  to 
phycoerythrin  (PE),  to  discriminate between  macrophages  and  tumor  cells, 
followed by the annexin V-FITC method (4.2.6) to detect cell death. In detail, 
quantification  of  macrophage  vs.  tumor  cell  contents  in  co-cultures  was 
performed  using  α-CD44-PE  (extinction  530  nm;  emission:  565  nm).  The 
macrophage  population  was  identified  by  staining  control  macrophages, 
thereby gating on this population, which was used to identify macrophages in 
co-cultures. All remaining cell counts were attributed to tumor cells.  
 
4.2.8  Caspase activity assays 
Caspase-3  or  -1  activity  was  quantified  following  the  cleavage  of  specific 
substrates  as  described  (147).  Briefly,  cells  were  lysed  in  200  µl  caspase 
buffer, sonicated for 10 sec, followed by centrifugation (15000 x g, 10 min, 
4° C). After that, the protein concentration in the  supernatant was determined 
with the Lowry method (4.2.9). 30 µg protein were filled up to 140 µl with 
caspase buffer and mixed with 10 µl caspase substrate (200 µM Ac-DEVD-
AMC for caspase-3 or 1 mM Ac-YVAD-AMC for caspase-1) in 96 well plates. 
The  cleavage  of  the caspase  substrate  was  followed for  1  h  at 30° C  with 
measurements being performed every 2 min on the Mithras LB 940 multimode 
reader  (extinction:  360  nm;  emission:  465  nm).  Caspase  activities  were 
calculated  as  substrate  cleavage  per  minute  relative  to  controls  using  the 
MikroWin 2000 software. 
 
4.2.9  Protein determination (Lowry method)  
The  protein  content  of  cell  lysates  was  determined  using  the  DC  Protein 
Assay kit, based on the Lowry method (148). Briefly, a standard dilution series 
of  BSA  in  H2O  was  prepared  (0.625  to  10  mg/ml).  Samples  as  well  as 
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A were added, and then the colorimetric reaction was started by addition of 
160  l solution B. After incubation for 15 min (RT with shaking), extinction was 
measured at 750 nm using the Mithras LB 940 multimode reader. 
 
4.2.10  SDS-PAGE and Western blot analysis 
For Western blot analysis, cells were incubated as indicated in the individual 
experiments, scraped off, lysed in 200 µl p-53 lysis buffer and sonicated for 3 
sec. Lysates were incubated on ice for 30 min and vortexed  each 10 min for 
10 sec, followed by centrifugation (15000 x g, 30 min, 4° C). Subsequently, 
protein concentrations were determined with the Lowry method (4.2.9). 80 µg 
protein and 10 µl 4 x SDS-PAGE sample buffer (4.1.2) were mixed, filled up to 
40 µl with H2O, denatured at 100° C for 10 min and put on ice imm ediately for 
2 min. Proteins were resolved on 10% SDS polyacrylamide gels (4.1.2) with 1 
x  SDS  running  buffer  (4.1.2).  After  that,  proteins  were  blotted  onto  a 
nitrocellulose  membrane  using  a  semi-dry  transfer  cell.  Unspecific  binding 
was blocked with 5% milk in TBS (4.1.2) for 1h, followed by washing with 
TTBS for  10  min. Primary  antibody  was  added  in  antibody  solution  (4.1.2)  
and incubated overnight at 4° C. Membranes were wash ed three for 10 min 
each  with  TTBS.  For  protein  detection,  blots  were  incubated  with  an 
appropriate (anti-rabbit or anti-mouse) secondary near infrared dye (IRDye) 
conjugated  antibody  (4.1.4)  in  antibody  solution  for  1  h.  Thereafter, 
membranes were washed 3 times for 10 min with TTBS, followed by detection 
of  specific  proteins  using  the  Odyssey  infrared  imaging  system.  Specific 
protein  expression  was  quantified  compared  to  actin  expression  using  the 
Odyssey infrared imaging system or AIDA software. 
 
4.2.11  Cellular fractionation 
Cellular fractions were obtained by lysis of cell pellets in fractionation buffer 
(4.1.2) followed by incubation on ice for 1 h, with regular vortexing. Lysates 
were  passed  40  times  through  25-gauge  needles.  Nuclei  were  pelleted  by 
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membrane  fraction  was  obtained  by  centrifugation  at  16.000  x  g  (30  min, 
4° C). Supernatant was used as the cytosolic fractio n.  
 
4.2.12  Electrophoretic mobility shift assays (EMSA) 
An established EMSA method, with slight modifications, was used (149). 5 x 
10
6 cells were suspended in 200 µl ice cold hypotonic cell lysis buffer (4.1.2) 
and incubated on ice for 10 min. Nuclei were collected (500 x g, 30 min, 4° C), 
resolved in 50 µl nuclear lysis buffer, incubated on ice for 20 min and pelleted 
(12000 x g, 20 min, 4° C). Protein content in the su pernatant was determined 
using the Lowry method (4.2.9.). Nuclear protein (20 µg) was incubated for 30 
min at  room  temperature  with  2  µg  poly(dI-dC),  2  µl  buffer  D  (4.1.2), 4  µl 
buffer  F  (4.1.2),  and  250  fmol  5’-IRD700-labelled  oligonucleotide  in  a  final 
volume of 20 µl. Specific p65 and p50 supershift antibodies (2 µg) were added 
as indicated. DNA–protein complexes were resolved at 200 V for 2 h using 
native  4%  polyacrylamide  gels,  and  visualized  with  the  Odyssey  infrared 
imaging  system.  Supershift  analysis  was  performed  with  α-p65  and  α-p50 
from Santa Cruz Biotechnology (Heidelberg, Germany). The latter antibody is 
known to attenuate the protein-DNA interaction rather than causing a classical 
supershift (150).  
 
4.2.13  Quantification of cytokine release from co-cultures 
For  the  measurement  of  cytokine  contents  in  the  supernatants  of  human 
primary macrophages from co-cultures with tumor cells, BD CBA Flex Sets or 
the CBA Human Inflammation Kit were used. In brief, 50 µl supernatant were 
incubated with beads, coated with antibodies against TNF-α, IL-10, IL-8 or IL-
12-p70  and  a  PE-labeled  detection  reagent  for  3  h.  The  samples  were 
acquired with the FACSCanto flow cytometer and analyzed with the FCAP 
Array  software.  The  performance  matched  the  specifications  of  the 
manufacturer. Minimal detection limits were 1.9 pg/ml for TNF-α, 3.8 pg/ml for 
IL-10, 4.9 pg/ml for IL-8 and 4.8 pg/ml for IL-12-p70. Routinely, medium from 
co-culture  set-ups  were  changed  every  24  h.  Thus,  cytokine  production 
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only. If not stated otherwise, co-cultures lasted for 5 days with changing the 
medium every 24 h.  
 
4.2.14  Down-regulation of S1PR1  
Internalization  of  S1PR1  was  induced  as  described  (116).  Briefly,  primary 
human  macrophages  were  incubated  with  100  nM  FTY720,  an  agonist 
inducing internalization upon binding, for 1 h. After that, cells were washed 
twice with PBS, cultured for another 48 h and used for further experiments. 
S1PR1 down-regulation was controlled by Western blotting compared to un-
stimulated controls. 
 
4.2.15  S1P quantification in cell culture supernatants 
S1P  quantification  using  liquid  chromatography-tandem  mass  spectrometry 
(LC-MS/MS) analysis, was performed in the Institute of Clinical Pharmacology 
by Helmut Schmidt (151). Therefore, cells were cultured in medium devoid of 
FCS, prior to stimulation. Alternatively, the medium in co-cultures of human 
macrophages and MCF-7 cells was replaced by medium free of FCS after 24 
h.  Co-cultures  were  maintained  for  another  24  h  and  supernatants  were 
harvested. Afterwards, lipids were extracted from supernatants of cell cultures 
with  chloroform/HCl  (50:1)  after  addition  of  the  internal  standard  C17-
sphingosine-1-phosphate (C17-S1P). Extraction was repeated three times to 
achieve maximum recovery. The combined organic phases were evaporated 
to  dryness  and  resolved  in  ethanol  for  quantification.  After  liquid-liquid 
extraction, concentrations of S1P and the internal standard were determined 
by  liquid  chromatography  coupled  to  tandem  mass  spectrometry.  HPLC 
analysis was done under gradient conditions using a Luna C18 column (150 
cm  x  2  mm  ID,  5  µm  particle  size  and  100  Å  pore  size,  Phenomenex, 
Aschaffenburg). MS/MS analyses were performed on a 4000 Q TRAP triple 
quadrupole  mass  spectrometer  with  a  TurboIonSpray  source  (Applied 
Biosystems, Darmstadt). Precursor-to-product ion transitions of m/z 380®82 
for  S1P  and  366®250  for  C17-S1P  were  used  for  the  Multiple  Reaction 
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controls  and  unknowns  were  evaluated  by  Analyst  software  1.4  (Applied 
Biosystems, Darmstadt). Linearity of the calibration curve was proven from 1 
to 250 ng/ml. The coefficient of correlation for all measured sequences was at 
least 0.99. The lower limit of quantification (LLOQ) was 0.5 ng/ml. Variations 
in  accuracy  and  intra-day  and  inter-day  precision  (n  =  6  for  each 
concentration, respectively) were <15% over the range of calibration. 
 
4.2.16  Sphingosine kinase activity assay 
Activity  of  sphingosine  kinase  2  was  followed  as  phosphorylation  of  NBD-
sphingosine  to  NBD-S1P.  An  established  protocol  with  slight  modifications 
was used (152). For preparation of whole cell lysates, cells were harvested, 
washed with ice cold PBS and solved in 100 µl ice cold sphingosine kinase 
lysis  buffer.  Subsequently,  lysates  were  sonicated  for  5  sec,  followed  by 
centrifugation (1600 x g, 30 min, 4° C). 10 µl of th e supernatant or 15 µl cell 
culture  supernatants were  then  added  to  100  µl  sphingosine  kinase  assay 
buffer, together with 10 µM NBD-Sphingosine and 1 mM ATP, for 1 h at 30° C. 
The  proximate  addition  of  1  volume  alkaline  potassium  phosphate  buffer, 
followed by chloroform/methanol (500 µl, 2:1) extraction ensured separation of 
the substrate (NBD-Sphingosine) to the lipid phase and of the product (NBD-
S1P) to the aqueous phase. 100 µl of the aqueous phase were then analyzed 
for NBD-S1P-dependent fluorescence (extinction: 485 nm, emission: 538 nm) 
in the Mithras LB 940 multimode reader.     
 
4.2.17  Transformation of bacteria by the heat shock protocol  
XL1-Blue  supercompetent  bacteria  were  transformed  using  the  heat  shock 
protocol.  For  this  purpose,  bacteria  were  thawed  on  ice,  and  100  ng  of 
plasmid DNA or specific reaction templates were added. After gentle mixing 
by pipetting up and down, cells were incubated on ice for 30 min. After a heat 
shock (45 sec, 42° C), they were kept on ice for 2 m in. Then, 400  l of SOC 
medium were added to the cells, followed by incubation for 60 min at 37° C 
with continuous shaking. To select transformed bacteria, 200  l of the cultures 
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clones were picked, cultured overnight at 37° C, and  subsequently used for 
plasmid preparation.  
 
4.2.18  Bacterial culture and plasmid preparation  
For  preparation  of  plasmids,  2  ml  LB  medium  with  bacteria  containing  the 
required  plasmid,  were  transferred  to  400  ml  LB  medium  (100   g/ml 
ampicillin)  and  grown  at  37° C overnight.  The  isolat ion  of the plasmid from 
bacteria was performed using the HiSpeed Plasmid Maxi Kit. In detail, after 
pelting the bacteria by centrifugation (6000 x g, 15 min, 4° C), the pellets were 
resuspended in 10 ml buffer P1. Then, buffer P2 (10 ml) was added and the 
suspension was mixed gently but thoroughly, by inverting 5 times, followed by 
5  min  incubation  at  RT.  Thereafter,  10  ml  chilled  buffer  P3  were  added, 
immediately  mixed  and  the  lysate  was  transferred  to  a  QIAfilter  cartridge, 
where it was incubated for 10 min at RT. Subsequently, the lysate was filtered 
into a previously equilibrated (with 10 ml buffer QBT) HiSpeed Maxi Tip and 
the filters were washed using 60 ml buffer QC. Then, the DNA was eluted 
using 15 ml buffer QF and precipitated by addition of 10.5 ml isopropanol (5 
min, RT). The precipitation reaction was filtered through the QIAprecipitator 
Maxi Module applying constant pressure. The bound DNA was washed with 
70% ethanol, followed by drying and elution with 1 ml H2O. The resulting DNA 
content was quantified using the NanoDrop ND-1000.  
 
4.2.19  Site-directed mutagenesis 
Site-directed mutagenesis for  generation  of  point mutations  in SphK2,  was 
performed using the QuickChange XLII kit. The HA-hSphK2/pCMV5 construct 
was used as a template (4.1.8). Oligonucleotides were designed according to 
the  manufacturer’s  specifications.  10  ng  of  the  vector  was  mixed  with  the 
specific  oligonucleotides  (4.1.7)  in  reaction  buffer,  followed  by  addition  of 
PfuTurbo  DNA  polymerase.  An  initial  denaturation  step  was  performed  at 
95° C for 1 min, followed by 18 cycles at 95° C for 5 0 s, annealing at 60° C for 
50 s, and extension at 68° C for 7 min. A final exte nsion phase was performed 
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with 10 U DpnI (37° C, 1 h) and the mutated plasmids  were transfected into 
XL1-Blue  supercompetent  bacteria  using  the  heat  shock  method  (4.2.17). 
Positive  clones  were  selected  and  plasmid  DNA  was  extracted  using  the 
QIAprep Spin Miniprep Kit. Correct sequence of the generated vectors was 
verified by sequencing, performed by AGOWA GmbH (Berlin), with pCMV5 
specific primers. 
 
4.2.20  Transfection of eukaryotic cells 
MCF-7 cells and Jurkat cells were transfected with the respective plasmids or 
siRNA using Cell Line Nucleofector Kit V on the Nucleofector. The required 
amount of cells was harvested by centrifugation. Then the cells were resolved 
in Nucleofector solution and mixed with 2 µg plasmid or siRNA. The mixtures 
were  transferred  to  an  appropriate  cuvette,  which  where  transferred  to the 
Nucleofector. After nucleofection, cells were seeded in 6 well plates in 1 ml full 
medium and incubated for 48 h, prior to use in individual experiments. HEK 
293 cells were transiently transfected by CaPO4-precipitation. In detail, H2O, 
CaCl2  and  the  2  µg  of  plasmid  were  mixed.  2  x  HBS  (4.1.2)  was  added, 
followed by vigorous vortexing. The resulting mix was incubated for 20 min at 
room  temperature,  to  allow  precipitation.  Subsequently,  an  appropriate 
amount of mix was added to cells, which then were incubated at 37° C for 24 
h. Medium was changed prior to the experiments. For transfection of NIH 3T3 
cells, 2 µg plasmid were mixed with 100 µl medium devoid of antibiotics, and 
10  µl  Roti®-Fect,  in  100  µl  medium  without  antibiotics  and  serum,  were 
added.  The  solution  was  mixed  by  pipetting  up  and  down,  followed  by 
incubation for 30 min at RT. The mixture was added to cells in medium devoid 
of antibiotics for 6 h at 37° C. Then, medium was re placed by full medium and 
cells  were  used  for  experiments  after  further  incubation  at  37° C  for  20  h. 
Transfection  efficiencies  were  measured  by  default  via  control  transfection 
with  pmaxGFP  (4.1.8)  and  subsequent  analysis  of  GFP  expression  using 
fluorescence  microscopy.  Overexpression  or  knock-down  of  proteins  was 
controlled by Western blot analysis (4.2.10). Specificity of siRNA knock-down 
was  ensured  by  control  transfection  with  siCONTROL  non-targeting  siRNA 
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4.2.21 Stable SphK2 knock-down 
For SphK2 knock-down, sequence specific siRNA oligonucleotides, designed 
following  the  guidelines  of  Ambion’s  siRNA  design  tool  on  their  website 
(4.1.7),  were  ligated  into  the  pSilencer
TM  4.1-CMV  neo  vector  (4.1.8). 
Oligonucleotides were annealed in DNA Annealing solution provided with the 
vector construction kit to obtain annealed hairpin siRNA at a concentration of 
8  ng/µl.  1   l  annealed  siRNA  insert  was  mixed  with  1   l  DNA  Annealing 
Solution,  6   l  Nuclease-free  water,  1   l  10X  T4  DNA  Ligase  Buffer,  1   l 
pSilencer 4.1-CMV neo vector and 1  l T4 DNA ligase (5 U/ l). Ligation was 
performed  for  1  h  at  22° C.  pSilencer-siSphK2  was  th en  transformed  into 
bacteria  using  the  heat  shock  protocol  (4.2.17).  Plasmids  were  amplified, 
extracted from bacteria (4.2.18) and were sequenced using specific primers 
(4.1.7) to verify efficient ligation. pSilencer-siSphK2 was transfected into MCF-
7 cells using Nucleofector technology (4.2.20). Stability of transfection was 
ensured by keeping MCF-7-siSphK2 cells under selective pressure using 500 
µg/ml  of  Neomycin  (G418)  during  cell  culture.  Efficient  knock-down  was 
verified by Western blot analysis (4.2.10).  
 
4.2.22  Immunofluorescence staining 
HEK293 cells were seeded directly onto a slide, and transiently transfected by 
CaPO4-precipitation (4.2.20) with HA-SphK2 or the mutated constructs. After 
transfection, cells were used for experiments and treated as indicated. Cells 
were incubated for 1 h at RT in fixation buffer, followed by permeabilization for 
20 min in 0.2% Triton X-100. After that, cells were incubated for 2 h with a 
mouse  anti-HA  antibody  and  rabbit  anti-caspase-1  antibody  followed  by 
washing  thrice  with  PBS.  Secondary  antibodies  (2  h)  were  goat  α-rabbit 
labeled with Alexa Fluor 546 and goat α-mouse labeled with Alexa Fluor 488. 
Cells were counterstained with DAPI (1  g/ml in PBS for 15 min). After a final 
5-min washing step in PBS, cells were covered  with Vectashield mounting 
medium and a cover slip. Localization of wild type and mutated HA-SphK2 as 
well  as  caspase-1  was  analyzed  using  the  AxioScope  fluorescence 
microscope with the ApoTome upgrade (lens 63./0.6 NA; ocular 10) at room 
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AxioVision Software. Alternatively, tumor cryosections were analyzed. Slides 
were washed with PBS for 5 min at RT, incubated in 0.1% Triton X-100 for 
another 5 min, followed by incubation for 1 h in blocking solution at RT. After 
that,  slides  were  incubated  overnight  with  rat  anti-CD31  or  rat  anti-F4/80 
antibody in blocking solution, washed thrice with PBS, followed by incubation 
with a Cy3-labelled anti-rat antibody in blocking solution for 2 h. Nuclei were 
counterstained with DAPI for 15 min, washed for 5-min in PBS and slides 
were  covered  with  Vectashield mounting  medium  and  a  cover  slip  prior  to 
fluorescence imaging. 
 
4.2.23 Tumor growth in nude mice 
Seven-week-old NMRI-nu/nu female mice were used (4.1.10). MCF-7 (n = 8) 
or MCF-7-siSphK2 cells (n = 6) (suspended in cell culture medium devoid of 
antibiotics)  were  injected  subcutaneously  at  the  right  and  left  dorsal  flank 
(1×10
7 cells per mouse). The mice received 10 mg/kg estradiolvalerate i.m. 
one  week  before  tumor  cell  injection,  followed  by  further  weekly 
estradiolvalverate-injection. The tumor volume was assessed three times a 
week with the calliper rule, as soon as control tumors started growing. Tumor 
volume was calculated according to the following formula: V = (a x b)
2/2 (V = 
tumor volume, a = length, b = breadth). After three weeks, mice were killed, 
followed  by  perfusion.  In  detail,  mice  were  anesthetized  and  the  thoracic 
cavity was opened to expose the heart. An 18-gauge needle, connected to a 
pump,  was  inserted  into  the  left  ventricle, followed  by  opening  of  the  right 
atrium. Mice were perfused with approximately 50 ml PBS (RT), followed by 
perfusion  with  50  ml  ice  cold  4%  PFA.  Afterwards,  tumors  were  removed, 
fixed in 4% PFA overnight at 4° C, followed by a fur ther overnight incubation in 
30% sucrose (4%) for cryoprotection. Fixed tumors were stored at -80° C and 
8  µm  cryosections  were  prepared  using  the  Jung  CM  3000  cryotome. 
Macrophage  infiltration  (F4/80),  as  well  as  blood  vessel  formation  (CD31), 
was  then  monitored  in  tumor  cryosections by  immunofluorescence  staining 
(4.2.22).  In  all  experiments  the  ethics  guidelines  for  investigations  in 
conscious animals were obeyed and the experiments were approved by the 
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4.2.24  Statistical analysis 
For Western  analysis  one  representative  experiment  is  displayed.  p-values 
were  calculated  using  one-factor  ANOVA  or  a  two-tailed  Student’s  t-test 
modified by Bonferroni’s multiple comparison test. Differences were regarded 
as significant for p < 0.05, unless indicated otherwise. Results                                                                                                                                   62                                                                                                                 
5  Results 
 
5.1  Macrophages cheat death after interaction with apoptotic cells 
Macrophages exert key functions in termination of inflammation, at least in 
part due to their interaction with AC. Therefore it should be warranted, that 
their immunosuppressive and curative properties carry on during the whole 
process  of  tissue  regeneration,  e.g.  in  wound  healing.  One  vital  means  to 
provide this security is resistance against cell death, as potentially harmful 
substances  are  aboard  especially  during  inflammation.  The  first  question  I 
addressed  was  whether  AC  influence  macrophage  resistance  against 
inducers of cell death or not. 
 
 
 
Figure 7: AC attenuate caspase-3 activation in murine and human macrophages. Caspase-3 
activity  in  (A)  murine  RAW  264.7  macrophages  and  (B)  human  monocyte-derived  THP-1 
macrophages normalized to untreated control cells. Macrophages were pre-treated with AC, 
NC,  VC  or  remained  as  controls  for  16  h.  Cell  death  was  induced  for  8  h  with  250  µM 
etoposide.  Data  are  presented  as  the  mean  ±  SD  from  three  independent  experiments. 
Differences between untreated and AC-treated cells are statistically significant (p < 0.05). (C) 
Apoptosis  in  Jurkat  cells  induced  with  0.5  µg/ml  staurosporine  followed  by  annexin-V/PI 
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5.1.1  Macrophage protection against apoptosis by apoptotic cells  
The  first  approach  to  determine  the  impact  of  AC  in  protection  of 
macrophages  from  apoptosis  was  incubation  of  RAW  264.7  mouse 
macrophages (Figure 7A) and THP-1 human monocyte-derived macrophages 
(Figure 7B) with apoptotic Jurkat cells, and subsequent induction of apoptosis 
with  etoposide,  an  inhibitor  of  topoisomerase  II  (153).  The  amount  of 
apoptosis in Jurkat cells was around 80% after 3 h-treatments with 0.5 µg/ml 
staurosporine (Sts), the time point when AC were applied to macrophages, 
while  necrosis  only  started  to  increase  from  6  h  onwards  (Figure  7C).  In 
contrast  to  necrotic  (NC)  or  viable  (VC)  Jurkat  cells,  co-cultures  with  AC 
attenuated  caspase-3  activation  in  RAW  264.7  as  well  as  THP-1  cells, 
compared to controls. Similar results were obtained with alternative apoptosis-
inducing  stimuli  such  as  nitric  oxide  (NO)  or  TNF-α  in  combination  with 
cycloheximide (CHX) (data not shown).  
 
 
 
Figure 8: AC attenuate macrophage apoptosis. (A to D) THP-1 cells were untreated or pre-
treated with AC for 16 h. Apoptosis was induced for 8 h with 250 µM etoposide. Viability was 
assessed  by  (A  and  C)  annexin-V/PI  staining,  (B  and  D)  JC-1  staining  and  subsequent 
analysis  by  flow  cytometry.  (C  and  D)  Data  are  presented  as  the  mean  ±  SD  from  four 
independent  experiments.  Differences  between  untreated  and  AC-treated  cells  are 
statistically significant (p < 0.05) for both parameters shown.  
 
Measurement of alternative apoptotic markers, which were phosphatidylserine 
exposure  and  mitochondrial  membrane  integrity,  confirmed  that  AC  indeed 
attenuated etoposide-induced apoptosis (Figure 8A to D). THP-1 cells pre-Results                                                                                                                                   64                                                                                                                 
incubated  with  AC  showed  significantly  less  annexin-V  binding  following 
treatment  with  etoposide  as  compared  to  controls  (Figure  8A  and  C). 
Macrophage  staining  with  the  fluorescent  dye  JC-1,  which  differentiates 
between  metabolically  active  (red  fluorescence)  and  defective  (green 
fluorescence) mitochondria, further verified prevention of cell death (Figure 8B 
and  D).  The  presence  of  AC  preserved  mitochondrial  integrity  in 
macrophages, which otherwise was lost upon etoposide treatment.  
 
 
 
Figure 9: Macrophage protection is caused by an apoptotic cell-derived soluble factor. (A-C) 
Caspase-3  activity  in  etoposide-treated  (8  h,  250  µM)  THP-1  macrophages  normalized  to 
untreated controls. Cells and media were pre-incubated for 16 h. Data are presented as the 
mean ± SD from three independent experiments. Statistical differences between samples are 
marked with asterisk (p < 0.05). (A) Cells remained untreated, were treated with AC alone or 
in combination with 2 µM cytochalasin D. (B) Cells remained untreated or were treated with 
conditioned media from macrophages co-cultured with AC (ACCM), necrotic cells (NCCM) or 
conditioned medium from AC (ACM). (C) Cells remained untreated or were pre-exposed to 
AC in transwell inserts for 16 h prior to stimulation with etoposide. 
 
5.1.2  Survival is transmitted by a soluble factor  
I questioned the type of interaction between AC and macrophages that was 
required to attenuate etoposide-evoked cell death. Therefore cytochalasin D, 
an inhibitor of phagocytosis via disruption of cytoskeletal rearrangement (154), 
was added to THP-1 macrophages prior to incubation with AC (Figure 9A). 
Upon stimulation with etoposide, there was no difference in the ability of AC to 
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cytochalasin  D.  This  excluded  a  contribution  of  phagocytosis  in  conveying 
protection.  
Next,  conditioned  medium  from  macrophage/AC  co-cultures  (ACCM)  was 
collected to check whether or not a macrophage-derived soluble factor might 
be involved. For control reasons, conditioned medium of macrophage/NC co-
cultures  (NCCM)  and  conditioned  medium  from  AC  (ACM)  only  was  used 
(Figure 9B). Interestingly, not only ACCM but also ACM protected THP-1 cells 
from etoposide-induced apoptosis, while NCCM did not (Fig 9B). This finding 
strongly  suggested  the  release  of  a  protective  factor  from  AC.  For  further 
validation,  transwell  experiments  were  performed,  separating  macrophages 
and AC by a permeable membrane to exclude direct cell/cell contacts. Spatial 
separation  of  macrophages  and  AC  still  conveyed  protection  (Figure  9C). 
These  results  argued  for  a  soluble,  apoptotic  cell-derived  factor,  mediating 
macrophage protection towards etoposide-induced cell death.  
 
5.1.3  Survival is irrespective of AC cell line and pro-apoptotic stimulus 
To analyze whether the production of an anti-apoptotic factor by AC was an 
inherent feature of apoptotic cell death, apoptosis was induced in different cell 
lines by activating intrinsic (Sts) as well as extrinsic pathways (TNF-α, anti-
Fas) of apoptosis. ACM from Jurkat, RKO, HEK293 or MCF-7 cells elicited 
protection against etoposide-induced THP-1 macrophage apoptosis (Table 2). 
These results imply that macrophage protection by AC resembles a general 
principle because it was reproduced by using distinct cell lines treated either 
with extrinsic or intrinsic pro-apoptotic stimuli. Moreover, by using caspase-3 
negative  MCF-7  cells  (35),  an  involvement  of  caspase-3  activation  in  the 
production of the protective factor was excluded.     
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Table 2: Macrophage protection by ACM from different cell lines and stimuli  
___________________________________________________________________ 
 
Cell line and stimulus        Protection (%) 
*   SD (n ≥ 3)
 
___________________________________________________________________       
Jurkat 
Staurosporine [0.5 µg/ml, 3 h]      100      ± 0   
Anti-Fas [0.05 ng/ml, 5 h]      91.1      ± 18.6   
RKO 
Staurosporine [0.5 µg/ml, 5 h]      103.3      ± 23.6   
MCF-7 
Staurosporine [0.5 µg/ml, 4 h]      91.3      ± 12.9   
HEK293 
Staurosporine [0.5 µg/ml, 8 h]      80.5       ± 19.7   
TNF-α/CHX [50 ng/ml/10 µg/ml, 24 h]    106.7      ± 27.5 
___________________________________________________________________ 
*100%  protection  is  set  as  the  difference  in  caspase-3  activity  (fold  of  control)  between 
untreated THP-1 macrophages and those treated with ACM (16 h) from Jurkat cells killed 
with staurosporine, followed by induction of apoptosis in macrophages with 250 µM etoposide 
for 8 h. Caspase-3 activity in whole cell lysates was quantified as described in Materials and 
Methods.  Differences  in  caspase-3  activity  between  untreated  and  ACM-treated 
macrophages were significant (p < 0.05) for each cell line and stimulus indicated.  
 
5.1.4  Characterization of the protective factor  
With the intention to characterize the nature of the protective factor present in 
ACM,  I  noticed  that  neither  heating  conditioned  medium  at  100° C,  nor 
digestion with proteinase K or trypsin abrogated the protective principle (Table 
3), thus ruling out a protein factor. However, extracting lipids from ACM with 
chloroform  completely  eliminated  protection  (Table  3).  These  experiments 
argued for a lipid factor as the messenger in question.  
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Table 3: Macrophage protection by ACM  
__________________________________________________________________________ 
 
ACM-Treatment     Protection (%) 
*     SD         p-value (n ³ 3)
† 
__________________________________________________________________________ 
 
none          100      ± 0    - 
 
heat inactivation [100° C]    87.4      ± 2.4    0.4 
 
proteinase K digestion [50 µM]    98.5      ± 8.2    0.39 
 
trypsin digestion [0.1%]     99.2      ± 12    0.46 
 
chloroform extraction       -5.2       ± 17.5    0.007 
__________________________________________________________________________ 
*100%  protection  is  set  as  the  difference  in  caspase-3  activity  (fold  of  control)  between 
untreated and ACM-treated (16 h) THP-1 macrophages after induction of apoptosis with 250 
µM etoposide for 8 h. Caspase-3 activity in whole cell lysates was quantified as described in 
Materials and Methods. 
†Statistical analysis was performed using the paired Student’s t-test.  
 
5.1.5  Characterization of the protective principle  
To establish the time-dependency for protection, THP-1 cells were incubated 
with ACM for 1 to 6 h prior to stimulation with etoposide. Significant protection 
was  first  detected  after  6  h,  with  the  further  notion  that  protection  once 
established  lasted  for  48  h  (data  not  shown).  Additional  examinations 
confirmed  protection  by  ACM  in  primary  human  monocyte-derived 
macrophages, as determined by annexin-V/PI staining and caspase-3 activity 
measurements (Figure 10A). To characterize protective signaling pathways, I 
used  pharmacological  inhibitors  known  to  interfere  with  anti-apoptotic 
pathways. LY294002, an inhibitor of PI3K-signaling, PD98059, an inhibitor of 
ERK1/2, and Bapta-AM, a calcium chelator, restored caspase-3 activation in 
human primary macrophages upon pre-incubation with ACM. Inhibitor studies 
implied  that  preferentially  a  PI3K-sensitive  pathway  transmits  protection  in 
response  to  ACM,  while  Ca
2+  as  well  as  ERK1/2  signaling  contributes  to 
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Figure 10: Protection of primary human macrophages by ACM is PI3K-, Ca2+- and ERK1/2-
dependent. (A) Human primary monocyte-derived macrophages remained untreated or were 
exposed to ACM for 16 h. Following a medium change, apoptosis was induced for 8 h with 10 
ng/ml TNF-α and 10 µg/ml CHX. Viability was assessed by annexin-V/PI staining and FACS-
analysis.  Data  in  histograms  are  presented  as  the  mean  ±  SD  from  three  independent 
experiments. Statistical differences are marked (p < 0.05). The lower part shows typical FACS 
traces. (B) Human primary macrophages were not treated, exposed to ACM for 16 h in the 
presence or absence of LY92004, PD98059 or  Bapta-AM at the indicated concentrations. 
Apoptosis was induced for 8 h with 10 ng/ml TNF-α and 10 µg/ml CHX. The upper histogram 
shows  caspase-3  activity.  Data  are  presented  as  the  mean  ±  SD  from  six  independent 
experiments. Significant differences between samples are marked by asterisks (p < 0.05). 
Western analysis shows expression of Bcl-2 and phospho-Ser136-Bad. One representative 
experiment out of three is displayed. Lower histograms show quantification of Western data 
normalized to actin by using AIDA software. Data are presented as the mean ± SEM from four 
independent experiments.  
 
Supportive  argumentation  comes  from  Bcl-2  expression  and  Ser136-Bad 
phosphorylation. Treatment of human primary macrophages with TNF-α and 
CHX decreased Bcl-2 levels and Bad-phosphorylation, compared to controls, 
with  the  notion  that  these  changes  were  restored  by  ACM.  In  analogy  to 
caspase  activity,  PD98059  reduced  Bcl-2  stabilization  while  Bad-
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(Figure  10B).  In  order  to  investigate  the  contribution  of  other  Bcl-2  family 
members towards protection, expression of Mcl-1 and Bcl-XL, which is known 
to be relevant for macrophage survival (155, 156), was analyzed in response 
to  ACM.  Although  Mcl-1  was  not  significantly  induced  by  ACM  in 
macrophages, up-regulation of Bcl-XL was obvious (Figure 11B). I concluded 
that the ACM-protective principle is reflected at the level of pro- and/or anti-
apoptotic  Bcl-2-family  members.  This  is  further  supported  by  JC-1 
experiments (Figure 8B and C), which imply the involvement of mitochondria.  
 
5.1.6  Contribution of sphingosine-1-phosphate towards protection  
Results so far pointed to a lipid mediator in protection of macrophages against 
apoptotic cell death. Therefore, I tested candidates such as platelet-activating 
factor (PAF), lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC) or 
sphingosine-1-phosphate (S1P), known to manipulate apoptosis in other test 
systems.  Increasing  concentrations  of  each  compound,  compared  to  ACM, 
were  added  to  primary  macrophages  in  combination  with  the  apoptosis-
inductors TNF-α/CHX (Table 4). Only S1P induced significant protection at a 
rather  low  concentration  of  1  µM  (Table  4).  LPC  attenuated  cell  death  at 
higher concentrations, only, and PAF as well as LPA increased rather than 
decreased death.  
Considering a potential impact of S1P, the effect of ACM-extracted lipids, the 
ACM aqueous phase as well as conditioned medium derived from necrotic 
cells  (NCM),  was  analyzed  regarding  the  modulation  of  death  in  primary 
human macrophages (Figure 11A). TNF-α/CHX-evoked caspase-3 activation 
was attenuated by the lipid but neither by the aqueous phase of ACM nor by 
NCM. Protection conveyed by ACM as well as S1P was reflected at the level 
of  Bcl-2,  Bcl-XL,  and  phosphorylated  Bad  (Figure  11B).  ACM  and  S1P 
increased  Bcl-2  as  well  as  Bcl-XL  expression  and  provoked  Bad 
phosphorylation in analogy to results shown in Figure 10B. To strengthen a 
protective role of S1P, dimethylsphingosine (DMS), an inhibitor of sphingosine 
kinases, was applied to Jurkat cells 3 h prior to initiation of cell death. ACM 
derived from DMS-treated Jurkat cells did not protect macrophages from TNF-
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Table 4: Bioactive lipids and human macrophage survival  
__________________________________________________________________________ 
 
Treatment        Caspase-3 activity
*    SD      p-value (n ³ 3)
 † 
__________________________________________________________________________      
 
none        30.6        ± 4    - 
 
ACM        5.3        ± 3.6    0.02 
              
LPA   [1 µM]      30.1        ± 12.8    0.35 
  [10 µM]     33.8        ± 19.7    0.49 
  [100 µM]    39.5        ± 20.8    0.35 
 
S1P  [1 µM]      13.2        ± 9.2    0.05 
  [10 µM]     10        ± 6.3    0.02 
  [100 µM]    6.1        ± 4    0.006 
 
PAF  [1 µM]      40.5        ± 5.1    0.4 
  [10 µM]     61.1        ± 41.3    0.15 
  [100 µM]    97.2        ± 59.6    0.09 
 
LPC  [1 µM]      54.2        ± 27.8    0.25 
  [10 µM]     32.1        ± 18.4    0.44 
  [100 µM]  20        ± 5.2    0.2 
__________________________________________________________________________ 
*Human primary macrophages were exposed to ACM, LPA, S1P, PAF or LPC at the indicated 
concentrations for 16 h. Apoptosis was induced with 10 ng/ml TNF-α and 10 µg/ml CHX for 8 
h.  Caspase-3  activity  in  whole  cell  lysates  was  quantified  as  described  in  Materials  and 
Methods. 
†Statistical analysis was performed using the paired Student’s t-test.  
 
To further substantiate a role of S1P in protection, I used a lipid extraction 
procedure, designed to be specific for S1P (143). The lipid extract from ACM 
gained  with  this  method  reproduced  protection  (Figure  11A),  which 
underscores the assumption that indeed S1P is released from AC to protect 
macrophages from entering pathways of cell demise. 
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Figure 11: Sphingosine-1-phosphate conveys protection. (A to C) Apoptosis in human primary 
macrophages  was  induced  for  8  h  with  10  ng/ml  TNF-α  and  10  µg/ml  CHX.  (A)  Cells 
remained  untreated  or  were  treated  with  ACM,  the  ACM-lipid  fraction,  the  ACM-aqueous 
fraction, with ACM derived from Jurkat cells exposed to DMS prior to initiation of apoptosis 
(ACM-DMS) or treated with the ACM-lipid fraction specific for S1P extraction (S1P-extraction), 
16  h  prior  to  induction  of  cell  death.  Caspase-3  activity  was  quantified  as  described  in 
Materials  and  Methods.  Data  are  presented  as  the  mean  ±  SD  from  four  independent 
experiments. Significant differences between samples are marked by asterisk (p < 0.01). (B) 
Cells were not treated, exposed to the ACM or stimulated with 10 µM S1P for 16 h. Western 
analysis  shows  expression  of  Bcl-2,  Bcl-XL  and  phosphorylated  Ser136-Bad.  One 
representative  experiment  out  of  three  is  displayed.  Histograms  show  quantification  of 
Western data normalized to actin by using AIDA software. Data are presented as the mean ± 
SEM from three independent experiments. (C) Cells remained untreated, were exposed for 16 
h to ACM alone or to ACM after pre-treatment with 100 nM FTY720 for 1 h followed by further 
incubations of 48 h. Afterwards TNF-α/CHX-treatments lasted for 8 h. Data are presented as 
the mean ± SD from four independent experiments. Significant differences between samples 
are marked by asterisks (p < 0.05).  
 
Next, the identity of the subtype of S1P receptor being expressed on human 
macrophages and participating in protection was questioned. Primary human 
macrophages were pre-stimulated with 100 nM of the S1P-receptor agonist 
FTY720, which induces internalization of S1PR1 after 48 h when applied for 1 
h (116). Western blot analysis revealed a strong down-regulation of S1PR1 
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When ACM was added to macrophages with S1PR1 being down-regulated, 
protection was significantly but not completely diminished in comparison to 
macrophages incubated only with ACM (Figure 11C). Since pre-stimulation of 
macrophages  with  100  nM  FTY720  was  shown  to  specifically  induce 
internalization  of  S1P-receptor  subtypes  1  and  5  (116),  I  concluded  that 
S1PR1 was at least partially responsible for macrophage protection by S1P 
because macrophages do not express S1PR5 (157, 158).     
 
 
 
Figure  12:  Measurement  of  S1P-secretion  by  AC.  (A)  Fragment  spectra  of  S1P  and  the 
internal  standard  C17-S1P  by  using  product  ion  scans  in  the  positive  ionization  mode. 
Product ion scans were obtained by infusion of 100-1000 ng/ml of the respective analyte in 
methanol with a flow of 10 µl/min. (B to C) Jurkat cells were cultured in FCS free medium, 
remained as controls (VCM) or were treated with 0.5 µg/ml staurosporine with (ACM-DMS) or 
without  (ACM)  the  previous  addition  of  DMS  for  3  h.  After  changing  medium,  incubation 
continued for another 2 h and conditioned media were analyzed for the S1P content with 
liquid  chromatography-tandem  mass  spectrometry.  (B)  Exemplary  chromatograms  of  S1P 
representing 22.0, 42.1 and 12.2 ng/ml, respectively. (C) Quantification of S1P release in the 
supernatant  of  Jurkat  cells.  Data  are  presented  as  the  mean  ±  SD  from  six  independent 
experiments. Significant differences between samples are marked by asterisks (p < 0.05). 
 
Many  hints  pointed  to  a  mechanism  involving  S1P  release  from  AC.  The 
finally  prove  this  assumption,  conditioned medium from  viable  Jurkat  cells, 
ACM and ACM from DMS-treated Jurkat cells was analyzed for S1P amounts 
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chromatography-tandem mass spectrometry analysis (Figure 12). Induction of 
Jurkat  cell  apoptosis  with  Sts  increased  the  release  of  S1P  into  the  cell 
supernatant  as  compared  to  non-stimulated  cells  (Figure  12B  and  C). 
Moreover,  S1P  release  from  AC  was  blocked  by  the  sphingosine  kinase 
inhibitor DMS (Figure 12B and C). These data corroborated the release of the 
anti-apoptotic molecule S1P from AC.  
 
5.1.7  S1P production during apoptosis is performed by SphK2  
Since two isoforms of SphK are known up to date, and DMS attenuates the 
activity  of  both  enzymes,  siRNA  technology  was  used  to  determine  which 
SphK isoform catalyzes S1P production during apoptotic cell death.  
 
 
 
Figure 13: SphK2 expression in AC contributes to the release of S1P. (A) Apoptosis in human 
primary macrophages was induced for 8 h with 10 ng/ml TNF-α and 10 µg/ml CHX. Cells 
remained untreated or were treated with ACM or ACM from Jurkat cells nucleofected with 
siRNA to target SphK1 or SphK2, 16 h prior to induction of cell death. Caspase-3 activity was 
quantified as described in Materials and Methods. Data are presented as the mean ± SD from 
four  independent  experiments.  Significant  differences  between  samples  are  marked  by 
asterisks (p < 0.05). (B) Jurkat cells were nucleofected with control siRNA or siRNA against 
SphK1 or SphK2. Western analysis shows SphK1 and SphK2 expression. One representative 
experiment out of three is displayed.  
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Therefore, Jurkat cells were nucleofected with siRNA for both SphK-isoforms, 
prior  to  being  used  for  the  preparation  of  ACM.  Importantly,  induction  of 
apoptosis with Sts in Jurkat cells was not affected by knock-down of either 
SphK1  or  SphK2  (data  not  shown).  Western  blot  analysis  revealed  strong 
down-regulation of SphK1 and SphK2 in Jurkat cells after nucleofection with 
corresponding siRNA, compared to control siRNA (Figure 13B). Incubation of 
human  primary  macrophages  with  ACM-siSphK2  significantly  reduced 
protection  compared  to  the  efficacy  of  ACM,  whereas  ACM-siSphK1  was 
marginally effective, only (Fig 13A). These data strongly suggested a role of 
SphK2 in the production of S1P in AC. Concluding, I can say that AC release 
S1P, which transmits a shift in the Bcl-2 family member profile towards anti-
apoptotic via S1PR1 in macrophages, thus protecting them from cell death.   
 
5.2  The mechanism of S1P production by apoptotic cells 
S1P  was  produced  and  released  during  apoptotic  cell  death  (5.1),  a 
phenomenon that likely enhances its biological importance, since apoptosis 
plays a fundamental role in the pathogenesis of many human diseases (26). 
Therefore I desired to understand the underlying mechanistic principle, since 
this could lead to the identification of targets for the treatment of disease. 
 
5.2.1  A truncated sphingosine kinase 2 is released during apoptosis 
Little is known how S1P is transferred from inside a cell to its surrounding. To 
approach the mechanism of its production in AC, I investigated subcellular 
expression  and  activity  of  SphK2  in  Jurkat  cells,  prior  and  subsequent  to 
apoptosis-induction  using  Sts  (Figure  14).  Corroborating  a  previous  report 
(108), reduced expression of SphK2, both of the L- and S-isoform (111), in the 
nuclear,  membrane  and  cytosolic  fractions  was  noticed  during  apoptosis 
(Figure  14A).  New  data  emerged  when  I  observed  a  protein  of  lower 
molecular weight in the supernatant of Sts-treated cells (Figure 14A), that was 
only visible with an antibody recognizing the C-terminus of SphK2, but not 
with  an  antibody  binding  to  the  N-terminus.  Using  a  fluorescence-based 
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Jurkat  cells  was  revealed,  whereas  extracellular  SphK2  activity  was 
significantly elevated (Figure 14B).  
 
 
 
Figure 14: A truncated active SphK2 (t-SphK2) is released into the supernatant of apoptotic 
Jurkat cells. (A and B) Jurkat cells remained as controls or were treated with staurosporine as 
described in Materials and Methods. (A) Western analysis of SphK2 expression in subcellular 
fractions (nuclear (N), membrane (M), cytosolic (C)) or the cell supernatant (S). (B) SphK2 
activity in cell lysates (white bars) and cell supernatants (black bars). Data are means ± SEM 
from four independent experiments. Asterisks indicate significant differences (* = p < 0.05). 
 
5.2.2  Caspase-1 cleavage sites in SphK2 
Since cleavage of SphK2 was not previously reported, I used PeptideCutter, a 
free  tool  on  the  ExPASy  Proteomics  Server,  to  identify  potential  protease 
cleavage  sites. With  a  focus  on  proteases  activated  during  apoptosis,  two 
putative caspase-1 cleavage sites were identified in human SphK2, at D138 
and  D552,  both  of  them  being  well  conserved  in  mammals  (Figure  15). 
Furthermore, the N-terminal cleavage site showed homology to a caspase-1 
cleavage site in pro-IL-b (12) (Figure 15). To ask for potential consequences 
of SphK2 cleavage by caspase-1 regarding protein distribution, I used WoLF 
PSORT (159), to predict localization of full length as well as cleaved SphK2. 
The  prediction  for  full  length  SphK2  to  be  localized  mainly  nuclear  and 
cytosolic, concurs with experimental data (120). Putative localization of the C-
terminal caspase-1 cleavage product was identical with the full length protein. 
Interestingly,  the  product  generated  by  N-terminal  cleavage  was  predicted, 
among other compartments, to localize extracellular (data not shown).  
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Figure 15: Caspase-1 cleavage sites in SphK2 are conserved in mammals. (A) Alignment of 
putative caspase-1 cleavage sites (bold letters) in SphK2 from different mammalian species is 
displayed. (B) Comparison of caspase-1 cleavage sites in human SphK2 with the N-terminal 
caspase-1 cleavage site in pro-interleukin 1β. Fragment sizes (aa) resulting from cleavage 
are displayed. 
 
5.2.3  Caspase-1 inhibition abrogates SphK2 release 
Taking this theoretical information into account, caspase-1 was inhibited with 
Ac-YVAD-CMK,  which  indeed  prevented  SphK2  cleavage  and  the 
concomitant  release  of  the  C-terminal  fragment  into  the  supernatant  of 
apoptotic, i.e. Sts-treated cells (Figure 16A). My previous studies showed that 
ACM  containing  S1P  attenuated  etoposide-induced  caspase-3  activation  in 
THP-1  macrophages  and  upregulated  Bcl-2  (5.1).  These  alterations  were 
reversed, when ACM was generated from Jurkat cells treated with Sts in the 
presence of the caspase-1 inhibitor Ac-YVAD-CMK or the sphingosine kinase 
inhibitor DMS (Figure 16B).  
To obtain more direct evidence for the involvement of caspase-1 in provoking 
SphK2 release, caspase-1 expression in Jurkat cells was targeted with siRNA. 
Expression of pro-caspase-1 and the active p20 subunit was reduced below 
the control level with caspase-1 being knocked down. Sts initiated the release 
of the truncated SphK2 to the supernatant, which was attenuated in caspase-
1  knock-down  cells  (Figure  16C).  Intracellular  expression  of  SphK2  in 
apoptotic caspase-1 knock-down Jurkat cells was comparable to that seen in 
controls. Sts also increased caspase-1 as well as caspase-3 activity, but only 
caspase-1  activity  was  reduced  in  caspase-1  knock-down  cells,  shown  via 
fluorescence-based  caspase  activity  assays  (Figure  16C).  Along  that  line, Results                                                                                                                                   77                                                                                                                 
ACM  from  caspase-1  knock-down  Jurkat  cells  failed  to  protect  THP-1 
macrophages  against  etoposide,  compared  to  ACM  from  Jurkat  cells 
transfected  with  non-targeting  siRNA,  as  demonstrated  by  caspase-3 
measurements  (Figure  16D).  I  concluded  that  caspase-1  provokes  SphK2 
cleavage and release of the truncated SphK2 during apoptosis.  
 
 
 
Figure  16:  Release  of  SphK2  demands  active  caspase-1.  (A) Western  analysis  of  SphK2 
expression  in  the  cytosol  and  supernatants  of  Jurkat  cells  left  as  controls,  treated  with 
staurosporine (Sts) or Sts in combination with the caspase-1 inhibitor Ac-YVAD-CMK (C1-I). 
(B) THP-1 macrophages were pretreated with supernatants of apoptotic Jurkat cells (ACM), 
or supernatants of AC generated with either DMS (ACM-DMS) or Ac-YVAD-CMK (ACM-C1-I) 
being present. Apoptosis was induced for 8 h with 250 µM etoposide. Caspase-3 activity in 
THP-1 macrophages normalized to untreated cells is shown. Data are means ± SEM from 
four  independent  experiments.  (C)  Jurkat  cells  were  controls  or  transfected  with  either 
siCONTROL  or  siRNA  directed  against  caspase-1  prior  to  induction  of  apoptosis  with 
staurosporine. Western analysis shows expression of pro-caspase-1 and the caspase p20 
subunit in the cytosol and t-SphK2 in the cell supernatant. Histograms display caspase-3 or 
caspase-1  activity  normalized  to  controls.  Data  are  means  ±  SEM  from  four  independent 
experiments. (D) THP-1 macrophages were pretreated with supernatants of apoptotic Jurkat 
cells  transfected  with  siCONTROL  (ACM-siControl)  or  siRNA  targeting  caspase-1  (ACM-
siCasp 1). Apoptosis was induced for 8 h with 250 µM etoposide. Caspase-3 activity in THP-1 
macrophages  was  normalized  to  untreated  cells.  Data  are  means  ±  SEM  from  five 
independent experiments. (B to D) Asterisks indicate significant differences (* = p<0.05; ** = 
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5.2.4  Mutational analysis of caspase-1 cleavage sites in SphK2 
The  following  experiments  were  planed  to  establish  a  system  allowing 
overexpression  of  SphK2,  which  at  the  same  time  could  be  utilized  for 
mutational analysis of caspase-1 cleavage sites. HEK293 cells are easy to 
transfect and exhibit low basal SphK2 expression. Some extracellular SphK2 
activity was elicited in supernatants of apoptotic HEK293 cells induced by Sts 
or tumor necrosis factor (TNF)-α, but again, this attenuated by the caspase-1 
inhibitor or by adding DMS, which was used as an internal control to block all 
SphK2  activity  in  the in  vitro  assay  (Figure  17A).  HEK293  cells were  then 
transfected with a plasmid encoding human N-terminal HA-tagged full length 
SphK2 (111). Induction of apoptosis in transfectants induced high extracellular 
SphK2  activity  compared  to  controls.  Intracellular  expression  of  HA-tagged 
SphK2  was  decreased  and  truncated  SphK2  appeared  in  the  supernatant. 
Again,  this  phenotype  was  ablated  when  caspase-1  was  blocked  with  Ac-
YVAD-CMK (Figure 17). Eliminating cleavage and release of SphK2 with the 
caspase-1 inhibitor was as potent as direct inhibition of SphK2 activity with 
DMS  in  the  supernatant  (Figure  17B).  Interestingly,  SphK2  cleavage  and 
release during apoptosis also occurred in the murine system. This was shown 
by using a plasmid encoding murine C-terminal V5-tagged SphK2 transfected 
into  NIH3T3  cells  (Figure  17C).  Unlike  in  the  human  system,  several 
intracellular  V5-tagged  fragments  appeared  during  the  time  course  of  V5-
SphK2 cleavage which may indicate further digestion by proteases, at least in 
the murine system (Figure 17C).  
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Figure 17: Overexpression of SphK2 in HEK293 and NIH 3T3 cells. (A) Apoptosis in HEK293 
cells was induced with staurosporine in the presence/absence of Ac-YVAD-CMK (C1-I), or 
using TNF-α. SphK2 activity in the supernatant, normalized to controls, is displayed. DMS 
was used as an internal control, added during the kinase assay. Data are means ± SEM from 
four independent experiments. (B) HEK293 cells were transfected with HA-hSPHK2/pCMV5. 
Cells  were  left  as  controls  or  treated  with  staurosporine  alone  or  in  combination  with  Ac-
YVAD-CMK. Histograms show SphK2 activity in the supernatant normalized to controls. DMS 
was used as an internal control. Data are means ± SEM from five independent experiments. 
Western  analysis  shows  cytosolic  expression  of  HA-SphK2  and  t-SphK2  in  the  cell 
supernatant. (C) NIH 3T3 cells were transfected with V5-mSphK2/pCDNA3.1. Cells were left 
as controls or treated with staurosporine for times as indicated. Western analysis displays 
intra-  and  extracellular  expression  of  V5-SphK2.  (A  and  B)  Asterisks  indicate  significant 
differences (*** = p<0.001). 
 
To  substantiate  N-terminal  cleavage  of  SphK2  by  caspase-1,  I  used  site-
directed  mutagenesis to  introduce  point mutations  in  the plasmid encoding 
HA-SphK2, changing aspartate to alanine in both putative caspase-1 cleavage 
sites. Mutated and wild type SphK2 were expressed in HEK293 cells to check 
basal SphK2 activity. Overexpression of the naïve plasmid vs. expression of 
the mutants produced comparable intracellular SphK2 activity (Figure 18A). 
Then, apoptosis was induced with Sts and extracellular SphK2 activity was 
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activity in the supernatant of apoptotic HEK293 cells. The same behavior was 
seen when expressing HA-SphK2-D552A. However, in cells expressing HA-
SphK2-D138A, extracellular SphK2 activity was drastically decreased (Figure 
18B). Checking for intracellular and extracellular protein expression revealed 
comparable information. Wild type and mutated proteins were expressed to a 
similar  extent.  Degradation  of  intracellular  HA-tagged  constructs  was  seen 
when expressing HA-SphK2 or HA-SphK2-D552A, but was absent with the 
HA-SphK2-D138A  mutant  (Figure  18C).  In  line,  the  release  of  truncated 
SphK2  was  detectable  in  supernatants  from  apoptotic  HEK293  cells 
expressing HA-SphK2 or HA-SphK2-D552A, but not in cells transfected with 
HA-SphK2-D138A (Figure 18D).  
 
5.2.5  Caspase-1 and SphK2 co-localize at the plasma membrane 
In the following experiments I determined localization of SphK2 before and 
after apoptosis induction with Sts. Therefore, paraformaldehyde fixed HEK293 
cells, expressing HA-SphK2 or HA-SphK2-D138A, were stained for the HA-
tag and caspase-1. Caspase-1 was stained as a marker for the cytosol and to 
possibly monitor co-localization with SphK2, while nuclei were counterstained 
using DAPI in control cells or following treatment with Sts for 2 h or 12 h. 
HA-SphK2 was visible throughout the cytosol in HEK293 cells as described 
previously (120) (Figure 18E, panel 1). The same holds for caspase-1. When 
Sts was added, HA-SphK2 translocated to the plasma membrane, where it co-
localized with caspase-1 (Figure 18E, panel 2). After 12 h of Sts, cell death 
was visible based on chromatin condensation (white arrows) and HA-SphK2 
was  scarcely  detectable  any  more  (Figure  18E,  panel  3).  The  same 
observation was made for caspase-1, which is known to be shed from dying 
cells and/or degraded subsequent to its activation. HA-SphK-D138A localized 
near  or  at  the  plasma  membrane  in  untreated  HEK293  cells  (Figure  18F, 
panel 1) and remained at the plasma membrane when Sts was added for 2 h 
(Figure 18F, panel 2). In contrast to HA-SphK2, HA-SphK2-D138A was not 
degraded, remained visible after 12 h Sts treatment and stayed membrane 
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Figure  18:  Mutation  of  the  N-terminal  caspase-1  cleavage  site  or  the  phosphatidylserine 
binding  site  in  SphK2  inhibits  cleavage  and  release  of  SphK2  during  apoptosis.  (A  to  D) 
HEK293 cells were transfected with HA-SphK2 or mutated constructs. (A) Intracellular SphK2 
activity normalized to controls. Data are means ± SEM from four independent experiments. (B 
and  C)  Transfectants  were  left  as  controls  or  treated  with  staurosporine.  (B)  Extracellular 
SphK2  activity  normalized  to  naïve  controls  is  shown.  Data  are  means  ±  SEM  from  five 
independent  experiments.  Asterisks  indicate  significant  differences  (***  =  p<0.001).  (C) 
Western analysis showing intracellular expression of wild type and mutated HA-SphK2. (D) 
Western analysis showing extracellular t-SphK2 expression in transfectants stimulated with 
staurosporine. (E to G) HEK293 cells, seeded on cover slips were transfected with (E) HA-
SphK2, (F) HA-SphK2-D138A or (G) HA-SphK2-T219A. Cells remained as controls or were 
treated with staurosporine for 2 or 12 h. Cells were fixed and stained for HA (green) and 
caspase-1  (red).  Nuclear  staining  was  performed  with  DAPI  (blue). White  arrows  indicate 
nuclear fragmentation. Each experiment was performed four times and representative images 
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Data so far indicated co-localization of SphK2 with caspase-1 after 2 h at the 
plasma membrane following induction of apoptosis with Sts and suggested 
that HA-SphK2-D138A, although located at the membrane, was not cleaved 
by caspase-1. These observations supported the assumption that caspase-1 
cleaves SphK2 at its N-terminus during apoptosis, with concomitant release to 
the extracellular space. 
 
5.2.6  Mutation of the PS binding site in SphK2 prevents its cleavage 
As noticed in Figure 16C I observed a residual activity of caspase-1 in Jurkat 
cells,  which  was  also  evident  in  most  other  cell  lines  that  were  used. 
Therefore, additional regulatory mechanisms, besides caspase-1 activation, 
must be critical in regulating SphK2 release during apoptosis. Interestingly, 
SphK2 as well as SphK1 contain phosphatidylserine (PS) binding sites, which 
are well conserved between both isoenzymes (Figure 19). Indeed, PS was 
shown to stimulate the activity of both isoforms (117). PS exposure on the 
outer leaflet of AC is considered to be a hallmark of apoptosis and crucial for 
provoking  anti-inflammatory  macrophage  polarization  after  their  interaction 
with AC (160). I therefore questioned whether PS exposure would affect the 
release or activity of SphK2 during apoptosis. The critical amino acid residues 
for  PS  binding  to  SphK1  have  been  identified  and  were  shown  to  have  a 
profound impact on SphK1 membrane targeting (161). I used this knowledge 
and mutated the analogous threonine 219 to alanine in SphK2.  
Mutation of the PS binding site did not significantly affect intracellular SphK2 
activity  compared  to  the  naïve  plasmid,  although  a  slight  reduction  was 
noticed  (Figure  18A).  However,  upon  induction  of  apoptosis  in  cells 
expressing  HA-SphK2-T219A,  extracellular  SphK2  activity  was  absent 
compared  to  cells  transfected  with  the  wt  plasmid  (Figure  18B).  In 
concordance, expression of HA-SphK2-T219A was only slightly reduced when 
comparing viable and apoptotic HEK293 cells (Fig 18C) and the release of 
truncated  SphK2  was  absent  (Figure  18D).  Taking  comparable  effects  on 
mutation of the N-terminal caspase-1 cleavage site and the PS binding site 
into  account  (Fig  18A  to  D),  intracellular  localization  of  the  mutant  was 
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paraformaldehyde and stained for the HA-tag and caspase-1. In contrast to 
cells expressing HA-SphK2 (Figure 18E) or HA-SphK2-D138A (Figure 18F), 
the HA-SphK2-T219A mutant remained cytosolic upon induction of apoptosis 
with Sts and was not degraded (Figure 18G). Apparently, binding of SphK2 to 
PS at the plasma membrane is critical for its cleavage and release.  
 
 
 
Figure 19: PS binding site is highly conserved between human SphK1 and SphK2. Sequence 
alignment of the PS binding sites in hSphK1 and hSphK2. The threonine residue, mutated in 
this study, is in bold. 
 
5.2.7  Lowering PS exposure attenuates SphK2 release 
To  obtain  more  information  on  the  role  of  PS,  I  applied  two  strategies  to 
modulate PS exposure during apoptosis. Besides initiating apoptosis in Jurkat 
cells with Sts, etoposide was used, which is known to induce apoptosis with 
only  minor  PS  exposure  (162).  Furthermore,  PS  exposure  was  attenuated 
during Sts- or etoposide-induced apoptosis with 100 µM nifedipine, which is 
an inhibitor of L-type calcium channels (163). Apoptosis in Jurkat cells elicited 
by Sts induced PS exposure, mitochondrial membrane depolarization ( Ψ) 
and cell shrinkage (Figure 20A and B). Nifedipine applied in combination with 
Sts  significantly  reduced  PS  exposure,  whereas  mitochondrial  membrane 
depolarization ( Ψ) and cell shrinkage remained unchanged (Figure 20A and 
B). Jurkat cells killed with etoposide showed a loss of  Ψ comparable to Sts, 
but less PS exposure, the latter one being further reduced in the presence of 
nifedipine  (Figure  20B).  These  conditions  allowed  initiating  Jurkat  cell 
apoptosis associated with a variable degree of PS exposure.  
SphK2 activity in supernatants of Sts- or etoposide-treated cells with/without 
the addition of nifedipine was reduced in parallel to PS exposure (Figure 20C 
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in whole cell lysate or supernatants. SphK2 was released into the supernatant 
of apoptotic Jurkat cells. Attenuating PS exposure decreased the release of 
truncated SphK2,  while  a  cleaved SphK2 fragment  accumulated  inside the 
cells  (Figure  20D).  Again,  the  inverse  correlation  between  released  SphK2 
and  accumulation  of  the  cleaved  fragment  inside  cells  correlated  with  PS 
exposure.  
 
 
 
Figure 20: SphK2 release during apoptosis is coupled to phosphatidylserine exposure. (A to 
D) Jurkat cells were killed with staurosporine or etoposide in the absence/presence of 100 µM 
nifedipine.  (A)  Left  FACS  histograms  show  phosphatidylserine  exposure  visualized  with 
Annexin V-FITC. Right FACS dot blots display phosphatidylserine exposure visualized with 
Annexin  V-FITC  compared  to  cell  size,  with  cell  shrinkage  indicating  cell  death. 
Representative data out of four experiments are shown. (B) Cells were stained with Annexin 
V-FITC (white bars) or DiOC6 (black bars) and analyzed by flow cytometry. Data are means ± 
SEM  from  four  independent  experiments.  (C)  Extracellular  SphK2  activity  normalized  to 
controls is shown. Data are means ± SEM from four independent experiments. (D) Western 
analysis of intra- and extracellular SphK2 expression. (B and C) Asterisks indicate significant 
differences  compared  to  cells  treated  with  staurosporine  alone  (*  =  p<0.05;**  =  p<0.01;  
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Taken  together,  I  showed  that  a  truncated,  enzymatically  active  SphK2  is 
shed from AC upon cleavage by caspase-1 at its N-terminus. This pictures a 
new  mechanism  how  S1P  is  released  from  cells.  The  outcome  of  this 
mechanism is the release of a protein factor, which could be a suitable target 
for  therapeutics,  like  neutralizing  antibodies  or  putative  specific  SphK2 
inhibitors. 
 
5.3  Tumor cell apoptosis polarizes macrophages via S1P 
As  mentioned  in  the  introduction  (3.3.3),  TAM  are  comparable  to  AC-
stimulated macrophages regarding their activation profile. Tumors may utilize 
the properties of macrophages in tissue repair and angiogenesis by providing 
signals  comparable  to  AC.  Since  S1P  is  highly  associated  with  tumor 
angiogenesis  (3.4.2),  the  connection  between  AC-derived  S1P  and  TAM 
development seemed striking. My next aim was to investigate this putative 
connection.  
 
5.3.1  Co-cultured MCF-7 cells alter the cytokine profile of macrophages  
In a first experimental approach, I asked whether or not a co-culture of breast 
carcinoma cells (MCF-7) with primary human monocyte-derived macrophages 
affected the cytokine profile in the latter ones. Therefore, macrophages were 
incubated with an equal amount of MCF-7 cells for 5 days and the contents of 
TNF-α,  IL-10  and  IL-8  in  the  co-culture  supernatants  were  quantified  at 
different time points (Figure 21). The co-culture provoked induction of TNF-α 
and  IL-10  at  24  h,  followed  by  a  decrease  from  48  to  120  h,  which  was 
markedly  stronger  in  case  of  TNF-α  (Figure  21A)  as  compared  to  IL-10 
(Figure 21B). In contrast, IL-8 production did not peak after 24h, but increased 
steadily  up  to  120  h  (Fig  21C).  Cytokine  production  in  either  control 
macrophages or MCF-7 cells, cultured for 24 h, was low. Interestingly, adding 
fresh MCF-7 cells for 24 h to the culture systems that already lasted for 120 h 
(2nd co-culture), failed to induce TNF-α (Figure 21A), but elicited an increase 
in IL-10 (Figure 21B), whereas IL-8 production remained high (Fig 21C). This 
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pro-inflammatory response, followed by an early production of TNF-α, a more 
persistent  formation  of  the  anti-inflammatory  cytokine  IL-10  and  a  strong 
induction of IL-8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  21:  Co-culture  of  human  macrophages  with  MCF-7  cells  induced  a  cytokine  shift. 
Supernatants of human monocyte-derived macrophages, MCF-7 cells or from co-cultures of 
macrophages with MCF-7 cells were assayed at times indicated for TNF-α (A), IL-10 (B) or IL-
8 (C). Quantification was by FACS with BD Cytometric Bead Array Flex Sets as described 
under Materials and Methods. Data are presented as the mean ± SEM from four independent 
experiments. Differences between supernatants from control macrophages and co-cultures 
marked with an asterisk are statistically significant (p < 0.05). 
 
To prove that a prolonged co-culture set-up provoked an alternative activation 
profile in macrophages, macrophages were stimulated with LPS/IFN-γ at the 
end  of  the  5  days  co-culture  with  MCF-7  cells  and  compared  to  control 
macrophages  (Figure  22A).  Residual  MCF-7  cells  were  removed  by Results                                                                                                                                   87                                                                                                                 
incubations with accutase for 5 min, which left adherence of macrophages 
unaltered,  thus  proving,  that  this  set-up  exclusively  determined  cytokine 
production from macrophages (Figure 22B). Activation of naïve macrophages 
with LPS/IFN-γ stimulated the production of TNF-α and IL-10 but not of IL-8 
as compared to resting cells. Addition of LPS/IFN-γ to macrophages from the 
co-culture  set-up  produced  significantly  less  TNF-α,  revealed  markedly 
increased levels of IL-8, while IL-10 remained unchanged.  
In  the  past,  decreased  production  of  pro-inflammatory  IL-12-p70  has  been 
connected  to  alternative  macrophage  activation  and  was  attributed  to 
increased  IL-10  (164).  Since  IL-10  levels  in  macrophages from  co-cultures 
were enhanced as compared to naïve macrophages even without LPS/IFN-γ 
stimulation (Figure 21B), I measured the amount of IL-12-p70 in the co-culture 
system.  Administration  of  LPS/IFN-γ  strongly  induced  IL-12-p70  in  control 
macrophages,  but  remained  significantly  less  effective  when  stimulating 
macrophages from the co-culture set-up (Figure 22A).  
These results suggested that MCF-7 cells provoked a macrophage phenotype 
shift towards an alternative activation profile. Activation of macrophages from 
co-cultures  with  LPS/IFN-γ  substantiated  this  phenotype  switch,  when 
following the production of classical pro- versus anti-inflammatory mediators. 
Although principal observations pointing to alternative macrophage activation 
during co-culture with MCF-7 cells were obvious (Figure 21), stimulation of 
naïve  vs.  co-culture  primed  macrophages  with  LPS/IFN-γ  made  the 
phenotype shift more definite. Therefore, LPS/IFN-γ stimulation was used in 
further experiments to demonstrate macrophage phenotype alterations. 
Infiltrating macrophages may comprise up to 50% of the tumor cell mass (88). 
Nevertheless, it was interesting whether or not higher cell numbers of tumor 
cells  would  change  the  phenotypic  alterations  that  were  observed.  When 
ratios of 5:1 or 10:1 were used in co-cultures, the decrease of TNF-α became 
more pronounced with more tumor cells added to macrophages, whereas the 
increase in IL-8 was unaffected (Figure 22C).  Results                                                                                                                                   88                                                                                                                 
 
 
Figure  22:  Co-culture  with  MCF-7  cells  induced  an  alternative  activation  profile  in  human 
macrophages. (A and C) Human primary macrophages were controls or were incubated with 
MCF-7 cells for 5 days. Subsequently residual MCF-7 cells were removed from co-cultures 
and 1 µg/ml LPS and 100 U IFN-γ were added to macrophages from co-cultures or control 
macrophages for 6 h. TNF-α (A and C), IL-10 (A), IL-8 (A and C) and IL-12-p70 (A) contents 
in supernatants were quantified by FACS with BD Cytometric Bead Array Flex Sets. Data are 
presented  as  the  mean  ±  SEM  from  at  least  six  independent  experiments.  Differences 
between  supernatants  from  LPS/IFN-γ  treated  macrophages  and  macrophages  from  co-
cultures marked with an asterisk are statistically significant (p < 0.05). (B) Macrophages and 
MCF-7  cells  were  co-cultured  for  12  h.  Co-cultures  were  harvested  after  incubation  with 
accutase for 30 min, with or without accutase pre-treatment for 5 min followed by washing, 
subsequent  staining  with  α-CD44-PE,  and  analysis  by  FACS.  (D)  Co-cultures  of  human 
primary macrophages with MCF-7 cells were maintained for the times indicated. Co-cultures, 
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stained with α-CD44-PE as a discrimination marker between macrophages and MCF-7 cells, 
and analyzed by FACS or fluorescence microscopy. Images display phase contrast and α-
CD44-PE staining of macrophage/MCF-7 co-cultures after 12 h. White arrows mark α-CD44 
positive  macrophages,  black  arrows  mark  MCF-7  cell  colonies.  FACS  traces  are 
representative for three independent experiments. The lower graph shows quantification of 
FACS data. Statistically significant (p < 0.05) reduced cell numbers of MCF-7 cells in co-
cultures are marked with asterisks. 
 
5.3.2  Viability changes of cancer cells in co-cultures with macrophages 
To follow the ratio of macrophages to MCF-7 cells, co-cultures were stained 
with  anti-CD44.  CD44  proved  to  be  a  valid  discrimination  marker  between 
highly CD44-positive macrophages and weakly CD44-expressing tumor cells 
(165) in the co-culture system (Figure 22D). I noticed a continuous reduction 
of MCF-7 cells starting at 24 h after initiating the co-culture, which resulted in 
a complete loss of tumor cells at 72 h (Figure 22D). To ensure that MCF-7 did 
not  simply  up-regulate  CD44,  the  morphology  of  cells  in  co-cultures  was 
additionally  monitored.  On  the  basis  of  morphological  criteria,  MCF-7  cells 
were  completely  absent  after  72h  (data  not  shown).  These  data  indicated 
macrophage-induced apoptotic cell death of cancer cells.  
To prove this assumption, cells from co-cultures were harvested after 12, 24 
and 48 h and stained with anti-CD44 to distinguish between macrophages and 
MCF-7  cells.  In  addition,  annexin  V  staining  was  used  to  monitor 
phosphatidylserine  exposure  as  an  early  marker  of  cell  death.  Annexin  V 
positive MCF-7 cells were noticed 24 h after co-culture with macrophages. 
The  amount  of  apoptotic  MCF-7  cells  increased  to  about  50%  after  48  h, 
whereas  no  significant  changes  in  annexin  V  binding  were  observed  in 
macrophages  from  co-cultures  or  control  macrophages,  i.e.  cultured  in  the 
absence of MCF-7 cells (Figure 23A).  
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Figure 23: Impact of human primary macrophages on the viability of different human cancer 
cell lines. Human primary macrophages remained as controls or were incubated with MCF-7 
cells (A), Bcl-2-overexpressing MCF-7 cells (B) or RKO cells (C) for the times indicated. Co-
cultures  and  control  macrophages  were  incubated  for  30  min  with  accutase,  harvested, 
stained with α-CD44-PE as a discrimination marker between macrophages and tumor cells, 
followed by annexin V-FITC staining as a marker for cell death, and analyzed by FACS. Data 
are presented as the mean ± SEM from three independent experiments. Differences between 
annexin  V  binding  of  macrophages  and  MCF-7  cells  from co-culture  (cc) marked  with  an 
asterisk are statistically significant (p < 0.05). (D) Western analysis shows Bcl-2 expression of 
control MCF-7 cells and MCF-7 cells transfected with a plasmid encoding human Bcl-2 (MCF-
7-Bcl-2). One representative experiment out of two is displayed.  
 
The working hypothesis predicted that only apoptotic tumor cells would evoke 
phenotype  changes  in  macrophages.  Therefore,  two  cells  lines  that  were 
resistant  to  cell  death  induced  by  co-cultured  macrophages  were  used  in 
further experiments. First, I used MCF-7 cells that over-express Bcl-2 (Figure 
23B  and  D)  and  second,  I  employed  RKO  cells,  which  turned  out  to  be 
naturally  resistant  (Figure  23C).  The  reason  for  RKO  cell  survival  in  co-
cultures remained unknown. However, they expressed higher amounts of Bcl-
2 than naïve MCF-7 cells, which may account for apoptosis resistance (data 
not shown). A 48-h lasting co-culture of MCF-7-Bcl-2 or RKO cells with human 
macrophages  showed  no  signs  of  cell  death,  neither  in  tumor  cells  nor  in 
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coexisted, without initiation of cell death parameters. This was in contrast to 
the co-culture of apoptosis sensitive MCF-7 cells exposed to macrophages.  
 
5.3.3  Alternative macrophage activation demands tumor cell apoptosis 
The notion that Bcl-2-overexpressing MCF-7 cells (MCF-7-Bcl-2) and RKO do 
not  enter  the  route  of  programmed  cell  death  upon  co-culture  with 
macrophages  qualified  these  cells,  compared  to  sensitive  MCF-7  cells,  to 
study LPS/IFN-γ-evoked cytokine responses after 5 days of co-culture (Figure 
24).  
 
 
 
Figure  24:  Activation  profile  of  human  macrophages  after  co-culture  with  different  human 
tumor cell lines. Human primary macrophages remained as controls or were incubated with 
MCF-7  cells,  Bcl-2-overexpressing  MCF-7  cells  (MCF-7-Bcl-2)  or  RKO  cells  for  5  days. 
Residual  tumor  cells  were  removed  from  co-cultures  with  5  min  accutase-treatment. 
Afterwards, 1 µg/ml LPS and 100 U IFN-γ were added to macrophages from co-cultures and 
control macrophages for 6 h. TNF-α, IL-10 and IL-8 contents in supernatants were quantified 
by FACS with BD Cytometric Bead Array Flex Sets. Data are presented as the mean ± SEM 
from five independent experiments. Statistically significant differences (p < 0.05) are marked 
with an asterisk. 
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Production of TNF-α, IL-10 and IL-8 in naïve macrophages following LPS/IFN-
γ-addition  was  significantly  increased  compared  to  un-stimulated  controls. 
Activation of macrophages coming from co-cultures with MCF-7-Bcl-2 or RKO 
cells  revealed  a  cytokine  profile  resembling  that  of  naïve  macrophages 
following classic stimulation with LPS/IFN-γ. In contrast, cytokine formation of 
macrophages derived from co-cultures with apoptosis sensitive MCF-7 cells 
was  different.  TNF-α  was  lower,  IL-8  was  higher  while  IL-10  remained 
unaltered. Apparently, MCF-7-Bcl-2 as well as RKO cells did not change the 
ability of macrophages to respond to LPS/INF-γ with the production of these 
cytokines  compared  to  naïve  cells.  Only  the  co-culture  with  MCF-7  cells, 
which  underwent  apoptotic  cell  death  upon  co-culture  with  macrophages, 
altered cytokine production following LPS/IFN-γ stimulation.  
To  corroborate  that  tumor  cell  death  indeed  was  essential  for  alternative 
macrophage  polarization,  apoptosis  was  induced  in  RKO  and  MCF-7  cells 
with  Sts  and  conditioned  medium  from  these  apoptotic  tumor  cells  was 
collected, which then was added to macrophages for 24 h. After changing the 
medium,  macrophages  were  stimulated  with  LPS/IFN-γ.  Supernatants  from 
apoptotic tumor cells alone induced significant changes in the macrophage 
cytokine  profile,  independent  of  direct  tumor  cell/macrophage  contacts. 
Secretion of IL-10 and IL-8 was enhanced, whereas IL-12-p70 production was 
decreased  compared to  naïve  macrophages  (Figure  25A).  Supernatants  of 
apoptotic RKO or MCF-7 cells per se did not contain detectable amounts of 
cytokines (data not shown), except for IL-8 (around 200 pg/ml), which was 
nevertheless extremely low compared to the amounts that were produced by 
macrophages. Stimulation of macrophages exposed to tumor cell conditioned 
medium  with  LPS/IFN-γ  elicited  those  phenotypic  alterations  that  were 
observed in direct co-cultures, where tumor cell death occurred. TNF-α and 
IL-12-p70 were decreased, IL-8 was enhanced, whereas IL-10 was high, but 
not significantly different from control macrophages (Figure 25A). I concluded 
that the macrophage phenotype shift was dependent on tumor cell apoptosis, 
rather  than  representing  intrinsic  features  of  different  tumor  cell  lines. 
Moreover, since supernatants of apoptotic tumor cells evoked macrophage 
phenotype alterations, macrophage polarization demanded soluble, apoptotic 
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Figure  25:  Activation  profile  of  human  macrophages  induced  by  conditioned  medium  of 
apoptotic  tumor  cells  and  different  tumor  cell  lines.  (A)  Human  primary  macrophages 
remained as controls or were incubated with conditioned medium from apoptotic MCF-7 (CM-
MCF-7) or RKO (CM-RKO) cells for 24 h. Thereafter, supernatants were removed, cells were 
washed with PBS, fresh medium was added and macrophages were stimulated with 1 µg/ml 
LPS and 100 U IFN-γ for 6 h. Production of TNF-α, IL-10, IL-8 and IL-12-p70 was quantified 
by FACS with BD Cytometric Bead Array Flex Sets. Data are presented as the mean ± SEM 
from five independent experiments. Statistically significant differences (p < 0.05) are marked 
with an asterisk. (B) Human macrophages were controls or incubated with different tumor cell 
lines, as indicated. Tumor cell death in co-cultures is marked with [†]. Residual tumor cells 
were removed from co-cultures with 5 min accutase-treatment. Afterwards, 1 µg/ml LPS and 
100 U IFN-γ were added to macrophages from co-cultures and control macrophages for 6 h. 
TNF-α and IL-8 contents in supernatants were quantified by FACS with BD Cytometric Bead 
Array Flex Sets. Data are presented as the mean ± SEM from six independent experiments. 
Statistically significant differences compared to LPS/IFNγ-stimulated control macrophages (p 
< 0.05) are marked with an asterisk. 
 
For validation concerning independence from specific tumor cell lines, I used 
four  additional  well  characterized  tumor  cell  lines,  such  as  the  colon 
carcinoma cell lines Caco-2 and Colo201, the lung cancer cell line A549 and 
the hepatocellular carcinoma cell line Hep-G2 in the co-culture system. After 5 
days  of  co-culture,  Caco-2,  Colo201 and A549  cells  were  absent from  co-
cultures, whereas Hep-G2 cells were growing normally (data not shown). After 
removal of residual tumor cells and stimulation with LPS/IFN-γ, macrophages 
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more  pronounced,  to  those  derived  from  MCF-7  co-cultures  (Figure  25B). 
TNF-α  was  significantly  lower  in  comparison  to  control  macrophages 
stimulated  with  LPS/IFN-γ,  whereas  IL-8  was  significantly  increased.  
Macrophages  from  co-cultures  with  Hep-G2  cells  displayed  an  activation 
profile  similar  to  control  macrophages,  stimulated  with  LPS/IFN-γ  (Figure 
25B).   
 
5.3.4  MCF-7 cell-derived S1P accounts for macrophage polarization 
Since I had evidence that AC release S1P into the culture medium and further 
considering  existing  evidence  that  associates  S1P  production  with  tumor 
vascularization  and  growth  (125,  126),  I  wanted  to  know  whether  S1P 
production in apoptotic MCF-7 cells contributed to macrophage polarization. 
This  question  was  approached  by  using  siRNA  technology  to  knock-down 
SphK1  vs.  SphK2  in  MCF-7  cells.  Knock-down  of  either  SphK  isoforms  in 
MCF-7  cells  was  successful  (Figure  26D).  SiRNA  supplied  was  isoform 
specific  and  a  control  siRNA  further  proved  specificity.  As  an  additional 
control, an interference of SphK1 or SphK2 knock-down on induction of MCF-
7 cell death upon co-culture with macrophages was ruled out (Fig 26E). 
Naïve macrophages, macrophages derived from a co-culture with MCF-7 cells 
or cells from a co-culture of MCF-7 cells with either SphK1 or SphK2 being 
knocked down were then used in the co-culture system (Figure 26). After 5 
days  of  co-culture,  tumor  cells  were  removed  and  macrophages  were 
stimulated  with  LPS/IFN-γ  to  follow  cytokine  production  of  TNF-α  (Figure 
26A),  IL-10  (Figure  26B),  or  IL-8  (Figure  26C).  As  seen  in  previous 
experiments,  macrophages  from  co-cultures  with  MCF-7  cells  displayed 
reduced TNF-α, increased IL-8 but unaltered IL-10 production compared to 
naïve  macrophages  exposed  to  LPS/IFN-γ.  Knock-down  of  SphK1  did  not 
alter macrophage cytokine production as compared to changes provoked by 
apoptotic MCF-7 cells. However, knock-down of SphK2 affected the ability of 
MCF-7  cells  to  alter  cytokine  production  in  macrophages  upon  LPS/IFN-γ 
stimulation.  With  SphK2  being  suppressed  in  MCF-7  cells  during  the  co-
culture,  the  macrophage  response  upon  LPS/IFN-γ  addition  was  similar  to 
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Figure  26:  Knock-down  of  SphK2,  but  not  SphK1  in  MCF-7  cells  restored  a  classical 
activation  profile  in  human  macrophages  upon  co-culture.  Human  primary  macrophages 
remained as controls or  were incubated for 5  days  with  MCF-7 cells or  MCF-7 cells  with 
SphK1  or  SphK2  being  knocked  down  with  specific  siRNA.  Residual  tumor  cells  were 
removed from co-cultures with 5 min accutase-treatment and 1 µg/ml LPS and 100 U IFN-γ 
were added to macrophages from co-cultures and control macrophages for 6 h. TNF-α (A), IL-
10 (B) and IL-8 (C) contents in supernatants were quantified by FACS with BD Cytometric 
Bead  Array  Flex  Sets.  Data  are  presented  as  the  mean  ±  SEM  from  five  independent 
experiments. Statistically significant differences (p < 0.05) are marked with an asterisk. (D) 
Western analysis shows SphK1 and SphK2 expression in MCF-7 cells transfected either with 
control  siRNA  (siControl),  siRNA  against  SphK1  (siSphK1)  or  SphK2  (siSphK2).  One 
representative experiment out of three is displayed. Western analysis was performed 48 h 
after nucleofection. (E) Human primary macrophages remained as controls or were incubated 
with  naïve  MCF-7  cells  or  MCF-7  cells  with  SphK1  or  SphK2  being  knocked  down  with 
specific siRNA for the times indicated. Co-cultures and control macrophages were incubated 
for  30  min  with  accutase,  harvested,  stained  with  α-CD44-PE  as  a  discrimination  marker 
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analyzed  by  FACS.  Data  are  presented  as  the  mean  ±  SEM  from  three  independent 
experiments.  (F)  Human  macrophages  remained  as  controls  or  were  incubated  with 
conditioned  medium  from  apoptotic  MCF-7  (CM-MCF-7)  or  MCF-7  cells  transfected  with 
siRNA  against  SphK2  (CM-MCF-7  siSphK2)  cells  for  24  h.  Thereafter,  supernatants  were 
removed, cells were washed with PBS, fresh medium was added and macrophages were 
stimulated with 1 µg/ml LPS and 100 U IFN-γ for 6 h. Production of TNF-α, IL-10 and IL-8 was 
quantified by FACS with BD Cytometric Bead Array Flex Sets. Data are presented as the 
mean ± SEM from five independent experiments. Statistically significant differences (p < 0.05) 
are marked with an asterisk. 
 
The same was true when supernatants from apoptotic MCF-7 cells, that were 
previously  transfected  with  siRNA  directed  against  SphK2,  were  added  to 
macrophages. Compared to supernatants from unmodified apoptotic MCF-7 
cells, the release of IL-8 and IL-10 from macrophages was largely suppressed 
(Figure 26F). Along that line, repression of TNF-α as well as induction of IL-8, 
elicited  with  LPS/IFN-γ  in  macrophages  stimulated  with  supernatants  from 
apoptotic MCF-7 cells, was significantly reduced when SphK2 was knocked 
down (Figure 26F).  
As a final prove that tumor cell apoptosis and SphK2 knock-down affected 
S1P  release,  LC-MS/MS  to  quantify  S1P  release  into  supernatants  of  co-
cultures and MCF-7 cell cultures was performed again in cooperation with the 
Institute of Clinical Pharmacology (Table 5). Supernatants of co-cultures of 
macrophages with MCF-7 cells, MCF-7 cells overexpressing Bcl-2 and MCF-7 
cells  with  SphK2  being  knocked  down,  were  collected  at  a  time  when 
apoptosis was high in MCF-7 cells (24-48 h of co-culturing). Whereas S1P 
amounts in supernatants of control macrophages, co-cultures of macrophages 
with Bcl-2-overexpressing- or SphK2-knock-down-MCF-7 cells were below the 
reliable  limit  of  quantification  (0.5  ng/ml),  S1P  levels  in  co-cultures  of 
macrophages with naϊve MCF-7 cells were significantly elevated (Table 5; p ≤ 
0.01).  The  same  results  where  obtained,  when  S1P  was  quantified  in 
supernatants of viable or apoptotic MCF-7 cells with or without SphK2 knock-
down. Supernatants of viable MCF-7 were devoid of S1P, whereas S1P was 
released from apoptotic MCF-7 cells. Knock-down of SphK2 abrogated this 
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generated by SphK2 and derived from dying MCF-7 cells, altered macrophage 
polarization.  
 
Table 5: S1P release from MCF-7 cells induced by co-culturing or staurosporine 
___________________________________________________________________ 
 
Sample         S1P [ng/ml]
*            SD (n ≥ 5) 
 
___________________________________________________________________       
 
MCF-7 cells: 
Control              n.d.             -     
   
Staurosporine [0,5 ng/ml]         4.02        ± 1.51     
siSphK2 + Staurosporine [0,5 ng/ml]       0.65        ± 0.12   
 
Co-cultures: 
Macrophages             n.d.             -     
Macrophages + MCF-7           5.65        ± 2.79 
Macrophages + MCF-7 siSphK2        n.d.             - 
Macrophages + MCF-7-Bcl-2         n.d.             -   
___________________________________________________________________ 
*S1P contents in supernatants were measured with LC-MS/MS as described in the Materials 
and Methods section. The lower limit of quantification was 0.5 ng/ml. S1P concentrations in 
supernatants below this limit are marked with n.d. 
 
5.3.5  MCF-7 cells or authentic S1P impair NF-κB activation in macrophages 
M2  polarization  of  TAM  has  previously  been  attributed  to  diminished  p65 
nuclear translocation and thus to defective NF-κB signaling (98). To validate 
the  co-culture  model  with  respect  to  this  TAM  marker,  NF-κB  activation  in 
macrophages exposed to apoptosis sensitive vs. resistant MCF-7 cells was 
investigated.  EMSA  analysis  showed  NF-κB  activation  in  response  to 
LPS/IFN-γ stimulation in macrophages from co-cultures with MCF-7-Bcl-2 or 
RKO cells (Figure 27A, lane 4-9). Supershift analysis was evident with an α-
p65  antibody  while  α-p50  reduced  NF-κB-DNA  binding  without  shifting  the 
complex to higher molecular mass. When macrophages had been co-cultured 
with MCF-7 cells prior to stimulation with LPS/IFN-γ, activation of NF-κB was Results                                                                                                                                   98                                                                                                                 
impaired (Figure 27A, lane 1-3). Negligible activation of NF-κB was also seen 
when macrophages were pre-exposed for 2 days to authentic S1P (Figure 
27B). Statistic quantification of relevant changes is shown in part C of figure 
27. 
 
 
 
Figure 27: Macrophages display reduced NF-κB activation after co-culture with MCF-7 cells or 
addition  of  S1P.  Human  primary  macrophage  remained  as  controls,  were  incubated  with 
MCF-7 cells, Bcl-2-overexpressing MCF-7 cells (MCF-7-Bcl-2), RKO cells for 5 days or 10 µM 
S1P for 2 days. Residual tumor cells were removed and 1 µg/ml LPS and 100 U IFN-γ were 
added to macrophages from co-cultures and control macrophages for 4 h. Activation of NF-κB 
was analyzed by EMSA using a specific 5’-IRD700-labelled oligonucleotide as described in 
Materials  and  Methods.  Supershift  analysis  was  performed  with  p65  and  p50  antibodies 
(Santa  Cruz  Biotechnology)  as  indicated.  (A)  EMSA  for  NF-κB  DNA  binding  activity  in 
macrophages from co-cultures. One representative experiment out of three is displayed. (B) 
EMSA for NF-κB DNA binding activity in control and S1P-exposed macrophages following 
LPS/IFN-γ stimulation. One representative experiment out of three is displayed. Cells were 
pre-exposed for 48 h with 10 µM S1P prior to stimulation with 1 µg/ml LPS and 100 U IFN-γ. 
(C) The histogram shows quantification of EMSA data. Data are presented as the mean ± 
SEM  from  five  independent  experiments.  Differences  between  LPS/IFN-γ-stimulated 
macrophages and macrophages from co-cultures or S1P-treated macrophages marked by 
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Collectively,  these  data  implied  that  S1P  as  well  as  apoptotic  tumor  cells 
suppressed  activation  of  NF-κB  in  macrophages  while  apoptosis-resistant 
tumor cells did not share this behavior. Macrophage polarization by apoptotic 
tumor cell-derived S1P was evident at the level of cytokine production as well 
as NF-κB activation. 
 
5.4  SphK2 is important for tumor growth in vivo 
Having evidence that SphK2-dependent S1P production in tumor cells was 
connected to TAM development, and thus possibly to tumor development, I 
wanted to establish an in vivo tumor model. MCF-7 breast cancer cells were 
efficient  inducers  of  TAM-like  macrophage  polarization.  Furthermore,  TAM-
dependent  tumor  promotion  is  well  established  for  breast  cancer  (93). 
Therefore  I  planned  to  knock-down  SphK2  in  MCF-7  breast  cancer  cells, 
implant these cells and naïve MCF-7 cells into nude mice, and look for tumor 
growth  and  vascularization.  Since  these  experiments  are  very  time-
consuming,  I  was  not  able to finish  them  until  now.  Nevertheless,  the first 
results are promising. 
 
5.4.1  Knock-down of SphK2 in MCF-7 cells 
For high stability of SphK2 knock-down in MCF-7, specific hairpin siRNA was 
ligated  into  pSilencer
TM  4.1-CMV  neo  vector,  since  this  expression  vector 
encodes  the  gene  for  resistance  against  the  selection  marker  neomycin 
(G418). This vector, then named pSilencer-siSphK2, was nucleofected into 
MCF-7 cells, followed by selection of positive clones (MCF-7-siSphK2) with 
500 µg/ml of G418. After three weeks, expression of SphK2 was verified by 
Western blot analysis in MCF-7-siSphK2 versus naïve MCF-7 cells (Figure 
28). MCF-7-siSphK2 cells displayed reduced SphK2 expression down to 25% 
compared to control MCF-7 cells. For comparison, expression of SphK1 was 
also  investigated.  SphK1  levels  were  not  reduced  by  transfection  with 
pSilencer-siSphK2. On the contrary, it rather seemed up-regulated. This may 
be  a  cellular  mechanism,  ensuring  stable  intracellular  levels  of  S1P,  a 
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SphK2 knockout mice. However, knock-down of SphK2, which was controlled 
every two weeks, was stable during culture. Therefore, MCF-7-siSphK2 cells 
were suitable for the mouse model. 
  
 
 
Figure 28: Knock-down of SphK2 in MCF-7 cells. MCF-7 cells were controls or transfected 
with pSilencer-siSphK2 (MCF-7-siSphK2). Western analysis shows expression of SphK2 and 
SphK1.  One  representative  experiment  out  of  five  is  displayed.  Histogram  shows 
quantification of Western data normalized to actin. Data are presented as the mean ± SEM 
from five independent experiments.  
 
5.4.2  Growth of MCF-7-siSphK2 tumors is impaired in nude mice 
Together  with  Dr.  Susanne  Schiffmann  from  the  Institute  of  Clinical 
Pharmacology, I started the first in vivo experiment. MCF-7 cells and MCF-7-
siSphK2 cells were injected subcutaneously at the left and right dorsal flank of 
female nude mice (166). Three weeks after the MCF-7 control tumors started 
growing, the mice were sacrificed, perfused and the tumors were extracted. 
The growth of MCF-7-siSphK2 xenografts was largely impaired in comparison 
to  MCF-7  xenografts  (Figure  29).  In  fact,  MCF-7-siSphK2  tumors  started 
growing  approximately  two  weeks  after  the  control  tumors.  Furthermore, 
tumor  growth  appeared  to  be  less  structured,  since  MCF-7-siSphK2 
xenografts grew rather flat compared to globular growing control tumors and 
displayed a spongy texture when touched.  
The extracted tumors were used for the preparation of cryosections. Sections 
from both xenografts were stained for infiltration of mouse macrophages with 
an antibody against the macrophage marker F4/80 (167), and for presence of 
blood  vessels  using  an  antibody  against  the  endothelial  cell  marker  CD31 
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Figure 29: Growth of MCF-7 and MCF-7-siSphK2 xenografts in nude mice. 1 x 10
7 MCF-7 
cells (n = 8) or MCF-7-siSphK2 cells (n = 6) were injected subcutaneously at the both dorsal 
flanks. The tumor volume is displayed three weeks after MCF-7 xenografts started to grow. 
Data  are the mean ±  SEM of the tumor volumes. Growth of MCF-7-siSphK2 tumors was 
significantly  reduced,  compared  to  MCF-7  tumors  (*  =  p  <  0.05).  Photographs  display 
representative mice. Xenografts are indicated with white arrows. 
 
 
 
 
Figure 30: Macrophage infiltration and blood vessel growth in tumor xenografts. Cryosections 
of MCF-7 or MCF-7-siSphK2 xenografts (A and B) were either stained for the macrophage 
marker  F4/80  (A)  or  the  endothelial  cell  marker  CD31  (B),  both  counterstained  with  Cy3-
labelled secondary antibody (red). Nuclear staining was performed with DAPI (blue), cytosol 
is  the  background  of  green  fluorescence  (green).  Cryosections  of  three  different  tumor 
xenografts each were stained and representative images are shown.  
 
Strikingly,  MCF-7-siSphK2  tumors  were  almost  completely  devoid  of  blood 
vessels  in  comparison  to  MCF-7  tumors  (Figure  30B),  although  both 
xenografts  were  infiltrated  with  macrophages  (Figure  30A).  Therefore,  if 
reduce tumor growth is due to SphK2 deficiency, it is a result of macrophage 
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6  Discussion  
 
Macrophages display opposing activities in human physiology and pathology 
by adopting different phenotypes. Thereby they shape inflammation (59) as 
well as diseases that are closely linked to inflammatory dysfunction, including 
cancer (169) and atherosclerosis (34). Activation patterns of macrophages are 
reflected at the level of their mediator profile. Macrophages may act as ‘killers’ 
(the  M1  phenotype),  when  they  produce  pro-inflammatory  cytokines  or 
present  antigens  on  their  surface,  thus  activating  other  immune  cell 
populations, or when they release bactericidal/cytotoxic agents like NO, ROS 
or  TNF  family  proteins  (61).  ‘Killer’  macrophages  drive  the  host  response 
against pathogens and destroy tumor cells, but they are also key players in 
chronic inflammatory disorders. On the other hand, macrophages can also act 
as  ‘healers’  (the  M2  phenotype)  by  modulation  or  suppression  of  immune 
responses,  which  is  associated  with  tissue  remodeling  and  promotion  of 
angiogenesis  (87).  ‘Healer’  macrophages  facilitate  the  termination  of 
inflammation  and  promote  TH2  immunity,  but  they  also  promote  tumor 
development by induction of angiogenesis and tumor cell survival.  
Distinct M2 phenotypes have been described (3.3.1), which are believed to be 
extremes  of  a  continuum  rather  than  fixed  patterns  (87).  Macrophage 
phenotypes are therefore often considered as extremely versatile, depending 
on the exact composition of the respective microenvironment. Contradictory, it 
has been suggested that macrophage activation profiles, once established, 
are  highly  stable  and  nearly  inconvertible.  This  is  especially  true  for  M2 
macrophages  (170).  Stable  functional  responses  may  be  a  reason  why 
macrophages  are  key  players  in  a  variety  of  human  pathologies.  After 
activation, reprogramming turns out to be highly intricate. Defects may then 
lead  to  prolonged  activation,  which  may  be  either  chronic  inflammation,  or 
likewise ‘chronic anti-inflammation’. Most interestingly, AC may be one of the 
rare means to shape macrophage polarization even after activation. Extreme 
pro-inflammatory  macrophage  phenotypes  associated  with  the  capacity  to 
induce apoptosis of tumor or glumerular cells are suppressed by the uptake of 
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detailed understanding of the mechanisms of macrophage programming may 
lead to the identification of therapeutic strategies, which are targeted at cutting 
the Gordian knot in inflammatory disorders (172).  
My  studies  where  therefore  aimed  at  a  mechanistic  understanding  of  how 
alternative macrophage polarization is achieved and preserved: 
 
1)   I started with investigations on macrophage survival after interaction 
with  AC  and  tried  to  understand  its  induction,  its  source  and  the 
molecular pathways involved in that process. 
 
2)   Knowing  that  S1P  was  released  by  AC,  my  aim  was  to  define  the 
underlying mechanistic principle. 
 
3)   Being  aware  that  activation  patterns  of  TAM  and  AC-primed 
macrophages are comparable, I investigated a putative connection in 
an in vitro co-culture system. 
 
4)   After  I  had  identified  SphK2-dependent  S1P  production  as  a 
prerequisite  for  macrophage  polarization  in  the  co-culture  system,  I 
started with an in vivo tumor xenograft model to clarify the relevance of 
SphK2 and S1P in tumor development. 
 
6.1  Macrophage survival induced by apoptotic cells 
 
The first part of my studies supports the notion that AC not only modulate pro- 
vs. anti-inflammatory mediator release from macrophages, but also affect their 
susceptibility towards apoptosis. Cell protection was initiated by liberating S1P 
from AC (Figure 31).  
So far, two studies have indicated macrophage resistance against apoptosis 
after  interaction  with  AC.  Reddy  et.  al.  observed  protection  of  murine 
macrophages  from  apoptosis  induced  by  cytokine  withdrawal,  which 
demanded phagocytosis of AC and activation of PI3K-signaling as suggested 
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colchicine is rather unspecific, and besides blocking phagocytosis it depletes 
calcium  from  internal  stores  (174).  Therefore,  this  study  cannot  determine 
whether  uptake  of  apoptotic  material  and/or  PI3K  activation  are  distinct  or 
uniform cell responses. However, protection from apoptosis induced by AC 
was corroborated for macrophages in another study and in addition shown for 
non-professional  phagocytic  epithelial  cells  (175).  Specifically,  the  authors 
achieved survival effects with supernatants from phagocytes co-cultured with 
AC.  This  implied  paracrine  signaling,  which  was  in  contrast  to  the  above-
mentioned  phagocytosis.  Promotion  of  survival  correlated  with  VEGF 
secretion from epithelial cells and up-regulation of Bcl-2. Although VEGF is 
known to act para- and autocrine in regulating epithelial cell survival, in part by 
PI3K/Akt-induced Bcl-2 expression (176, 177), a direct connection between 
VEGF secretion and Bcl-2 has not been investigated (175).  
Connections to the results I obtained are striking. Macrophage protection in 
my  system  against  apoptosis  was  mediated  via  S1P  from  AC.  The 
participation of S1P cannot be excluded from the results obtained in the other 
studies, since no control experiments with ACM were performed. However, 
the  results  obtained  for  activation  of  the  PI3K-pathway  and  Bcl-2  up-
regulation, are supported by my data.  
S1P is known to provoke survival in different cell types by binding to its high 
affinity G-protein coupled receptors (102, 178, 179). Five different receptors 
for  S1P  are  known  to  date,  of  which  subtypes  1  to  4  are  shown  to  be 
predominantly  expressed  on  human  macrophages  (157,  158).  Down-
regulation of S1PR1 on primary macrophages partially diminished protection 
by  supernatants  from  AC.  This  may  indicate  that  protection  of  S1P  in 
macrophages is transmitted by more than one S1PR subtype expressed on 
their surface. Further experiments using knock-down approaches should be 
performed to clarify the relative contribution of S1PRs towards macrophages 
protection by S1P. 
S1P-receptors activate PI3K and/or ERK1/2 (179). Inhibitor studies pointed to 
these  pathways  in  conveying  protection  by  ACM,  which  resulted  in 
phosphorylation of Bad at Ser136. It is an established function of the PI3K/Akt 
pathway  to  attenuate  the  apoptotic  machinery  (180),  among  other  cells  in Discussion                                                                                                                             105                                                                                                                 
macrophages (181). These data are in close concordance with the studies 
mentioned above. 
 
 
Figure 31: Macrophage protection by AC-derived S1P. AC produce sphingosine-1-phosphate 
(S1P) depending on sphingosine kinase (SphK) 2. S1P then binds to its specific receptors 
(S1PRx), especially S1P-receptor 1 (S1PR) on the macrophage surface. S1P activates Ca
2+-, 
phosphatidylinosotol-3  kinase  (PI3K)-  and  extracellular  signal-regulated  kinase  (ERK)-
dependent signaling, which induces a shift in the macrophage’s Bcl-2 family protein activity 
pattern towards anti-apoptotic. 
 
ERK1/2 activation in macrophages usually is a signal downstream to growth 
factors or cytokines such as M-CSF, IL-3 or TGF-b (182, 183). TGF-b seems 
of interest, because it is secreted by AC (83). Yet the possibility that ERK1/2 
is activated by TGF-β to contribute to Bcl-2 up-regulation must be excluded 
under the used experimental conditions, bearing in mind the lipophilic nature 
of the factor under investigation. It was shown previously that extracellular 
S1P inhibits bone marrow-derived macrophage cell death induced by M-CSF 
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expression,  and  decreased  acid  sphingomyelinase  activity,  thus  reducing 
ceramide production. Although I noticed increased expression of Bcl-XL, its 
induction was not affected by blocking PKB. These data provide evidence that 
besides  PKB,  another  pathway  seems  to  be  involved  in  Bcl-XL  induction. 
However, expression of Bcl-2 and Bcl-XL as well as Bad phosphorylation was 
noticed with ACM and authentic S1P. 
S1P  receptor  activation  triggers  intracellular  Ca
2+-signals  (102,  178,  179). 
Ca
2+-signals are involved in ACM-mediated macrophage survival, as shown 
by  the  use  of  the  intracellular  Ca
2+  scavenger  Bapta-AM.  Although  Ca
2+ 
signals  usually  promote  apoptosis  by  mitochondrial  Ca
2+  overload  and 
subsequent release of pro-apoptotic factors (184), there are indications that a 
modest  Ca
2+  increase  elicits  anti-apoptotic  responses  via  Ca
2+/calmodulin-
dependent  kinase-induced  PKB  activation,  which  results  in  Bad 
phosphorylation (185). This agrees quite well with my findings showing that 
Bad phosphorylation not only depends on PI3K- but also on Ca
2+-signaling. 
Furthermore, this may explain the results obtained with colchicine by Reddy 
et. al., since colchicine may block Ca
2+-mediated responses. It remains to be 
clarified,  whether  PI3K-  and  Ca
2+-pathways  work  synergistically  or 
independently. Since either reducing the expression of Bcl-2 or diminishing 
Ser136-Bad phosphorylation were sufficient to recover caspase-3 activity, I 
assume  that  the  Bcl-2-family  rheostat  is  more  important  than  expression 
modulation or phosphorylation of individual proteins such as Bcl-2 or Bad.  
Release of S1P from apoptotic Jurkat cells was necessary for macrophage 
protection, as was demonstrated by transwell experiments, by the use of ACM 
in  combination  with  the  sphingosine  kinase  inhibitor  DMS,  and  via  liquid 
chromatography-tandem  mass  spectrometry.  Knock-down  studies  using 
siRNA revealed a vital role of SphK2 in apoptosis-dependent S1P production. 
SphK2 activity during apoptosis has been previously reported but was linked 
to promotion of apoptosis (121, 186). However, knock-down of SphK2 did not 
diminish the induction of apoptosis in Jurkat cells. So far, my data expanded 
the role of SphK2 in regulating apoptosis: it is not only involved in apoptosis 
induction inside cells but also acts as an inhibitor once it releases its product.  
Other  potential  mediators  released  from  AC  can  formally  be  excluded  to 
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messenger. LPC (187) only attenuated macrophage apoptosis when supplied 
at high concentrations of roughly 100 µM, a concentration that is unlikely to be 
of  physiological  relevance.  Arachidonic  acid  and/or  derived  metabolites, 
released during apoptosis (188) could also be excluded, because they are not 
extractable with chloroform (35). The new role of S1P as an anti-apoptotic 
mediator released from AC adds to existing concepts on the anti-inflammatory 
role of S1P. This might be relevant to fully understand the phenotype switch in 
macrophages that is induced by AC. As the production and release of S1P 
during apoptosis have not been reported so far, future studies were needed to 
define the role of SphK2 in this process, as well as release pathways for S1P.  
 
6.2  The mechanism of S1P release from apoptotic cells 
 
Exploring the mechanism of S1P release from AC, I found that a truncated, 
enzymatically active SphK2 was shed from AC upon cleavage by caspase-1 
at its N-terminus (Figure 32). It is important to stress that sphingosine kinases 
may  produce  S1P  outside  the  cell  because  all  enzymes  necessary  for 
degradation of sphingomyelin to sphingosine are present at the outer leaflet of 
the plasma membrane or are constitutively secreted (189). This was already 
corroborated  in  vivo  since  the  presence  of  catalytically  active  SphK1  was 
observed in mouse plasma (107).  
SphK2  co-localized  with  caspase-1  at  the  plasma  membrane  during 
apoptosis.  Preventing  translocation  of  SphK2  to  the  plasma  membrane 
inhibited its cleavage by caspase-1 (Figure 12). In HEK293 cells, SphK2 was 
distributed mainly throughout the cytosol. Other cell types with predominant 
nuclear localization have been described, based on the NLS in the N-terminus 
of SphK2 (120), which raises the question how SphK2 can be cleaved and 
released under these conditions. However, during apoptosis caspase-1 may 
also enter the nucleus (190), which may allow nuclear cleavage. Furthermore, 
a putative nuclear export signal (NES) in SphK2 was identified recently (191). 
Together with the removal of the NLS by caspase-1, this might prepare SphK2 
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Alternatively to caspase-1 dependent cleavage, other mechanisms preserved 
in  the  apoptotic  machinery  may  contribute  to  SphK2  release  from  AC. 
Recently,  the  sources  for  apoptotic  body  membranes  were  defined  (192). 
Budding of apoptotic bodies from cells is strictly associated with an extension 
of the cell membrane surface. Franz et. al. could verify the ER as a source for 
apoptotic body membranes in late apoptosis. In one study dealing with the 
implications of SphKs in apoptosis, SphK2 translocated to the ER during cell 
death to promote increases in ceramide levels (108). Combining these results, 
the  following  pattern  might  be  conceivable:  SphK2,  being  coupled  to  ER 
membranes, is recruited to apoptotic bodies, where it produces S1P, which is 
then  transported  into  the  extracellular  space  by  specific  ABC  family 
transporters.  Although  there  was  no  indication  for  a  cleavage-independent 
release of SphK2 in the time frame of my investigation, this might contribute to 
S1P production during late apoptosis.    
Attenuating PS exposure during apoptosis blocked the release of truncated 
SphK2  (Figure  20).  These  findings  raise  the  exciting  possibility  that  PS 
exposure  is  directly  involved  in  SphK2  release  or  even  is  the  primary 
mechanism. The release of proteins that is linked to PS exposure may require 
a  flipping  mechanism,  which  was  previously  suggested  for  annexins  (193, 
194)  and  which  might  work  for  SphK2  as  well.  In  such  a  model,  SphK2 
translocates  to  the  inner  leaflet  of  the  plasma  membrane  early  during 
apoptosis, binds to PS, is cleaved by caspase-1 and subsequently transported 
to the cell surface together with PS. PS externalization requires the action of 
scramblase  (195).  Therefore,  knock-down  of  scramblase  would  be  another 
approach  to  prove  that  SphK2  is  directly  connected  to  PS  exposure. 
Obviously, the necessity for caspase-1 dependent cleavage is questionable in 
this model. One might speculate that regulatory proteins are possibly bound to 
the  N-terminus  of  SphK2,  thus  preventing  externalization,  and  are  then 
removed by specific N-terminal cleavage. However, my observations provide 
a new mechanistic explanation how PS exposure on AC may influence the 
phenotype of phagocytes by promoting the release of SphK2 with proximate 
S1P formation. In fact, SphK2 could be another PS ‘receptor’, in this case 
provided  by  AC,  transmitting  the  most  prominent  cellular  alteration  during 
apoptosis to functional responses in macrophages. Discussion                                                                                                                             109                                                                                                                 
 
 
 
Figure  32:  The  mechanism  of  S1P  production  by  AC.  Sphingosine  kinase  (SphK)  2 
translocates to the plasma membrane during apoptosis by binding to phosphatidylserine (PS) 
at the inner leaflet of the plasma membrane. Moreover, caspase-1 (Casp1) is activated and 
cleaves SphK2 at its N-terminus. Mitochondria-derived oxidized cytochrome c (Cyt c) oxidizes 
PS, which is transported to the extracellular side of the plasma membrane by scramblase. 
Cleaved  SphK2  is  externalized  due  to  its  PS-binding.  Subsequently,  it  phosphorylates 
sphingosine  to  sphingosine-1-phosphate  in  the  extracellular  space.  SphK2  may  also  be 
localized  in  the  nucleus,  where  it  can  be  cleaved  by  Casp1,  thereby  losing  its  nuclear 
localization signal (NLS). SphK2 may then leave the nucleus, bind to PS and be externalized.  
 
Taken together, my results show a hitherto neglected role of caspase-1 in 
modulating  immune  responses.  Besides  promoting  the  maturation  of  pro-
inflammatory  cytokines  (14),  its  activation  during  apoptosis  in  combination 
with PS exposure delivers a signal to cleave and release SphK2, which allows 
to produce S1P outside of cells. S1P formation is capable of inducing TH2 
responses by polarizing immune cell populations such as dendritic cells (196) 
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in the context of PS exposure, may actually have anti-inflammatory properties 
regarding immune cell polarization. On the other hand, S1P plays a major role 
in lymphocyte recruitment (103). Therefore, caspase-1 activation again might 
secure  proper  inflammatory  responses  against  invading  pathogens  by 
attracting lymphocytes and dendritic cells to inflamed areas via assembling 
S1P  gradients.  However,  given  the  importance  of  S1P  in  several  human 
pathologies  including  cancer  (125),  extracellular  SphK2  may  represent  an 
interesting drugable target, at least if cell death is involved.  
 
6.3  Macrophage polarization by S1P 
 
Increasing evidence suggests TAM as important players in tumor progression. 
In some human cancers they even emerge as prognostic markers (89, 90). 
Their  pro-tumor  activities  are  associated  with  polarization  towards  an  M2 
phenotype.  This  alternative  activation  program  is  driven  by  the  tumor 
microenvironment, which includes tumor-derived immunosuppressants as well 
as  tumor  hypoxia  (92).  My  studies  pointed  to  tumor  cell  apoptosis  as  an 
additional  process  in  affecting  the  tumor  microenvironment  and  thus 
macrophage  polarization  (198).  Previous  research  has  shown  that 
pretreatment  of  macrophages  with  apoptotic,  but  not  necrotic,  tumor  cells 
reduces their cytotoxicity, i.e. their capability of producing NO and ROS (96).  
Considering the production of TNF-α as a potentially harmful agent (there is a 
reason why it is called tumor necrosis factor), my data support the notion that 
TNF-α is produced in a co-culture of macrophages with MCF-7 cells, with the 
latter ones being killed. However, once AC had been generated in the co-
culture  set-up,  the  production  of  TNF-α  declined  and  co-cultures  produced 
substantially  smaller  amounts  of  the  cytotoxic  agent  upon  LPS/IFN-γ 
stimulation in comparison to activation of naïve macrophages. Moreover, a 
second administration of fresh tumor cells to macrophages, previously primed 
by apoptotic tumor cells, did not elicit a new peak of TNF-α formation and did 
not result in tumor cell killing. Along that line, MCF-7 cells overexpressing Bcl-
2  were  not  killed  by  macrophages,  because  Bcl-2-overexpressing  cells, 
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apoptosis  (199).  Thus,  the  presence  of  AC  attenuates  TNF-α  formation  in 
macrophages,  and  affects  their  cytotoxic  potential  towards  tumor  cells. 
Presumably,  the  interaction  with  apoptotic  tumor  cells  affects  other 
mechanisms  of  macrophage  cytotoxicity,  that  were  investigated  previously 
(96). Nevertheless, tumor cell killing by macrophages that had been primed 
with dying tumor cells beforehand was disabled.    
Besides reducing macrophage cytotoxicity, AC may further affect the tumor 
microenvironment because they release immune modulators such as TGF-b 
and  IL-10  (83,  84).  In  my  system,  dying  tumor  cells  did  not  release  IL-10 
(quantified with the CBA as a control), although this may depend on the tumor 
cell  type.  Nevertheless,  conditioned  medium  from  apoptotic  tumor  cells 
induced phenotype alterations in macrophages.  
As  in  co-cultures  with  MCF-7  cells,  IL-10  production  in  macrophages  was 
enhanced  with  conditioned  medium  from  dying  tumor  cells.  Although 
mechanistically unexplained, an increase in IL-10 was correlated to defective 
NF-κB  binding  in  TAM  (164)  and  the  inability  to  activate  NF-κB  was  also 
observed upon recognition of AC by macrophages (79). In the latter system, a 
short-term binding of AC to macrophages did not affect NF-κB DNA binding, 
but  depleted  p300,  thus  impairing  transcriptional  activation  of  NF-κB  (79). 
Importantly,  attenuated  NF-κB  activity  is  a  critical  marker  of  the  TAM 
phenotype (98). My experiments favored S1P, a soluble factor, in blocking 
NF-κB  following  long-term  exposure  of  AC  to  macrophages.  This  was 
unexpected, since NF-κB activation rather than inhibition was shown for S1P 
in  other  cell  systems  (200).  Despite  S1P  itself  might  induce  low  NF-κB 
activation  also  in  macrophages,  it  completely  abrogated  TNF-α-mediated 
stimulation of NF-κB in THP-1 human monocytes (201). Further supporting 
evidence emerged from a study investigating the effect of the S1PR agonist 
FTY720 in an in vivo model of liver injury. FTY720 induced expression of A20 
(202), a deubiquitinase capable of terminating Toll-like receptor (TLR)- or TNF 
receptor-induced NF-κB signaling (203). Up-regulation of A20 started after 6 h 
and  hence  was  dependent  on  S1PR  activation  rather  than  internalization. 
Although the impact of S1P on NF-κB signaling is unclear at present, it may 
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Activation  vs.  inhibition  may  depend  on  the  S1PR  expression  profile  in 
different cell types and/or on the duration of S1P exposure, as well as the 
presence or absence of co-stimuli such as LPS/IFN-γ.  
S1P from apoptotic MCF-7 cells changed the LPS/IFN-γ activation profile in 
macrophages. It suppressed TNF-α formation but increased IL-8 production in 
macrophages  upon  LPS/IFN-γ  activation  and  most  likely  provoked  IL-10 
liberation during interaction with dying cells. Reduced TNF-α production may 
result  from  a  diminished  NF-κB  activity,  whereas  alterations  in  interleukin 
production may be associated with activation of STAT1 and/or PI3K-signaling 
because  activity  of  these  signaling  pathways  is  characteristic  for  M2 
macrophages (98, 204). 
Production of the immunosuppressive cytokine IL-10 is characteristic for TAM. 
Although underlying molecular pathways remain unclear, it is known that S1P 
can  provoke secretion of IL-10 from T-cells and dendritic cells, which was 
furthermore correlated to a diminished pro-inflammatory activity in these cells 
(196,  197).  IL-10  formation  may  require  PI3K  signaling,  a  pathway  that  is 
activated  downstream  of  S1PRs  (179).  Furthermore,  PI3K  may  negatively 
regulate  TLR-signaling  during  inflammation,  thus  down-regulating  NF-κB 
signaling (205) and has been proposed as a potential target to circumvent 
immunosuppression  in  cancer  (206).  In  this  respect,  knockout  of  Src 
homology2-containing  inositol-5’-phosphatase  (SHIP),  a  potent  negative 
regulator  of  PI3K,  induced  on  itself  a  M2-like  phenotype  in  mouse 
macrophages, which was strikingly associated with impaired NO-production 
and  enhanced  tumor  growth  (204).  Moreover,  phosphorylation-dependent 
inhibition of glycogen synthase kinase 3 (GSK3)-β, a downstream target of 
PI3K, reduced TNF-α and IL-12 but increased IL-10 release from monocytic 
cells (207) thereby adding evidence for a immune regulatory role of PI3K.  
As stated above, IL-10 was previously related to defective IL-12 production in 
TAM, which was furthermore explained by defective NF-κB signaling (164). IL-
10 was produced in co-cultures with MCF-7 cells, even after tumor cells were 
killed. Therefore, co-culture primed macrophages should produce less IL-12-
p70,  which  indeed  was  the  case.  IL-12-p70  and  TNF-α  production  in 
macrophages  from  co-cultures  were  equally  affected.  Therefore  I  did  not 
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observed that S1P reduced NF-κB DNA-binding. Since NF-κB is the principal 
pro-inflammatory transcription factor, it is likely to attenuate generation of IL-
12-p70 as well (205).   
Enhanced production of IL-8 in macrophages derived from MCF-7 co-cultures 
is not immediately apparent considering the attenuated activity of NF-κB, a 
prominent  inducer  of  IL-8  (208).  Under  conditions  of  S1P  release,  other 
transcriptional  activators  of  IL-8  such  as  C/EBPβ,  AP-1,  or  STAT1  may 
substitute for NF-κB and it will be interesting in the future to define how S1P 
enhances IL-8 production.  
Despite uncertainties in IL-8 regulation, its production may explain how S1P 
contributes to tumor angiogenesis, since IL-8 expression was related to TAM-
dependent  angiogenesis  and  poor  prognosis  in  uterine  cancer  (209).  As 
mentioned in the introduction, recent in vivo studies refer to a role of S1P in 
tumor  vascularization  (125,  126).  Forced  S1P  receptor  desensitization  with 
FTY720  abrogated  S1P-  and  VEGF-induced  angiogenesis  and  attenuated 
metastatic  tumor  growth  (126).  Moreover,  the  use  of  a  monoclonal  S1P 
antibody  reduced  tumor  growth  via  inhibition  of  tumor  angiogenesis  and 
survival (125). These observations support a direct connection between S1P 
production and tumorigenesis, although the source of S1P in human tumors is 
undefined.  
Considering  that  high  levels  of  SphK1  in  glioblastoma  correlated  with  low 
patient  survival  (210),  it  seems  attractive  to  assume  gain  of  expression 
regulation as an underlying mechanism. My studies identified SphK2 activity 
in close association with tumor cell apoptosis induced by macrophages as 
another possible S1P origin. The release of S1P from apoptotic, but not viable 
tumor  cells  induced  macrophage  polarization  towards  an  alternatively 
activated  phenotype,  characterized  by  a  change  in  cytokine  production, 
reduced tumor cytotoxicity and an attenuated NF-κB response (Figure 33).  
As mentioned, other factors such as TGF-β or PS may account for phenotype 
alterations  in  macrophages  after  interaction  with  AC  (10,  83).  Since 
suppression  of  S1P  release  via  SphK2  knock-down  did  not  restore  TNF-α 
completely,  these  molecules  might  also  be  involved  in  triggering  the 
macrophage  phenotype.  Nevertheless,  one  has  to  keep  in  mind  that  S1P 
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S1P was shown to mimic the anti-inflammatory signaling properties of TGF-b 
by  cross-activating  the  TGF-bII  receptor  (211).  Therefore,  functional 
responses  depending  on  these  two  molecular  signals  may  depend  on  a 
crosstalk with S1P signaling.  
 
 
 
Figure  33:  Tumor  cell  apoptosis  polarizes  macrophages.  Macrophages  produce  tumor 
necrosis factor (TNF)-α, and potentially other cytotoxic mediators, upon recognition of tumor 
cells. Tumor cells undergo apoptosis, whereupon they produce Sphingosine kinase (SphK) 2-
derived sphingosine-1-phosphate (S1P). S1P most likely binds to its receptors (S1PRx) on 
the macrophage surface. S1P suppresses lipopolysacharide (LPS)/interferon (IFN)-γ-induced 
TNF-α and interleukin (IL)-12 release from macrophages,  probably  via  inhibition of NF-κB 
DNA binding. Furthermore, S1P mediates the production of IL-10 and IL-8.  
 
Taken together, my results suggest that induction of tumor cell apoptosis by 
invading macrophages may account as an additional process to explain the 
existence of TAM. This may be true at least in early stages of tumor formation, 
where the tumor has not yet acquired full resistance against apoptosis via a 
series of beneficial mutations. 
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6.4  In vivo evidence for SphK2 implication in cancer development 
 
Being aware of the co-culture system’s limitations in proving a role of S1P 
produced by apoptotic tumor cells via SphK2 in cancer development, I started 
the tumor xenograft model in nude mice. It could be argued that the nude 
mouse model is limited as well for the study of immunity-dependent aspects of 
tumor development, since nude mice are devoid of thymus-derived T cells. 
However, this model might be considered as straightforward for studying the 
role  of  macrophage  polarization  in  this  context,  because  nude  mouse 
macrophages tend to exhibit a basal M1 phenotype even without respective 
stimulation (212). This would fit well to the hypothesis that emerged from my 
previous observations: Macrophages would then induce tumor cell death upon 
which they would develop a TAM-like phenotype, promoting growth, survival 
and sustentation (via blood vessel infiltration) of remaining tumor cells (Figure 
34). 
The first results that emerged from the nude mouse xenograft model were 
encouraging. I noticed markedly reduced growth of MCF-siSphK2- compared 
to  MCF-7  xenografts.  This  was  accompanied  by  reduced  angiogenesis  in 
MCF-7-siSphK2 tumors. Importantly, the number of infiltrating macrophages 
was not decreased in MCF-siSphK2 tumors in comparison to control tumors. 
Indeed, rather the reverse was observed. Because Lin et. al. provided strong 
evidence that macrophage are essential in promoting the angiogenic switch, 
at  least  in  this  model  of  breast  cancer,  it  can  be  concluded  that  rather 
macrophage polarization than their simple presence is crucial.  
I must admit, that although the current data could be interpreted in that way, 
the persuasiveness is weak at present. It could simply be argued that SphK2 
knock-down in tumor cells interferes heavily with total sphingolipid metabolism 
since production of ceramide species during apoptosis may depend on the 
action  of  SphK2  (108),  thereby  producing  macrophage-independent  side 
effects. However, following this objection consequently, it is more likely that 
SphK2  depletion  would  foster  tumor  progression  by  reducing  pro-apoptotic 
ceramide levels. Contrarily, my data clearly show tumor growth suppression 
by SphK2 depletion.  Discussion                                                                                                                             116                                                                                                                 
 
 
Figure 34: A role of tumor cell death-derived S1P in tumor development. During early stages 
of  tumor  progression,  macrophages  may  induce  tumor  cell  death,  e.g.  via  tumor  necrosis 
factor (TNF)-α. Induction of tumor cell death is furthermore a major aim in chemotherapy. 
Apoptotic tumor cells produce lysophosphatidylcholine (LPC), which attracts macrophages. 
Moreover,  sphingosine  kinase  (SphK)  2  may  be  released  from  apoptotic  tumor  cells  after 
binding to phosphatidylserine (PS) on the intracellular plasma membrane surface, followed by 
caspase-1 (C1)-mediated N-terminal cleavage and subsequent release into the intracellular 
space, due to PS binding. SphK2 catalyzes the conversion of sphingosine to sphingosine-1-
phosphate, which induces an alternatively activated phenotype (M2) in macrophages. The M2 
macrophages release cytoprotective and/or pro-angiogenic factors such as interleukin (IL)-10 
and IL-8, which provokes protection of tumor cells against cell death and to enhanced tumor 
angiogenesis. 
 
Another possible demur against my hypothesis is the missing experimental 
evidence  for  tumor  cell  death  induction  in  the  nude  mouse  model.  One 
approach  to  solve  this  problem  could  be  the  use  of  Bcl-2-overexpressing 
MCF-7-siSphK2 cells for the xenograft model. These cells should be protected 
from  apoptosis  (5.3.2)  and,  in  concordance  with  the  hypothesis,  should 
produce well growing tumors. 
Conclusively, SphK2 seems to be important for tumor growth in vivo. Whether 
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Therefore,  macrophages  will  be  isolated from  MCF-7-siSphK2-  and  MCF-7 
xenografts and analyzed for cytokine production, both under basal conditions 
and after stimulation with M1 phenotype-inducing agonists. If the hypothesis 
proves to be correct, extracellular SphK2 should be considered as a target for 
tumor therapy, at least in breast cancer. 
 
6.5  Concluding remarks 
 
Recognition  of  AC  by  macrophages,  which  provokes  a  macrophage 
phenotype shift towards M2, is crucial for the termination of inflammation and 
plays  a  role  in  human  pathologies  that  are  associated  with  inflammation 
and/or  apoptosis.  Many  aspects  of  AC-dependent  macrophage  polarization 
where attributed to specific recognition of PS and/or subsequent release of 
TGF-β, acting in an autocrine manner to reprogram macrophages (3.3.2). I 
could  show  that  AC-derived  S1P  considerably  contributes  in  shaping 
alternative macrophage polarization. Interestingly, this was also dependent on 
PS. Therefore, S1P production by AC could be considered as another feature 
of ‘specific recognition’, besides e.g. PS recognition by VnR or identification of 
CD31  modification,  which  in  this  case  is  binding  of  S1P  to  its  specific 
receptors (most likely S1PR1) on the macrophage surface. Furthermore, S1P 
might  be  important  to  support  the  effects  of TGF-β,  via  cross-activation  of 
TGF-β  receptor-dependent  signaling  pathways  (211).  Moreover,  S1P  may 
account for additional characteristic features of macrophage polarization that 
are induced by AC. It may induce expression of COX-2, thereby eliciting PGE2 
production  (213),  which  was  indeed  recently  observed  in  our  laboratory 
(Johann et. al., The Journal of Immunology, in revision). My studies irradiate a 
new aspect of AC-dependent macrophage polarization. What exactly are the 
contributions  of  S1P  and  SphK2,  compared  to  other  mediators,  regarding 
regulation of inflammation and tumor development might well be of value to 
understand the development of certain human diseases. 
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